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Abstract 
Objectives: The aim of this thesis was to evaluate the potential of new technologies, 
including two stem cell technologies, mesenchymal stem cells (MSCs) and induced 
pluripotent stem cells (iPSCs), to understand the molecular basis of human diseases. 
These technologies were evaluated for their ability to restore diabetes-induced defects 
in wound tissue repair (MSCs) and to generate mature neutrophils after in vitro 
differentiation of iPSCs. The latter used iPSCs from a patient with abnormal function 
due to impaired WASp (Wiskott Aldrich syndrome protein) signalling. Other 
techniques evaluated were differentiation of the myeloid cell line, PLB-985 
(expressing exogenous genes) into mature neutrophils and new advances in 
metabolomics, to identify altered neutrophil function in human diseases.  
Methods: The potential of MSCs and oral vitamin C to generate factors that could 
promote healing of diabetic wounds, was measured by RT-PCR for eight genes 
associated with either angiogenesis or extracellular matrix production, after incubation 
under normoglycaemic and hyperglycaemic conditions with and without vitamin C. 
The angiogenic effects of the MSC secretome on wound healing was measured using 
a tubular formation assay (in vitro) and a nude mice diabetic wound model (in vivo). 
The bilateral full-skin thickness wounds were created in an in vivo wound model using 
diabetic nude mice. Oral vitamin C (1.5 g/L) was administered in combination with 
topical MSC treatment (MSCs 1x 106 cells per wound). Diabetic wound models were 
divided into five groups; control (CON; n=6), diabetes (DM; n=12), diabetes treated 
with MSCs (DM+MSCs; n=12), diabetes treated with VitC (DM+VitC; n=6), and 
diabetes treated with MSCs and VitC (DM+MSCs+VitC; n=12). The capillary density 
was measured under in vivo fluorescent microscopy, and the tissue VEGF levels were 
measured. WAS dermal fibroblasts were reprogrammed using retrovirus transfection, 
and the corrected-WAS-iPSCs were differentiated into the neutrophil-like cells via the 
formation of iPS-sacs (the sac-like structure containing haematopoietic progenitor 
cells derived from iPSCs). Neutrophil (from WAS patients and healthy controls) 
chemotaxis was measured using transwell migration towards N-formylmethionine-
leucyl-phenylalanine (fMLP). PLB-985 and KCL-22 cells were differentiated into 
neutrophil-like cells using RPMI-1640 media containing N,N-dimethyl formamide, 
sodium pyruvate, all-trans retinoic acid, human AB serum and dimethyl sulfoxide 
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(with penicillin/streptomycin). Morphology was assessed by cytospin. PLB-985 cells 
were transduced with enhanced green fluorescent protein (EGFP)-tagged Myeloid 
Cell Leukaemia-1 (Mcl-1), sub-cloned into a pLVX-TetOne-Puro system. 1H NMR 
metabolomics was carried out using protocols optimised for neutrophils as part of this 
thesis. An intracellular metabolite extraction method was developed to minimise the 
loss of neutrophil metabolites and to avoid contaminants arising during the extraction 
procedure. The NMR analyses were also optimised to identify neutrophil metabolites 
and allow the comparison from resting and activated states and in health and disease 
(rheumatoid arthritis patients).  
Results: Upregulation of angiogenic genes, vascular endothelial growth factor-α 
(mVEGF-α) and platelet-derived growth factor-BB (mPDGF-BB), in response to TGF-
β1 in MSCs was lower following incubation under hyperglycemia (compared to 
normoglycaemic controls), but vitamin C treatment re-sensitised the MSC response to 
TGF-β1. A diabetic mouse model showed that administration of oral vitamin C, as an 
adjunct to MSC therapy, resulted in accelerated wound healing that was associated 
with increased capillary density. Preliminary experiments with WAS neutrophils 
showed significantly lower rates of chemotaxis towards fMLP compared to healthy 
controls. iPSCs from WAS fibroblasts were cultured and differentiated into neutrophil-
like cells. The efficiency of both PLB-985 and KCL-22 cells to differentiation into 
neutrophil-like cells was evaluated and PLB-985 cells differentiated more efficiently 
into neutrophil-like cells than the KCL-22 cells. PLB-985 cells, transfected with Mcl-
1:EGFP in pLVX-TetOne-Puro system were generated. Nuclear magnetic resonance 
(NMR) metabolomics identified metabolites and pathways altered during in vitro 
activation with PMA (including metabolites of NADPH synthesis and inhibitors of 
reactive oxygen species (ROS)) and in vivo activation in rheumatoid arthritis identified 
metabolites of the ketosis pathway, citrullination pathway and tryptophan metabolism. 
Conclusions: A number of technologies have been evaluated to study the molecular 
basis of human disease, including metabolic (diabetes mellitus) and genetic (WAS) 
diseases. Vitamin C modulated the secretome of MSCs, increasing angiogenesis and 
accelerating wound healing, providing a potential new approach for designing adjuncts 
to existing therapies. Neutrophils from WAS patients demonstrated chemotactic 
defects, and the potential of WAS-iPSCs to differentiate into neutrophil-like cells was 
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demonstrated. The approach could be applied in further studies to study genetic defects 
of leukocyte function. PLB-985 cells transduced with EGFP-tagged Mcl-1 in an 
inducible expression vector, was developed as a cell-line model of neutrophil 
differentiation, to facilitate further studies into the role of the Mcl-1 gene in regulating 
neutrophil survival. Protocols for human neutrophil metabolomics, using 1H NMR 
spectroscopy were developed and applied to the study of in vitro and in vivo activated 
neutrophils. The results demonstrated the potential of metabolomics for future studies 
of human diseases. 
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CHAPTER 1 INTRODUCTION  
Scope of this thesis 
This thesis sets out to evaluate the usefulness of a number of emerging new 
technologies to understand or correct the molecular basis of human diseases. Recent 
technological developments in stem cells and –omics based technologies have 
provided unprecedented insights in the fine structure and detailed composition of 
human cells and tissues, and how these become dysregulated or mutated in human 
disease. Many of these also have therapeutic or diagnostic potential. For example, stem 
cell technologies can be successfully used to treat degenerative diseases or promote 
tissue repair, and some of these approaches, using autologous stem cells, have the 
potential to correct for human conditions that arise from inherited genetic defects. 
Many –omics-based technologies can also be used to obtain detailed molecular 
“fingerprints” of human cells and tissues to identify particular genes, transcripts or 
metabolites that may be altered in disease. Such changes can often be used 
diagnostically, and the sensitivity of such techniques is now sufficient to profile 
individual patients and inform specific therapeutic strategies, via “personalised” or 
“precision” medicine approaches.    
This thesis first explores the potential of two stem cell technologies to 
understand the molecular basis of human conditions. The first of these is the use of 
mesenchymal stem cells (MSCs), which have the potential to differentiate into a 
variety of cell types, including osteoblasts, chondrocytes and myocytes, but these cells 
can also secrete important growth factors and angiogenic molecules. Chapter 3 of this 
thesis explores the potential of MSCs to promote wound healing in an animal model 
of diabetes mellitus. A second stem cell technology was also evaluated for its ability 
to generate a mature blood cell, the neutrophil. This approach, using induced 
pluripotent stem cells derived from fibroblasts (iPSCs), has the advantage in that it 
can, potentially, be used to correct genetic diseases. Identification and correction of 
the genetic lesion in stem cells, should in theory, enable the generation of mature, 
differentiated cells with a corrected phenotype. In Chapter 4, preliminary experiments 
are described in which iPSCs from a patient with impaired signalling via WASp 
(which results in impairments in neutrophil function) were isolated, the genetic defect 
corrected and differentiated into cells that morphologically resembled mature 
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neutrophils. These preliminary experiments provide “proof of principle” that this 
approach can be used to generate functionally-mature blood cells during in vitro 
differentiation. 
Another approach that is commonly-used to explore the function of human 
genes and proteins is to transfect mature tissues or cells with exogenous genes to probe 
the function of that gene (or mutations thereof) with the ultimate aim of in vivo 
manipulation of that gene. However, cells such as mature human neutrophils are 
notoriously difficult to transfect with exogenous genes or proteins because they do not 
divide and have a very short half life. One approach to overcome these problems, is to 
use immature myeloid cell lines that can be transfected and then induced to 
differentiate in vitro. However, many of these cell lines lead to the differentiation of 
cells with only some of the properties of mature neutrophils: hence they can at best be 
termed “neutrophil-like” cells. Another major problem with this approach is that as the 
cultured cells mature into neutrophils, they undergo spontaneous apoptosis, making 
their experimental usefulness rather limited. Chapter 4 describes experiments in which 
the human Mcl-1 gene (which is the major cell survival gene in human neutrophils) 
was cloned into a lentiviral vector for the generation of transfectants of PLB-985 cells. 
Recently-modified culture conditions result in the generation of mature PLB-985 cells 
which morphologically resemble neutrophils, in particular possession of a “late stage” 
differentiation marker; a multi-lobed nucleus. 
Finally, this thesis explores the potential of a new –omics technology, namely 
nuclear magnetic resonance (NMR) metabolomics, to profile the metabolome of 
human neutrophils stimulated in vitro with a number of activating agents. The 
experiments in Chapter 5 describe the optimisation of this new technology for human 
neutrophil studies and also some preliminary experiments on the analysis of the 
metabolites present in diseased synovial fluid or in neutrophils isolated from the blood 
of patients with rheumatoid arthritis. The results of this Chapter confirm the usefulness 
of this technique to profile the metabolomes of neutrophils activated in vitro but also 
its potential to identify metabolic changes that may occur in disease.  
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1.1 New approaches to understanding and correcting human 
diseases 
1.1.1 The study of human diseases 
 1.1.1.1 Clinical studies 
The diagnosis of a human disease requires a clinical examination and 
evaluation of a patient’s signs and symptoms, and is based initially on the physical 
examination and patient history. These physical examinations usually prompt the 
physician to request a range of suitable diagnostic laboratory tests (e.g. assays of blood 
or urinary metabolites or antibodies) or physical procedures (e.g. ECG, MRI scan, X-
ray) to confirm diagnosis and prompt interventions, such as prescription of medicines. 
An appropriate response of a patient to a particular medicine may also help to confirm 
diagnosis. 
1.1.1.1.1 Clinical studies: Current approaches and their limitations 
Understanding the underlying genetic, environmental or metabolic defect that 
is responsible for the symptoms of the disease usually requires more detailed 
investigative procedures. For example: haematological disorders may require specific 
measurements or assays on isolated blood or marrow samples; solid cancers may 
require measurements on biopsy or resected materials; inflammatory disorders may 
require measurements on cells or fluids isolated from the inflamed sites (e.g. lung or 
synovial joints). Sometimes, tissue materials from these disease sites can be cultured 
ex vivo, for short times in the case of blood cells or for longer times if the isolated cell 
retains its proliferative potential, as a result of either in vitro or in vivo transformation. 
Such approaches have resulted in the generation of a vast range of human (and animal) 
cell lines that can be used in in vitro experiments to “model” the disease from which 
the cell or tissue was isolated and to understand the genetic or biochemical defects 
responsible for the disease phenotype. It is also possible to use such cell lines in drug 
screening programmes to identify potential new therapeutic agents prior to 
consideration of their development for clinical use as new drugs. 
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1.1.1.2 Use of ex vivo cells or cell lines 
These approaches have led to great advances in our understanding of human 
disease and have provided a platform for drug discovery programmes, many of which 
have found their way into clinics to successfully treat human diseases (e.g. the tyrosine 
kinase inhibitors, typified by imatinib to treat chronic myeloid leukaemia). Such 
approaches have many advantages. For example: (a) the cell lines can be shared 
amongst researchers across the globe so that multiple groups can work on the same 
biological materials; (b) there are few ethical issues to consider when working on such 
cell lines, that have been derived from isolated somatic cells, either via blood samples, 
biopsy or surgery; (c) toxic effects of exploratory medicines are not problematic and 
indeed cell lines are highly suited for high throughput screening assays; (d) specific 
genes or sets of genes may be “knocked in”, “knocked out” or mutated, and their 
effects on the disease phenotype measured, again, with few ethical issues to consider. 
1.1.1.2.1 Use of ex vivo cells or cell lines: Current approaches and their 
limitations 
However, a disadvantage of the use of such cell lines is that they can lose their 
particular disease phenotype or properties the longer they are cultured after isolation 
from the patient or donor. If they change their properties (which they inevitably do) 
then their usefulness as disease models may be compromised. Another disadvantage 
is that these cells could never be re-introduced into a patient to correct the disease. 
Also, there is a limit to their usefulness in toxicology studies because it is not possible 
to extrapolate the effects of a particular concentration of drug on an isolated, 
homogenous cell population, to the effects of that concentration of a particular 
molecule on “off target” cells or tissues or after the molecule has undergone 
biochemical modification in the body. 
Another consideration of using ex vivo cells or tissues from a diseased patient, 
is that some cells cannot be cultured and do not replicate in the laboratory. For 
example, human neutrophils are terminally-differentiated cells that have lost their 
proliferative properties and have a short half life ex vivo of a few hours, even in the 
presence of survival-enhancing cytokines. Because of this short half life and lack of 
proliferation, genetic manipulation of human neutrophils is not possible. There are a 
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few reports describing the introduction of exogenous proteins, genes or antisense 
molecules into human neutrophils, but such approaches are highly variable, lack 
reproducibility and are not without criticisms of the experimental validity (1). One 
approach to genetically modifying neutrophils is to use myeloid cell lines that can 
proliferate in vitro, but that can also be induced to terminally differentiate e.g. 
following genetic manipulation. Such myeloid cell lines include those isolated from 
the blood or peritoneal fluid of patients with haematological disorders (such as HL-60, 
U-937 and PLB-985 cells). These cell lines (discussed in more detail in Chapter 5) 
proliferate in vitro and can be genetically modified to express EGFP-tagged genes or 
mutated genes. The addition of specific agents can induce differentiation into more 
mature cells, but is questionable if these differentiated “neutrophil-like” cells acquire 
all of the properties of mature blood neutrophils (2,3). Furthermore, neutrophil-like 
cells will undergo apoptosis (4) and therefore there is a finite time in which to study 
the properties of these differentiated cells.  
1.1.1.3 Animal models 
To overcome many of these above limitations in the use of ex vivo cells from 
patients with particular diseases or human cell lines, a number of model systems have 
been studied. These include animal, insect, non-vertebrate or microbial models. For 
toxicology testing of new pharmaceuticals, cell lines have very limited use (see above) 
and whole animal testing is required to determine “off target” effects or effects on 
development. Many species can be used for such studies, but with varying degrees of 
suitability. Ultimately, toxicological testing on humans is the only definitive method 
of determining toxic effects of new drugs, although genetic diversity can result in 
varying responses of individual humans to particular drugs. This diversity forms the 
basis of new “precision medicine” approaches to find the right drug for the right 
patient. Toxicological testing of new medicines on primates is also of value, but this 
approach is highly legislated and very controversial. 
1.1.1.3.1 Animal models: Current approaches and their limitations 
There are many advantages to the use of animal models to understand the 
genetic and molecular basis of human disease, ranging from the use of insects (e.g. 
Drosophila), worms (e.g. Caenorhabditis elegans), yeast (e.g. Saccharomyces 
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cerevisiae) and fish (e.g. zebrafish, Danio rerio). The use of such model systems has 
led to many landmark discoveries and several Nobel prizes, for example identification 
of genes regulating apoptosis (Bcl-2 and caspase family genes in C. elegans (5)), 
development (e.g. homeobox genes in Drosophila (6,7)) and cell cycle genes (in yeast 
(8)). A major advantage to the use of such model systems is the relative ease with 
which specific genes can be mutated, “knocked out”, “knocked in” or “humanised”. 
New technologies based around Clustered Regularly Interspaced Short Palindromic 
Repeats/CRISPR-associated protein-9 nuclease (CRISPR/cas9) allow for very subtle, 
specific and rapid gene editing (9). Mutations can be animal-wide or conditional, such 
that only specific cells or tissues carry the genetic change.  
An additional advantage to the use of animal models is that human diseases or 
conditions can be experimentally induced and the underlying mechanisms explored or 
therapeutically manipulated. For example: the MRL/lpr mouse strain spontaneously 
develops lupus-like symptoms (10); adjuvants or serum transfer can induce 
inflammatory joint disease in rodents (11) and diabetes mellitus can be induced in 
animals by the administration of streptozotocin which destroys pancreatic β-cell (12) 
(see Chapter 3). The ability to induce such human-like diseases, coupled with the 
ability to genetically modify specific genes and administer new therapeutic agents, has 
again led to many major advances in human biology and understanding and treatment 
of human diseases.  
There are a number of disadvantages, however, in the use of such animal 
models. Firstly, experiments with mice or other vertebrates requires specialised, 
highly-regulated animal facilities that are expensive to maintain to the appropriate 
legal requirements within different countries. Consequently, such experiments (which 
require appropriate project- and personal-licenses) are usually performed in dedicated, 
specialised animal handling units. Secondly, there are a number of ethical issues to 
consider in such animal experiments, and much interest in approaches that minimise 
the use of animals in such experiments and decrease the pain and suffering that an 
animal experiences in these studies. Finally, there is an emerging debate developing 
on the appropriateness of some animal models to study human diseases. For example, 
many experimental approaches assume that genetic manipulations in mice are accurate 
representations of human gene function. However, there is a growing acceptance that 
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many genes, particularly those of the immune system, have sufficient structural and 
functional differences in mice and humans (13). Therefore, it may not always be 
possible to extrapolate observations of mouse experiments to human processes and 
disease.  
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1.2 Stem cells and their use in human diseases 
Technologies based on the use of stem cells offer great potential to both 
understand and then correct for specific genetic or cellular defects that underpin human 
diseases. Stem cells can be derived from many sources, including embryonic stem 
cells, mesenchymal stem cells and induced pluripotent stem cells. Each of these has 
particular advantages and disadvantages, and there a number of ethical and technical 
issues to consider before such technologies will become routinely used to treat human 
diseases. Among the stem cell technologies, mesenchymal stem cell (MSC) and 
induced pluripotent stem cell (iPSC) have been used in this thesis and so these systems 
will be described here in detail. These two technologies have particular advantages. 
First, they can be derived from adult cells (e.g. bone marrow for MSCs or fibroblasts 
for iPSCs) thus overcoming some of the moral issues that have been raised with the 
use of embryonic stem cells. Second, they can be derived from patients with particular 
diseases. Such stem cells can be analysed in vitro to identify any genetic defect, and 
this genetic defect can often be corrected in vitro. The use of CRISPR-cas9 technology 
can now provide relatively rapid and highly-selective changes in the genome of stem 
cells to correct such genetic defects (14). This approach therefore has the potential to 
re-introduce genetically-corrected stem cells back into the same patients to generate 
new cells that have the correct function. Such an approach is particularly attractive to 
genetic diseases that involve blood cells. The aberrant cells and their progenitors can 
be eliminated by radiotherapy or chemotherapy, and then the bone marrow restored 
with corrected stem cells.  
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1.3 Mesenchymal Stem Cells (MSCs) 
1.3.1 Background 
 Mesenchymal stem cells (MSCs) are multipotent stem cells, originally derived 
from bone marrow (15). MSCs were first defined as a subset of fibroblast-like cells 
from the bone marrow stroma that can generate bone, fat cells, cartilage and reticular 
cells following bone marrow transplantation. Since then, MSCs have been discovered 
in the stromal fraction of many adult tissues, including adipose tissue and skin. 
However, there is no equivocal identification of MSCs from different tissues. In 
practice, MSCs are defined by their ability to differentiate into osteoblasts, adipocytes 
and chondrocytes, with self-renewal capacity. Some studies have reported the ability 
of these cells to differentiate into multiple other cell types, including cells of both of 
mesodermal (for example, hepatocytes (16)) and non-mesodermal origins (for 
example, endothelial cells (17), neural cells (18)).   
1.3.2 MSC characterisation 
 Currently, no unique surface marker unequivocally distinguishes MSCs from 
other cells. Therefore, the International Society for Cell Therapy has established the 
minimum criteria to characterise MSCs (19). First, MSCs must adhere to a plastic dish 
in standard culture conditions. Second, the cells must express the surface molecules 
CD105, CD73 and CD90, in the absence of CD45, CD34, CD14, CD11b, CD79a or 
CD19 and HLA-DR surface molecules. Third, MSCs must be able to differentiate into 
osteoblasts, adipocytes and chondroblasts in vitro. 
1.3.3 Limitations and Concerns 
There is great heterogeneity in MSCs depending on the tissue from which they 
were derived. For example, the single-cell derived clones of MSCs from human 
umbilical cord display varying degrees of in vitro multi-differentiation (20) and 
proliferative capacities (21). The in vivo localisation and identification of MSCs in 
tissues are largely unknown due to the low frequency of these cells in tissues, and the 
lack of a distinct MSC-specific immune-phenotype to enable their identification and 
isolation. Therefore, in order to compare the properties of MSCs, including their 
therapeutic potential, their biological properties must be thoroughly characterised.   
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1.4 Induced Pluripotent Stem Cells (iPSCs)  
1.4.1 Background 
Induced pluripotent stem cell (iPSC), a newly-developed stem cell technology, 
provides a promising new model system to study the molecular biology of cellular 
development (such as neutrophil development) and to probe the mechanisms of genetic 
diseases.  
iPSCs were discovered in 2008 (22). These stem cells are derived by re-
programming adult, somatic cells into a pluripotent stem cell state, or embryonic stem 
cell-like state. Embryonic stem cells (ESCs) are derived from the inner cell mass of a 
blastocyst (a human embryo 4-5 days after fertilisation), which is an early-stage pre-
implantation embryo. Therefore, ESCs have the potential to be maintained indefinitely 
in their undifferentiated state, while sustaining their capability to differentiate into cells 
of three germ layers, including haematopoietic cells. One limitation, however, is that 
their genetic background is unique to the donor and this must be considered if they are 
to be used to treat a recipient with a different genetic background with a specific 
disease. In addition to the ethical considerations of using human embryonic materials, 
this genetic diversity (and possible genetic incompatibility) is a major consideration 
that limits their applications as either a disease model or a therapeutic option (23).  
 iPSCs have the equivalent capability of ESCs to differentiate into three germ 
layers while still possessing the potential to be expanded in culture indefinitely. These 
cells offer many new possibilities for studying the genetics of human disease processes 
(24). Additionally, as they can be derived, for example from the skin of patients with 
a particular genetic disease, they may be genetically-corrected and re-introduced back 
into the donor patient. This circumvents many of the ethical issues and technical 
constraints (e.g. tissue rejection) associated with the use of embryonic stem cells.  
1.4.2 iPSC as a disease model e.g. in genetic diseases 
iPSCs contain the patient’s own genetic background and possess full stem cell 
capacities (24). Therefore, the major advantages of iPSC technology result from the 
opportunity to generate disease- or patient-specific iPSCs through the reprogramming 
of somatic cells from patients with specific diseases. However, major considerations 
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for the use of iPSCs as disease models include the development of effective methods 
for differentiating iPSCs into mature somatic cells, and ensuring that the properties of 
iPSC-derived cells match those of mature tissue cells. Furthermore, while both genetic 
and environmental factors may contribute to disease mechanisms, only genetic factors 
can be effectively manipulated when iPSCs are used as a disease model.  
1.4.3 Limitations and Concerns 
 As iPSCs are obtained through reprogramming adult somatic cells with 
pluripotent transcription factors, the epigenetic traits from the cell of origin are 
somehow retained (25,26). This could result in an obstacle for the iPSCs to 
differentiate towards the required cell lineage. Moreover, the differentiation of iPSCs 
towards mature somatic cells requires a mimicking of natural development in humans, 
therefore, the efficiency of the differentiation protocols and the functions of the 
resulting differentiated cells require proper evaluation. 
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1.5 Diabetes Mellitus (DM) 
Diabetes mellitus (DM) is a chronic metabolic condition characterised by 
hyperglycaemia (high blood glucose) resulting from either insulin resistance (inability 
of cells to effectively respond to insulin) and/or insufficient pancreatic insulin 
production (27). Diabetes mellitus can be classified into four categories: type 1 DM; 
type 2 DM; gestational DM (GDM); and DM due to other specified causes. However, 
all patients with diabetes mellitus share common clinical characteristics of chronic 
hyperglycaemia that is responsible for increasing the risks of long-term microvascular 
and macrovascular complications. In the general population, type 1 DM (due to 
pancreatic β-cell destruction) and type 2 DM (due to insulin resistance and insufficient 
pancreatic insulin production) are the most common, and hence will be discussed in 
more detail in this thesis.  
1.5.1 Epidemiology 
In 2015, 415 million people worldwide were reported to have a form of 
diabetes mellitus (approx. 4 million in Thailand and approx. 3 million in the UK) (28). 
It has been estimated that by 2040, approx. 642 million adults worldwide will have 
diabetes mellitus. In the UK, men aged 35 - 54 (8.4% of men) are almost twice as 
likely to have diabetes mellitus compared to females (4.8% of women) (29). Over the 
last decade in the UK, the incidence of diabetes mellitus in men aged 35 - 54 has risen 
faster compared to women in the same age group. These statistics are consistent with 
the fact that more men are overweight than women. Among these forms of the disease, 
type 2 DM is responsible for the majority (approx. 90%) of cases, the major risk factors 
of which are related to obesity and physically inactive lifestyles. 
1.5.2 Diagnosis 
Patients are usually diagnosed with diabetes mellitus when their blood glucose 
is abnormally high, with or without any symptoms of hyperglycaemia (for example, 
polyuria, polydipsia, and excessive weight loss) or hyperglycaemic complications 
(including acute and chronic complications). The diagnostic criteria for diabetes 
mellitus proposed by the WHO recommendation (2006) (30) are shown in Table 1.1. 
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Table 1.1: Diagnosis of diabetes mellitus by World Health Organisation 
(WHO) (2006)    
Diagnostic criteria for diabetes mellitus (WHO 2006) 
1. Diabetes mellitus symptoms (e.g. polyuria, polydipsia and unexplained weight 
loss for Type 1) plus: 
          - A randomly-sampled venous plasma glucose concentration ≥ 11.1 mmol/L 
or 
          - A fasting plasma glucose concentration ≥ 7.0 mmol/L (whole blood ≥ 6.1 
mmol/L) or 
          - A plasma glucose concentration ≥ 11.1 mmol/L, measured 2 h after ingestion 
of 75 g anhydrous glucose in an oral glucose tolerance test (OGTT) 
2. When no symptoms are evident, diagnosis should not be based on a single 
glucose determination but requires confirmatory venous plasma measurements. At 
least one additional glucose test result on another day with a value in the diabetic 
range is essential, either fasting, from a random sample or from the 2 h post-glucose 
load. If the fasting random values are not diagnostic, the 2 h value post-glucose test 
should be used. 
1.5.3 Clinical manifestations 
Clinical presentation may vary in the different categories of diabetes mellitus, 
and also at the time of presentation. However, symptoms include: polyuria (frequent 
urination); polydipsia (feeling very thirsty); polyphagia (feeling very hungry); extreme 
fatigue; blurry vision; impaired wound healing; excessive weight loss (type 1), and 
numbness in the extremities (type 2). 
 
Page 41 of 280 
1.5.4 Pathophysiology 
 In type 1 DM, autoimmunity is generally considered as the major underlying 
pathophysiology. The β-cells of the islets of Langerhans in the pancreas are destroyed, 
and so insulin production is inadequate to maintain normal blood glucose levels (31). 
Type 2 DM is a metabolic disturbance, comprised of insulin resistance, 
impaired insulin secretion, and inappropriate glucagon secretion (32). Patients with 
type 2 DM usually have accompanying metabolic conditions, including lipid 
dysfunction, obesity and high blood pressure. 
1.5.5 Laboratory Findings 
The high values of blood glucose levels seen in diabetes mellitus are described 
in Table 1.1. Either fasting or random blood glucose concentrations are routinely 
measured in diabetes mellitus. However, for monitoring and controlling long-term 
blood glucose levels, the glycated proteins, including haemoglobin A1c (HbA1c) and 
fructosamine, are measured to indicate cumulative blood glucose levels. HbA1c is a 
glycosylated form of haemoglobin, formed from haemoglobin and glucose, and is used 
to estimate an average measurement of blood glucose levels during the previous 2 - 3 
months. HbA1c is widely used in clinical assays as an indicator for monitoring and 
controlling blood glucose levels. Fructosamine, formed from glucose and an amine 
group on proteins, is another glycated protein used for monitoring and controlling 
blood glucose levels, but is less commonly used.  
 Moreover, there are numerous other laboratory findings are used to either 
detect or follow-up the possible diabetic complications that may occur, including 
damage to kidneys, retina, and other cardiovascular problems.  
1.5.6 Treatment  
Current clinical care and management of diabetes mellitus includes lifestyle 
modifications (diet and exercise) and medical interventions aimed at preventing and 
controlling hyperglycaemia (33). When blood glucose levels of diabetic patients are 
controlled such that they remain in the normal range, the risks for developing either 
short-term or long-term complications are markedly decreased. Medications are aimed 
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at lowering blood glucose levels. Oral hypoglycemic drugs normally involve either 
mechanisms that result in insulin sensitisation or increased insulin secretion (insulin 
secretogogues). Otherwise, exogenous insulin is injected to control blood glucose 
levels to control the most severe forms of diabetes mellitus (usually type 1).    
There are also treatments for some of the complications that arise as a 
consequence of diabetes mellitus. However, for some diabetic complications, and 
diabetic wound in particulars, there are no specific treatments (see Chapter 3).  
1.5.7 Prognosis  
 Currently, there is no cure for either type 1 or type 2 DM. Therefore, diabetes 
mellitus is still a chronic disease for which life-long medications are usually needed. 
The major goal for management of the disease is to control blood glucose levels to 
those within the normal range, as morbidity and mortality, and microvascular and 
macrovascular complications in particular, are associated with the persistently high 
blood glucose levels in uncontrolled disease. Cardiovascular complications remain the 
major cause of death in diabetic patients (34).    
1.5.8 Complications  
 In general, diabetic complications are classified as microvascular (neuropathy, 
retinopathy and nephropathy) and macrovascular complications (coronary artery 
disease, peripheral artery disease and stroke) (33). Prolonged hyperglycaemic 
conditions disturb the physiologic conditions of the vessels through different 
mechanisms, including the pathologic effects of advanced glycation end product 
accumulation, impaired vasodilatory response attributable to nitric oxide inhibition, 
smooth muscle cell dysfunction, overproduction of endothelial growth factors, chronic 
inflammation, hemodynamic dysregulation, impaired fibrinolytic ability, and 
enhanced platelet aggregation (35). Thus, prolonged hyperglycaemia results in 
microvascular complications and, at the same time, induces to the formation and 
acceleration on atherosclerotic plaque formation, which are major contributing factors 
of macrovascular complications. 
Page 43 of 280 
1.6 New approaches to the treatment of diabetic wounds and 
enhanced diabetic wound healing 
1.6.1 Diabetes mellitus and diabetic wound  
Diabetes mellitus is a leading cause of non-traumatic lower limb amputation, 
which is often a consequence of an impaired wound healing process. Many 
physiological factors, including cytokines and other compounds that contribute to 
normal wound healing are impaired in the diabetic wound microenvironment, 
including growth factors (36–38), angiogenic factors (38,39), extracellular matrix 
components (40) and immunologic responses (38,41). Moreover, current therapeutic 
approaches to improve healing of diabetic wounds are not specific to the underlying 
pathologic condition that is responsible for the defect and this can contribute to 
ineffective therapy.                                                              
Wound healing is a complex process that requires an intricate orchestration of 
multiple cellular functions. During wound healing, affected tissues undergo phases of 
inflammation, proliferation and remodeling, which require regulated expression of 
inflammatory cytokines, angiogenic factors and extracellular matrix proteins. 
However, prolonged hyperglycaemia alters the inflammatory response and disrupts the 
microvasculature (38). Therefore, delayed and impaired wound healing is often 
clinically observed in diabetic patients, sometimes leading to infections or more 
severely, amputations. New approaches are therefore needed to address the problem 
of non-healing of chronic wounds to prevent morbidity and mortality, particularly in 
diabetic patients. 
1.6.2 Current clinical management in diabetic wound  
Current clinical management regimens for the care of diabetic wounds mainly 
centre around moisture, tissue debridement and epithelial edge advancement (42), but 
these frequently fail to address the pathologic characteristics of diabetic wounds, in 
particular poor perfusion and persistent inflammation. Therefore, outcomes for 
diabetic wound management are still relatively poor. Recently, research has focused 
on identifying novel modes of intervention, including the use of cell therapy and 
exogenous growth factors to modulate angiogenesis and inflammation (43). Among 
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the growth factors tested clinically, platelet-derived growth factor (PDGF) has shown 
promise as it has an important role in the formation of connective tissue during wound 
healing (44). However, despite FDA approval, topical PDGF-BB has only shown 
limited effects on ischemic wounds, which are characteristic of diabetic wounds (45–
48).  
1.6.3 Possible role of MSCs in diabetic wound healing 
More recently, the potential for cell therapy to address this important issue, 
including the use of MSCs, has been trialled, exploiting the ability of these cells to 
generate paracrine factors that can promote wound healing (49–51). Several clinical 
studies using bone marrow-derived MSCs (BM-MSCs) for the treatment of chronic 
non-healing wounds, including diabetic wounds, have shown that application of MSCs 
to the wound can promote normal wound healing by facilitating re-epithelialisation 
and angiogenesis (49,52), and in effect, decreasing wound closure times (53). 
However, when used as a single therapy, MSCs usually show only limited beneficial 
effects on diabetic wounds compared to normal wound healing. Of interest, many MSC 
functions, including angiogenesis, are impaired by the chronic hyperglycaemic 
conditions associated with diabetes mellitus (54,55). It is believed that an underlying 
mechanism of MSCs in tissue repair is via the secretion of soluble factors that alter the 
tissue microenvironment. These factors may enhance regeneration of injured cells, 
stimulate proliferation and differentiation of endogenous stem-like progenitors found 
in most tissues, decrease inflammatory and immune reactions, rather than to induce 
transdifferentiation of the stem cells into epithelial or endothelial cells (56,57). Thus, 
compounds that can stimulate MSCs to secrete growth factors or alter the wound 
microenvironment, have the potential to promote more effective wound healing by 
MSCs in diabetes mellitus. 
The mechanisms that have been proposed to be regulated by MSCs in the 
wound healing process, include secretion of soluble factors associated with 
angiogenesis (51), immunomodulation (58), and extracellular matrix production 
(59,60). Support for the involvement of soluble factors comes from the fact that 
conditioned media from MSCs can enhance wound healing (61,62). However, MSC 
treatment in a genetic mouse model of diabetes mellitus actually delayed wound 
closure time compared to their effects in non-diabetic mice (53). It was suggested that 
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hyperglycaemic conditions in diabetic wounds impair MSC function through induction 
of replicative senescence and apoptosis, as well as decreasing paracrine signalling 
(63,64). Therefore, research is needed to identify new ways to restore the wound 
healing activities of MSCs under hyperglycaemic conditions. 
1.6.4 Other supplements in diabetes mellitus and regulation of MSC functions in 
wound healing 
Vitamin C, a natural compound that is an essential dietary component, has been 
shown in a number of studies (65) to stimulate MSC proliferation without a reciprocal 
loss of their phenotype or differentiation ability: this mechanism may be related to 
both the antioxidant and non-antioxidant properties  of vitamin C (65–68). Vitamin C 
also enhances cell survival by inhibiting cell senescence and may prolong MSC 
function in the wound. Additionally, the effect of vitamin C on extracellular matrix 
production may be to provide a more suitable microenvironment for MSCs to function 
appropriately. Consequently, oral vitamin C may be suitable as a synergystic treatment 
with MSCs in diabetic wound healing. Vitamin C is a micronutrient that facilitates 
wound healing, mainly through promotion of collagen synthesis and its antioxidative 
effects (69,70). In some conditions including diabetes mellitus, relatively low levels 
of vitamin C in either cells or serum have been proposed to contribute to ineffective 
wound healing (71,72). Apart from its antioxidative effects, vitamin C might play other 
roles in regulation of cellular metabolism. In this thesis, both in vitro and in vivo wound 
healing models have been used to investigate the effects of vitamin C on MSC function 
during wound healing under hyperglycaemic conditions (see Chapter 3).  
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1.7 Neutrophil Defects 
1.7.1 Neutrophil  
 Neutrophils are the most abundant white blood cells in the circulation and 
much of the activity of the bone marrow is to generate and release mature neutrophils. 
In the circulation, neutrophils represent approximately 60 - 70% of white blood cells 
in the resting state, but only remain in the circulation for 6 - 9 h before undergoing 
apoptosis or migrating into tissues such as the lung, liver and spleen (73). In response 
to infection and inflammation, blood neutrophils become activated to stimulate their 
specific antimicrobial activity, and in parallel their numbers in the circulation increase 
(via mobilisation of mature cells from the bone marrow) and their lifespan is increased 
(73). Because of these mechanisms, processes and functions, neutrophils are the 
prominent innate immune cells that are responsible for the clearance of bacterial and 
fungal infections (74). Neutrophil activation requires coordinated activation of 
multiple cellular mechanisms: identification of chemotactic gradients via 
chemoattractant receptors; the mobilisation of secretory granules and vesicles; 
reorganisation of the actin cytoskeleton to allow for chemotaxis and phagocytosis 
(rolling and adhesion); penetration of the endothelial basement membrane and 
directional movement towards the infection or inflammation site (diapedesis). At the 
inflammation/ infection site, the transmigrated neutrophils phagocytose microbes 
which are subsequently killed by mechanisms that involve the reactive oxygen species 
(ROS) producing NADPH oxidase and granule proteins (such as myeloperoxidase, 
proteases and defensins). Once the neutrophil has completed its role in inflammation 
or infection, the cell undergoes apoptosis, which is required for the resolution of 
inflammation (75) (Figure 1.1). Consequently, patients with neutrophil defects in one 
or more of these mechanisms suffer from infections that are often life-threatening.   
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Figure 1.1: Regulation of inflammation and infection. (1) The 
identification of chemotactic gradients, for example interleukin 8 (IL-8) and 
Leukotriene B4 (LTB4), via chemoattractant receptors and the mobilisation of 
secretory granules and vesicles. (2, 3) Rolling and adhesion: reorganisation of the 
actin cytoskeleton to allow for chemotaxis and phagocytosis. Neutrophils roll on and 
off the endothelial walls of capillaries, sensing changes in their surface properties via 
interactions between selectins (P-Selectin on neutrophils and E-Selectin on endothelial 
cells). During adhesion, changes in the surface properties of endothelial cells, such as 
increased E-selectin and P-selectin expression triggers L-selectin shedding on 
neutrophils and upregulation of adhesion molecules (VLA-4, LFA-1 and MAC-1 on 
neutrophils and ICAM-1, VCAM-1 and MADCAM-1 on endothelial cells). (4) 
Diapedesis: the penetration of the endothelial basement membrane and directional 
movement towards the infection or inflammation site. Surface ligands such as ICAM-
2, PECAM-1 and JAM family proteins facilitate neutrophil migration through gaps in 
the endothelial cells and into the tissue. (5) Phagocytosis: at the inflammation/ 
infection site, the transmigrated neutrophils phagocytose the microbes which are then 
killed by mechanisms that involve the reactive oxygen species (ROS) producing 
NADPH oxidase and granule proteins (such as myeloperoxidase, proteases and 
defensins). (6) Apoptosis: once the neutrophil has completed its role in inflammation 
or infection, neutrophil apoptosis is required for the resolution of inflammation (75). 
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1.7.2 Neutrophils: Health and Disease 
 Many haematological diseases affect the differentiation of neutrophils and 
other myeloid cells, leading to defects in neutrophil number or function. Although 
several genetic mutations in key neutrophil genes have been identified in these 
haematological diseases, detailed understanding of the pathophysiology of many 
conditions is still unclear in many cases. Identifying the genetic lesion underlying 
altered neutrophil function has been important for understanding the clinical 
symptoms, but has also been important for understanding of the function of normal, 
healthy neutrophils. 
One of the most studied genetic disease of human neutrophils is chronic 
granulomatous disease (CGD), in which circulating neutrophils have an impaired 
ability to generate reactive oxidants via the respiratory burst that requires activation of 
a normally dormant NADPH oxidase (76). The disease can be X-linked (more severe 
and often fatal) or autosomal recessive (milder disease), and the phenotype is an 
impaired ability to generate reactive oxygen species, defective killing of certain types 
of bacterial or fungal pathogens and increased morbidity and mortality from infections 
(77). Molecular characterisation of the biochemical defects responsible for this life 
threatening condition have been extremely important in defining the components of 
the NADPH oxidase and the ways in which this oxidase is activated (76). These studies 
have shown that the X-linked form of the disease is characterised by defective 
expression or absence of the membrane bound cytochrome b of the oxidase (gp91phox 
and gp22phox) (78), while the autosomal recessive form of the disease arises via 
defective activation or expression of the cytosolic components, gp47phox (79) or 
gp67phox (80). These discoveries have been invaluable in identifying the mechanisms 
for activation and assembly of the oxidase, in particular identification of 
polymorphisms in the gene structure of the defective components has been 
instrumental in identifying structure: function relationships and the mapping of key 
amino acid residues that control oxidase function (81). Importantly, identification of 
these genetic lesions led to some of the first clinical trials for gene therapy to correct 
this defect in CGD patients with the most severe (X-linked) form of the disease (81).   
Other neutrophil genetic defects that have been identified include leukocyte 
adhesion deficiency (LAD) (83) and myeloperoxidase deficiency (84). LAD-1 results 
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from impaired expression of CD18, the common ß2 subunit of the lymphocyte 
function-associated antigen (LFA) family of integrins (85). Many leukocytes express 
LFA with CD18 forming a heterodimer with CD11a, CD11b or CD11c. Human 
neutrophils have high expression of the CD11b/CD18 heterodimer (Mac-1 or CR3) 
(86). Patients with this condition suffer from life threatening infections as neutrophils 
fail to adhere to the endothelial wall of the capillaries in their attempts to migrate into 
the site of infection (85). Myeloperoxidase deficiency may be complete (rare) or partial 
(more common) and only patients with the complete deficiency show severe clinical 
symptoms, such as impaired killing of Candida albicans or Aspergillus (87), 
particularly against a background of diabetes (88). Partial myeloperoxidase-deficiency 
is usually asymptomatic because the enzyme is normally present in the granules of 
mature neutrophils at very high concentrations, representing ~5% of the total 
neutrophil protein content (88).  
There are, however, many limitations in current models and systems that can 
be used to explore the molecular basis of diseases associated with neutrophil defects. 
There are a number of “neutrophil”-like or myeloid cell lines available, but even 
following in vitro differentiation, these lines do not possess all of the properties of 
mature neutrophils (89). Furthermore, as discussed above (Section 1.1.1.3.1), there are 
significant differences in the properties of human immune cells and murine cells, 
particularly neutrophils. The two major sources of cells for studies of human 
neutrophils are CD34+ cells (that can be induced to mature in vitro) and mature cells 
isolated from the peripheral blood (of patients with diseases or controls). While there 
has been some success in genetic modification of CD34+ cells and their maturation 
into mature neutrophils in vitro, results are highly variable and there have been only a 
few reports of the re-introduction of genetically-corrected CD34+ into patients. In 
previous studies, Haematopoietic stem cells (HSCs), or CD34+, gene therapy for 
adenosine deaminase (ADA)–deficient severe combined immunodeficiency (SCID) 
has shown the limited clinical efficiency due to the small proportion of engrafted 
genetically corrected HSCs (90). Therefore, new approaches are needed to correct 
human diseases and conditions associated with defective neutrophil function, and to 
design new ways to re-introduce genetically-corrected cells back into the patients to 
improve the disease symptoms.  
Page 50 of 280 
1.8 Wiskott-Aldrich syndrome (WAS) 
Wiskott-Aldrich syndrome (WAS) is caused by mutations in the WAS gene 
resulting in either the absence of, or expression of, a truncated Wiskott-Aldrich 
syndrome protein (WASp) (91). WAS patients are characterised by 
microthrombocytopaenia, eczema and recurrent infections. Currently, more than 160 
mutations in the WAS gene have been discovered (92). However, the role of WASp in 
haematopoietic cells is not fully characterised. WASp is a 502-amino acid, proline-
rich protein, which is constitutively expressed in the cytoplasm of all non-erythroid 
haematopoietic cells. This protein is involved in signal transduction pathways that are 
important for responses to cellular growth factors and in cytoskeleton reorganisation 
events of haematopoietic cells, possibly in response to cellular activation (93). Clinical 
manifestations of defective WAS are caused by loss-of-function mutations in the WAS 
gene. Most WAS patients suffer from severe infections that are normally associated 
with neutrophil dysfunction, although the absolute neutrophil count is not affected. As 
a result, infection represents the leading cause of death, along with bleeding in WAS 
patients (94) (Table 1.2). Early studies of WAS neutrophils demonstrated a chemotaxis 
impairment that could be corrected by addition of endotoxin-activated serum (95). 
However, until now, the role of WASp in neutrophil differentiation and function has 
not been elucidated.  
Constitutive expression of WASp results in a clinically-distinct WASp-
associated disorder, an X-linked neutropaenia (XLN). The clinical presentations are 
mainly the consequences of low numbers of neutrophils, which leads to proneness to 
bacterial infections (96). The XLN patients may also suffer from myelodysplasia and 
other cytopaenias (Table 1.2).  
 The purpose of the studies in this Thesis was to use WAS-iPSCs as a disease 
model. WAS is a monogenic disease that mainly affects haematopoietic cells. In 
addition, WAS is an early onset and non-developmental disease. Consequently, it may 
be possible to reproduce cellular phenotypes experimentally by generating iPSCs from 
WAS patients, defining their genetic defects and then differentiating the cells in vitro 
into mature neutrophils. Furthermore, it may be possible to correct the genetic defect 
in the iPSCs from these patients and then determine if normal neutrophil functions are 
restored after in vitro differentiation. While some functions of WASp are defined in 
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normal cells, the role of this protein in the pathophysiology of disease needs further 
studies. Therefore, this thesis aimed to investigate the use of iPSC-derived neutrophils 
as a WAS disease model.  
Table 1.2: Comparison between loss-of-function and gain-of-function 
mutations in WAS 
 Loss-of-function mutation  Gain-of-function mutation 
Genotypes Xp11.23, WAS  Xp11.23, WAS  
WAS 
mutations 
Nonsense; frameshift caused 
by deletions, insertions; 
splicing defects 
Missense in the Cdc42-binding 
site of WAS gene (97,98)  
 
Phenotypes Wiskott-Aldrich syndrome 
(WAS) 
X-linked neutropaenia (XLN) 
WASp 
expression 
Absent or truncated Present 
Clinical 
features 
Eczema, 
microthrombocytopaenia, 
proneness to infection, 
bloody diarrhoea 
Recurrent major bacterial 
infections; severe congenital 
neutropaenia; monocytopaenia; 
predisposition to myelodysplasia 
in the absence of 
thrombocytopaenia and T-cell 
immunodeficiency; maturation 
arrest at the promyelocyte/ 
myelocyte stage in bone marrow 
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 Loss-of-function mutation  Gain-of-function mutation 
Neutrophil 
count 
Normal Low (neutropaenia) 
Pathogenesis Absence of WASp, a key 
regulator of actin 
polymerisation in 
haematopoietic cells; five 
well-defined domains have 
been identified in WASp that 
are involved in signalling, 
cell locomotion and immune 
synapse formation (93,99). 
Loss of WAS autoinhibition; the 
Leu270Pro mutation in the WAS 
gene encoding the conserved 
GTPase binding domain (100) 
 
 
Animal model WASp-deficient mice are 
not as severely affected as 
WAS patients. WASp may 
be a candidate for 
involvement in 'scurfy' 
(101), a T cell-mediated fatal 
lymphoreticular disease of 
mice that had previously 
been proposed as a mouse 
homolog of Wiskott-Aldrich 
syndrome (102). 
Mutations in the mouse WAS 
gene corresponding to the 
human Leu270Pro mutation 
(L270P; 300392.0012) and 
Ile294Thr (I294T; 300392.0025) 
mutations; interfered with 
normal lymphocyte activation 
by inducing a marked increase 
in polymerised actin; decreased 
cell spreading and increased 
apoptosis, associated with 
increased genomic instability 
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1.9 New approaches to the use of iPSCs to understand and 
correct neutrophil genetic defects 
1.9.1 Genetic manipulation of iPSCs to understand and correct human disease 
Targeted double-strand breaks in DNA enables precise genome editing. In 
nature, a double-strand break (DSB) can be repaired through two main mechanisms, 
the endogenous homology-mediated repair machinery using an exogenous provided 
repair template and the non-homologous end joining (NHEJ)-DNA repair pathway 
(103). The introduction of gene-targeting DSB into iPSCs results in homologous 
recombination as a DNA-repair mediated genome editing including genetic correction. 
The genome editing technologies have been developed from the use of site specific 
nucleases (SSNs) such as zinc finger nucleases (ZFNs) and transcription activator-like 
effector nucleases (TALENs), to the use of bacteria adaptive immune systems, 
Clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-
associated protein-9 nuclease (Cas-9), as a SSN. Zinc finger nucleases (ZFNs) will be 
described in details as the technique was applied in this thesis. 
1.9.1.1 Genetic manipulations to reverse abnormal cellular phenotypes: 
Zinc finger nucleases (ZFNs) technique 
Zinc finger nucleases (ZFNs) technique (104): Zinc finger nuclease (ZFN)–
facilitated homologous recombination–mediated gene targeting in iPSC-derived 
haematopoietic progenitors and iPSC-derived neutrophils could allow for precise 
genomic modifications. ZFNs induce a sequence-specific double-strand DNA break, 
enhancing site-specific homologous recombination. Previous studies of iPSCs have 
shown that the AAVS1 locus lies within the first intron of the PPP1R12C gene on 
chromosome 19, and this can be used as a non-pathogenic “safe harbour”, with 
persistent and strong transgene expression, to target a function-correcting minigene. 
The AAVS1 locus resides in an open chromatin structure, flanked by insulator elements 
preventing the integrated cassette from trans-activation or repression. Gene insertion 
at the AAVS1 locus may affect PPP1R12C gene expression. However, disruption of 
one AAVS1 allele in human iPSCs appears to have no adverse effects. 
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1.9.2 The potential use of genetically-corrected iPSCs as a potential therapy 
 The derivation of patient-specific pluripotent cells with genetically-corrected 
fibroblasts allows the generation of corrected iPSCs (105). The differentiation of 
genetically-corrected iPSCs into adult somatic cells, including haematopoietic cells, 
establishes new pathways for implementing iPSC therapy. Moreover, the 
differentiation protocols have been developed to generate the functional adult somatic 
cells including haematologic cells, for example, neutrophils (106). iPSCs, therefore, 
may become a personalised medicine by allowing the autologous cells as the 
therapeutic sources, including haematopoietic stem cells. 
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1.10 Aims of this thesis 
 The overall aim of this thesis is to explore the potential of several new 
technologies to understand the molecular basis of human diseases. These technologies, 
their potential uses and the experimental approaches used in this study are shown in 
Table 1.3. 
 Table 1.3: Experimental design and approach of this thesis 
Technology 
evaluated 
Potential 
application 
Experimental approach used 
in this thesis 
Chapter 
Mesenchymal 
Stem Cells 
(MSCs) 
Tissue 
repair/regeneration 
 
Generation of 
growth/angiogenic factors from 
cultured MSCs; 
use of MSCs to promote 
wound healing in a murine 
model of diabetes mellitus and 
effects of vitamin C 
supplementation 
3 
 
Induced 
Pluripotent 
Stem Cells 
Correction of 
genetic defects: 
generation of 
mature blood cells 
Isolation of iPSCs from a 
patient with Wiskott-Aldrich 
syndrome; 
generation of mature 
neutrophil-like cells after in 
vitro differentiation of iPSCs 
4 
Transfected 
cultured cell 
lines  
Generation of 
mature neutrophils 
expressing 
exogenous gene(s) 
Cloning of EGFP-tagged 
human Mcl-1 into a lentivrus 
vector; 
5 
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and with extended 
lifespan 
transfection of PLB-985 cells 
and differentiation in vitro 
1H NMR 
metabolomics 
Identification of 
neutrophil 
metabolites in 
health and disease 
Development of new protocols 
to extract, identify and quantify 
the metabolome of human 
neutrophils;  
changes in composition of the 
neutrophil metabolome after in 
vitro activation and activation 
in vivo in disease 
6 
 
Objectives: 
- to investigate the potential of mesenchymal stem cells (MSCs) and vitamin C  
- supplementation in the treatment of diabetic wounds using the diabetic nude 
mouse model 
- to investigate the ability of induced pluripotent stem cells (iPSCs) isolated from 
a patient with Wiskott-Aldrich syndrome to differentiate into mature 
neutrophils in vitro 
- to develop a cell-line model of neutrophil differentiation using PLB-985 cells 
and to produce clones expressing EGFP-tagged Myeloid Cell Leukaemia-1 
(Mcl-1), an anti-apoptotic protein that plays a key role in regulating neutrophil 
survival 
- to develop protocols to profile of metabolome of human neutrophils from 
healthy individuals and patients with inflammatory disease, using 1H NMR 
spectroscopy 
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CHAPTER 2: METHODS 
2.1 MSC experiments 
2.1.1 Mesenchymal stem cell (MSC) isolation and culture  
MSCs were selected from adult mouse bone marrow (BM)-derived cells by 
their lack of surface antigen markers of haematopoiesis, in particular CD34 and CD45, 
using Fluorescence Activated Cell Sorting (FACS). BM-MSCs were further 
characterised by having a spindle-like shape with self-renewal capability, and ability 
to differentiate into osteoblasts (data not shown). MSCs at early passage (usually 20 - 
40 passages) were cultured in 3 different conditions: (i) basal media (α-MEM with 
20% FBS); (ii) normoglycaemic (D-Glucose 5.56 mmol/L (100 mg/dL)); (iii) 
hyperglycaemic (D-Glucose 55.56 mmol/L (1,000 mg/dL)). MSCs were cultured for 
one month under these latter conditions to study the effects of chronic hyperglycaemia 
on MSC function. Cells were seeded at a density of 2 x 104 cells/well (6-well plate) 
and counted (after culture as indicated in the text) using a haemocytometer.  
2.1.2 Real-time reverse transcription-polymerase chain reaction (RT-PCR) 
Mouse BM-MSCs were routinely cultured under normoglycaemic conditions. 
After 24 h incubation with and without TGF-β1, (a key inflammatory cytokine 
generated during cutaneous wound healing) at 20 ng/mL, RNA was isolated using 
TRIzol reagent (Invitrogen, USA). Subsequently, real-time RT-PCR was used to 
measure expression levels of mRNA of genes associated with (a) angiogenesis: 
vascular endothelial growth factor-α (mVEGF-α); angiopoietin-1 (mANGPT-1); 
platelet-derived growth factor-BB (mPDGF-BB); hepatocyte growth factor-1 (mHGF-
1); or (b) the extracellular matrix production: insulin-like growth factor-1 (mIGF-
1); fibronectin-1 (mFN-1); stromal cell-derived factor 1 (mSDF-1); tenascin C 
(mTNC). The primer sequences, obtained from other published studies (107–115), are 
listed in Table 2.1. Expression levels were normalised to those of the house-keeping 
gene, glyceraldehyde-3-phosphate dehydrogenase (mGADPH). 
Four genes (mVEGF-α, mPDGF-BB, mFN-1, and mTNC) were selected for 
further studies, and their expression levels were compared in MSCs cultured under 
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normoglycaemia and hyperglycaemia after 24 h culture in the presence or absence of 
TGF-β1 (20 ng/mL) and/or vitamin C (100 μg/mL).   
Table 2.1: Primer Sequences for real-time RT-PCR of genes associated 
with either angionesis or the extracellular matrix production 
Genes Primers Sequences (5΄3΄) Products 
(bp) 
mVEGF-α Forward CAGAAGGAGAGCAGAAGTCC 188 
Reverse CTCCAGGGCTTCATCGTTA 
mANGPT-1 Forward GCAAATGCGCTCTCATGCTA 146 
Reverse GGAGTAACTGGGCCCTTTGAA 
mPDGF-BB Forward AGCAGAGCCTGCTGTAATCG 315 
Reverse GGACTTCTAGTCACAGGCCG 
mHGF-1 Forward CCCCTATGCAGAAGGACAGAA 159 
Reverse GCCCTGTTCCTGATACACC 
mIGF-1 Forward CTGAGCTGGTGGATGCTCT 118 
Reverse CACTCATCCACAATGCCTGT 
mFN-1 Forward TACCAAGGTCAATCCACACCCC 366 
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Genes Primers Sequences (5΄3΄) Products 
(bp) 
Reverse CAGATGGCAAAAGAAAGCAGAGG 
mSDF-1 Forward GTCCTCTTGCTGTCCAGCTC 192 
Reverse AGATGCTTGACGTTGGCTCT 
mTNC Forward GTTTGGAGACCGCAGAGAAGAA 344 
Reverse TGTCCCCATATCTGCCCATCA 
2.1.3 Proliferation assay 
Mouse BM-MSCs were cultured under three different conditions: control (α-
MEM + 20% fetal bovine serum); normoglycaemia (α-MEM + 20% fetal bovine serum 
+ 5.56 mmol/L (100 mg/dL) D-glucose); hyperglycaemia (α-MEM + 20% fetal bovine 
serum + 55.56 mmol/L (1,000 mg/dL) D-glucose), for more than one month. At day 
0, the cells were seeded at 2 x 104 cells in each 6-well plate. The cells were counted at 
day 3 and day 5 after seeding using haemocytometer. The culture medium was 
replaced every 2 days. 
2.1.4 Tubular formation assay 
Tubular formation by human umbilical vein endothelial cells (HUVECs) was 
used as a model of angiogenesis (116). HUVEC medium (Endothelial cell growth 
medium, Lonza, USA) was used to maintain HUVEC cultures, that were seeded at 3 
x 104 cells/500 μL in each well of a 24-well plate covered with matrigel. Cells were 
incubated in the presence and absence of conditioned medium from MSCs and the 
effects of angiogenic cytokines secreted into the conditioned medium by the MSCs 
were assessed by measurements of tubular formation. Conditioned media was prepared 
from serum-free basal media (M199) derived from 80% confluence of MSCs after 
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overnight culture in different conditions (as detailed in the text and figure legends), 
such as hyperglycaemia (HyperCM) or normoglycaemia (NormoCM). After 6 h 
incubation, tubular formation was evaluated using ImagePro software and Pipeline 
software (Madison, USA).  
 Image analysis of tubular formation, such as area density, tubular length, 
number of branch points and tubular thickness, was evaluated by two separate 
investigators in a blinded manner.  
2.1.5 Animals model of induced diabetes mellitus 
Male BALB/C nude mice (7 - 8 week-old, weight 20 – 25 g), from the National 
Laboratory Animal Center, Salaya Campus, Bangkok, were housed according to the 
guidelines for the use of experimental animals by The National Research Council of 
Thailand. All experimental procedures were approved by the Ethics Committee, 
Faculty of Medicine, Chulalongkorn University. The mice were allowed to acclimatise 
for 1 - 2 weeks in the animal house after delivery, and then streptozotocin (Sigma 
Chemical Co., USA.) at 45 mg per kg body weight in citrate buffer pH 4.5 (Sigma 
Chemical Co., USA.), was intraperitoneally injected once a day for 5 continuous days 
to induce diabetes mellitus. Control nude mice were injected with citrate buffer pH 
4.5. The induction of diabetes mellitus was confirmed by measuring tail-venous 
plasma glucose levels (≥ 11.11 mmol/L (200 mg/dL)) at the 2nd and 3rd weeks after 
induction (Figure 2.1). To ensure that this diabetic state was stable, these treated mice 
were used 4 - 6 weeks after the diagnosis of diabetes mellitus in the wound model 
experiments. 
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Figure 2.1: Schematic representation of the generation of diabetic mice 
and the diabetic wound model. 7 - 8 week old BALB/C male nude mice were 
intraperitoneally injected by Streptozotocin, once daily for 5 continous days. Two 
weeks after the injection, the tail-venous blood glucose was measured. Only the mice 
with the blood glucose level of 11.11 mmol/L (≥ 200 mg/dL) on two separate occasions 
were included into the diabetic groups. After 4 - 6 weeks of diabetes mellitus, full-skin 
thickness wounds were created bilaterally on the backs of the mice. Treatments were 
either MSCs, vitamin C or the combinations of the two.  
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Figure 2.2: The diabetic wound model. Mice were divided into five groups; 
control (CON; n = 6), diabetes mellitus (DM; n = 12), diabetes mellitus treated with 
MSCs (DM+MSCs; n = 12), diabetes mellitus treated with VitC (DM+VitC; n = 6), 
and diabetes mellitus treated with MSCs and VitC (DM+MSCs+VitC; n = 12). For the 
MSC treatment groups (DM+MSCs and DM+MSCs+VitC), MSCs (1 x 106 cells) were 
applied in combination with fibrin glue topically on the first day of wound. Oral 
vitamin C, at 1.5 g/L, was supplemented daily into the drinking water in the vitamin C 
treatment groups (DM+VitC and DM+MSCs+VitC).  
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2.1.6 Generation of wounds in diabetic mice 
Bilateral full-thickness excisional skin wounds (0.6 x 0.6 cm2), were created 
on the backs of nude mice under intraperitoneal pentobarbital anesthesia (55 mg per 
kg body weight). For all experimental groups, the wounds were treated with fibrin glue 
(fibrinogen and thrombin, Shanghai RAAS Blood Products Co., China) and then 
covered by tegaderm (3M, USA). MSCs (1 x 106 cells) were applied in combination 
with fibrin glue topically on the first day of wound. Oral vitamin C, at 1.5 g/L, was 
supplemented daily into the drinking water, as indicated in the text and figures. The 
mice were examined at 7 and 14 days after wounding. For this wound model, mice 
were divided into five groups; control (CON; n = 6) (non-diabetic nude mice with the 
fibrin glue applied on the wound), diabetes mellitus (DM; n = 12) (diabetic nude mice 
with the fibrin glue applied on the wound), diabetes mellitus treated with MSCs 
(DM+MSCs; n = 12) (diabetic nude mice with MSC treatment in combination with the 
fibrin glue on the wound), diabetes mellitus treated with VitC (DM+VitC; n = 6) 
(diabetic nude mice with the fibrin glue applied on the wound and the oral vitamin C 
treatment), and diabetes mellitus treated with MSCs and VitC (DM+MSCs+VitC; n = 
12) (diabetic nude mice with the MSC treatment in combination with the fibrin glue 
on the wound and oral vitamin C treatment) (Figure 2.2). 
2.1.7 Measurement of wound area closure 
Digital image software analysis (Image Pro II 6.1) was used to measure the 
percentage of wound closure (% WC) which was quantified using the equation 
(117,118):  
 
 Each image was analysed by two separate investigators, in a blinded method. 
Briefly, the images of wounds were given a code. The images were then randomly 
distributed between four research staff and the mean values of the two measured 
wound values were recorded and used in the above equation.  
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2.1.8 Capillary vascularity (CV) of the wound 
At day 7 and 14 post-wounding, mice were cannulated (after anesthetisation 
with pentobarbital), and 0.2 mL 5% fluoresceinisothiocyanate (FITC)-labeled dextran 
(MW. 150,000, Sigma Chemical Co., USA) was injected through the jugular vein. The 
degree of capillary vascularity (CV) was examined by intravital fluorescence video 
microscopy using a 10x objective lens. The percentage of capillary vascularity (% CV) 
was quantified using digital image software (Image Pro II 6.1). Images were analysed 
in a blinded manner. Histopathological study of the wound was conducted to confirm 
re-epithelialisation, rather than wound shrinkage, in the area of wound closure.   
2.1.9 Tissue vascular endothelial growth factor (VEGF) levels 
After the in vivo studies of wounds at day 7 and 14, wound biopsies from the 
area of the original wound were performed by needle punch. Skin tissues were 
homogenised using mechanical agitation and then ultra-sonication on ice at 90% 
amplitude (10 cycles of 30 s sonication followed by 30 s rest) to generate cell-free 
homogenates that were analysed for tissue VEGF levels by ELISA (Sigma Aldrich, 
USA).   
2.1.10 Statistical analysis 
All data are presented as mean ± standard deviation (SD), using one-way 
ANOVA and Tukey post-hoc multiple comparison tests. Statistical significance was 
considered at ≤ 5% (p value ≤ 0.05). The R project (version 3.2.3) for statistical 
computing were used (From: https://www.r-project.org/). 
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2.2 iPSC Experiments 
2.2.1 Generation of Wiskott-Aldrich syndrome (WAS) induced pluripotent stem 
cell lines for use as a disease model 
 Studies using human cells were approved by the Institutional Review Board of 
the Faculty of Medicine of Chulalongkorn University and were conducted in 
accordance with the Declaration of Helsinki.   
Previous work in this laboratory established protocols to generate iPSCs from 
skin fibroblasts and WAS-iPSCs were generated from skin fibroblasts of WAS patients 
(119). Skin fibroblasts were derived from punch skin biopsies, which were dissected 
into 4-mm round pieces, before being placed on an inverted glass slide and cultured in 
0.1% gelatin-coated 6-well plates. The culture media was DMEM (Dulbecco's 
Modified Eagle Medium, Thermo Fisher Scientific, USA) with 20% FBS, and 
replaced every 2 days until confluence. The derived fibroblasts (WAS fibroblasts) 
were further characterised by immunostaining using Anti-SERPHIN-1 (Anti-rabbit, 
mAB, Sigma Aldrich, USA). 
To generate Retrovirus-iPSCs (ReV-iPSCs), 6 × 106 GP-293 cells (a HEK 293-
based retroviral packaging cell, Clontech, USA) were transfected with 13 μg of each 
of the following retroviral vectors (Addgene, USA): pMIG-OCT4 (clone 17225); 
pMIG-SOX2 (clone 17226); pMIG-KLF4 (clone 17227); pMXS-cMYC (clone 
13375), and 5 μg of pVSV-G (vesicular stomatitis virus-G envelope protein) 
(Clontech, USA) using X-tremeGENE HP DNA Transfection Reagent (Roche, USA). 
48 h after transfection, the media were collected and filtered through a 0.45-μm pore-
size filter. Virus-containing supernatants were collected, filtered, and centrifuged at 
25,000 g for 90 min. Viral pellets were resuspended in Opti-MEM (Invitrogen, USA), 
to generate an OKSM (OCT4, KLF4, SOX2, and cMYC transcription factors) retrovirus 
cocktail, which was supplemented with 6 μg/mL polybrene prior to the transduction 
of the WAS fibroblasts. 
 Five days after transduction, transduced WAS fibroblasts were seeded onto 
mitotically inactivated (using mitomycin-C treatment), human foreskin fibroblasts (as 
feeder cells) and cultured with iPS media (mTeSR™1 Medium, STEMCELL 
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Technologies, USA) until iPSC colonies were visible under the microscope as 
microcolonies. 
2.2.2 Characterisation of WAS-iPSC line  
 After transduction, only WAS-iPSC lines generated compact colonies with 
morphology and cell-cycle profiles similar to those of embryonic stem cell (ESC) 
controls were then selected for further characterisation (120–122). 
2.2.2.1 Immunofluorescence staining 
Human iPSCs were fixed with 4% formaldehyde for 15 min at room 
temperature and then permeabilised with 1xPBS supplemented with 0.3% Triton X-
100 for 15 min at room temperature. Human iPSCs were then blocked in blocking 
solution (10% goat serum and 0.3% Triton X-100 in PBS) for 30 min at room 
temperature and stained with primary antibodies for expression of the following 
transcription factors: Oct4, Nanog, Tra-1–60 and Tra-1–181 (StemLiteTM-
Pluripotency Immunofluorescence (IF) kit, Cell Signalling, Danvers, MA, USA) at 4 
°C overnight. Cells were stained with the Alexa Fluor conjugated secondary antibody 
(Molecular Probes, Invitrogen) for 1 h. 
All fluorescence images were obtained by using Axio Observer fluorescence 
microscope (Carl Zeiss, Jena, Germany).  
 2.2.2.2 Tri-lineage differentiation in vitro and in vivo 
The tri-lineage differentiation potential of iPSCs was tested in vitro by 
embryoid body (EB) formation assays. iPSCs were collected by enzymatic passaging 
using collagenase (to detach the iPSC colonies from the plate), dissected and 
resuspended in 10% fetal bovine serum (FBS) containing Knockout Dulbecco's 
Modified Eagle Medium (Knockout DMEM, with no L-Glutamine, used as a basal 
medium optimised for growth of undifferentiated induced pluripotent stem cells). 
Embryoid body (EB) formation was continued for up to 2 weeks, and cystic formation 
was observed as early as 6 days. Then, the EBs were disrupted into smaller clumps 
before passaging onto gelatin-coated plates for an additional 2 days, followed by fixing 
and staining for the three embryonic germ layers. In vivo differentiation was tested by 
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teratoma formation assays. iPSCs were collected using a cell-scraper, centrifuged and 
the cell pellet resuspended on ice in 400 mL of a 1:1 mixture of matrigel and Knockout 
DMEM, with no L-Glutamine. The suspension was injected intramuscularly into the 
hind limb of an immunodeficient mouse. Teratoma formation was observed at 6 weeks 
and the presence of tissues of three germ layers was confirmed by histopathological 
studies. 
2.2.2.3 Real-time reverse transcription-polymerase chain reaction (RT-
PCR)  
Total RNA was extracted by using TRI reagent (Molecular Research Center, 
Cincinnati, OH, USA) and reverse transcribed with RevertAid™ H Minus M-MuLV 
(Fermentas, Glen Burnie, MD, USA). Real-time PCR was performed by using Maxima 
SYBR Green/ROX qPCR Master Mix (2x) (Fermentas, USA) on ABI 7500 Fast Real-
Time PCR System. The expression of pluripotency marker genes, including OCT3/4, 
NANOG, SOX2, cMYC and Nodal, were studied to confirm the differential expression 
of the genes which were absent in the original fibroblasts, but should be expressed in 
their pluripotent state, iPSCs. The primer sequences, obtained from other published 
studies (123–125), are listed in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
Page 68 of 280 
Table 2.2: The primer lists of pluripotency marker genes 
Genes Primers Sequences (5΄ 3΄) Products 
(bp) 
OCT3/4 Forward GACAGGGGGAGGGGAGGAGCTAGG 144 
Reverse CTTCCCTCCAACCAGTTGCCCCAAAC 
NANOG Forward CAGCCCCGATTCTTCCACCAGTCCC 391 
Reverse CGGAAGATTCCCAGTCGGGTTCACC 
SOX2 Forward GGGAAATGGGAGGGGTGCAAAAGAGG 151 
Reverse TTGCGTGAGTGTGGATGGGATTGGTG 
cMYC Forward GCGTCCTGGGAAGGGAGATCCGGAGC 328 
Reverse TTGAGGGGCATCGTCGCGGGAGGCTG 
Nodal Forward GGGCAAGAGGCACCGTCGACATCA 234 
Reverse GGGACTCGGTGGGGCTGGTAACGTTTC 
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2.2.3 Western blot for WASp expression  
5 x 106 WAS-iPSCs were collected and resuspended with cold PBS. The cell 
suspension was centrifuged at 3,000 g for 5 min, and the supernatant was discarded. 1 
mL cold radio-immuno-precipitation assay (RIPA) buffer, with freshly-added protease 
inhibitors, was added into the pellet. The mixture, WAS-iPSCs:RIPA, was incubated 
on ice for 30 min, with vortexing every 10 min, and then centrifuged at 14,000 g for 
15 min at 4 oC. The supernatant was collected as the protein lysates. 40 μg of total 
protein lysates were mixed with 6x loading dye, Laemmli sample buffer, boiled at 95 
°C for 5 min, and loaded onto 10% sodium dodecylsulfate polyacrylamide gels. A 
mouse anti-WASp monoclonal antibody raised against a recombinant protein 
corresponding to the N-terminal region of human WASp (B-9; Santa Cruz 
Biotechnology, USA) and a goat anti-mouse IgG2a-HRP (sc-2005; Santa Cruz 
Biotechnology, USA) were used as primary and secondary antibodies, respectively. 
GAPDH was used as a control for protein loading. In the antibody staining step, milk 
protein (in 5% non-fat milk in wash buffer (Tris-buffered saline (TBS, 10mM Tris, 
150 mM NaCl, pH 8.0) with 0.1% Tween20) was applied to block non-specific binding 
sites.  
2.2.4 Cell culture and differentiation of multipotent haematopoietic progenitors 
from human WAS-iPSCs via “iPS-sacs” 
 OP9 stromal cells (as feeder cells in a co-culture system) were treated with 
mitomycin and plated onto gelatin-coated 10-mL dishes. Small clumps of human 
WAS-iPSCs (suspended in PBS containing 0.25% trypsin, 1 mM CaCl2 and 20% 
knockout serum replacement) were transferred onto OP9 cells and cultured in iPSC 
differentiation medium (Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 10 μL/mL, Insulin/ transferrin/ selenite (ITS) 100x stock solution, 
2 mM L-glutamine, 0.45 μM α-Monothioglycerol (MTG), 50 μg/mL ascorbic acid and 
15% fetal bovine serum (FBS)), which was refreshed every 3 days. For the first 7 days, 
iPSCs were cultured under hypoxic conditions, to allow the generation of 
haematopoietic stem cells in the form of induced pluripotent stem cell–derived sacs 
(iPS-sacs). On day 14 to 15 of culture, iPS-sacs were collected into a 50-mL tube, 
gently crushed with a pipette, and passed through a 40-μm cell strainer to obtain 
haematopoietic progenitors (126,127). 
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2.2.4.1 Flow cytometry analysis 
Progenitor cells isolated from iPS-sacs were stained with allophycocyanin 
(APC)-conjugated anti-human CD34 (BD Biosciences, USA) and Peridinin 
Chlorophyll Protein Complex (PerCP)–conjugated anti-human CD45 (BD 
Biosciences, USA) for haematopoietic cell analysis on day 14 of differentiation. 
Stained cells were analysed by using BD FACSAria II (Becton Dickinson, Franklin 
Lakes, USA).  
2.2.4.2 iPS-sac formation and terminal differentiation to mature 
neutrophils  
 iPSCs were dissociated into small clumps of approx. 100 cells using 
collagenase, which were then transferred onto mitotically-activated OP9 cells in a 
haematopoietic cell differentiation medium (IMDM supplemented with a cocktail of 
10 μg/mL human insulin, 5.5 μg/mL human transferrin, 5 ng/mL sodium selenite, 2 
mM L-glutamine, 0.45 mM α-monothioglycerol, 50 μg/mL ascorbic acid, 15% FBS 
and 20 ng/mL human vascular endothelial growth factor (VEGF; R&D Systems, 
USA)). The sac-like structures, called iPS-sacs, were observed 5 - 7 days after seeding. 
At 14 days, the sac membrane was gently opened by a pipette and the contents were 
filtered through a 40-μm cell strainer to discriminate haematopoietic progenitors from 
the membranous structure which was discarded.  
The haematopoietic progenitors were transferred onto newly mitomycin-
treated OP9 cells, with terminal differentiation medium (IMDM supplemented with 
10% FBS, 0.1 mM 2-mercaptoethanol, 100 U/mL penicillin, 100 µg/mL streptomycin, 
and 50 ng/mL granulocyte colony-stimulating factor (G-CSF)). The culture medium 
was replaced with fresh medium on day 3. This terminal differentiation phase was 
continued for 6 - 7 days. 
2.2.5 Neutrophil morphology (128,129)  
Cell morphology and granule characteristics of iPSC-derived neutrophils were 
assessed by Wright-Giemsa staining, in particular examining nuclear morphology 
(multi-lobed nucleus) and granular cytoplasm. Myeloperoxidase and alkaline-
phosphatase staining were performed by immunohistochemistry.  
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2.2.6 Functional studies of mature neutrophils (128,129)  
Chemotaxis assay: Neutrophil chemotaxis was determined using a modified Boyden 
chamber method. First, 800 µL of the reaction medium (RPMI-1640, Thermo Fisher 
Scientific, USA) with or without 0.01 μM formyl-Met-Leu-Phe (fMLP) was placed 
into each well of a 24-well plate. A cell culture hanging insert (3.0-µm pores) was use 
to separate the well into upper and lower chambers (Figure 2.3). Neutrophils were 
suspended in reaction medium at 5 X 106 cells/mL and 200 µL cells (1 X 106 cells) 
were added to the upper well. After 120 min incubation at 37 °C to allow the migration 
of neutrophils, the number of neutrophils that migrated through the membrane were 
counted using a microscope with a high-power lens (X400) in 3 different fields 
selected at random. The percentage of migrating cells were calculated using the 
following equation: 
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 Figure 2.3: Schematic diagram of chemotaxis assay. 106 neutrophils were 
placed in the upper chamber, in either the presence (experiment) or absence (negative 
control, to observe random migration) of 0.01 μM fMLP in lower chambers. The upper 
and lower chambers were created by placing a 3.0-μm hanging insert into each well. 
After 120 min, the cells in both chambers were counted using a haemocytometer. 
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2.3 Culture and Differentiation of Myeloid Cell Lines 
2.3.1 Differentiation of PLB-985 cells towards neutrophils 
Exponentially growing PLB-985 cells, were seeded at a concentration of 2 × 
105 cells/mL, and cultured in either differentiation medium or maintenance medium. 
The maintenance medium comprised RPMI-1640/glutamine medium with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin, while in the differentiation 
medium, FBS concentration was decreased to 5% plus the addition of the following 
differentiating agents: 0.5% N,N-dimethyl formamide (DMF), 1% sodium pyruvate 
and 0.1 µM all-trans retinoic acid (ATRA). 
 The cells were analysed twice daily for 5 continuous days to assess cell density, 
morphology and viability.  
2.3.2 Differentiation of KCL-22 cells towards neutrophils 
 Exponentially growing KCL-22 cells, at a concentration of 2 × 105 cells/mL, 
were cultured in either differentiation medium or maintenance medium. The 
maintenance medium consisted of RPMI-1640/glutamine medium with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin, while in the differentiation 
medium, FBS was decreased to 5% with the addition of differentiating agents 
including 0.5% N,N-dimethyl formamide (DMF), 1% sodium pyruvate and 0.1 µM 
all-trans retinoic acid (ATRA). Different differentiation media and culture conditions 
were tested (see Table 2.3) to determine the conditions that resulted in optimal 
differentiation into neutrophil-like cells.  
 The cells were collected once daily for 7 continuous days to assess cell density, 
morphology and viability. (see Section 2.3.3; 2.3.4)   
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Table 2.3: Culture conditions used to optimise the differentiation of KCL-
22 cells to neutrophils 
Conditions Differentiation media Media changed 
Differentiation media 1 RPMI-1640/glutamine medium + 
5% FBS + 0.5% DMF + 1% 
sodium pyruvate + 0.1 µM ATRA 
No 
Differentiation media 2 RPMI-1640/glutamine medium + 
5% FBS + 0.5% DMF + 1% 
sodium pyruvate + 0.1 µM ATRA 
Day 2 and 5 
Differentiation media 3 RPMI-1640/glutamine medium + 
5% FBS + 0.5% DMF + 1% 
sodium pyruvate + 0.1 µM ATRA 
+ 5 ng/mL GM-CSF 
Day 2 and 5 
Differentiation media 4 RPMI-1640/glutamine medium + 
5% human AB serum + 0.5% DMF 
+ 1% sodium pyruvate + 0.1 µM 
ATRA  
Day 2 and 5 
Differentiation media 5 RPMI-1640/glutamine medium + 
5% FBS + 0.5% DMF + 1% 
sodium pyruvate + 0.1 µM ATRA 
+ 1.2% DMSO 
Day 2 and 5 
(Abbreviations: FBS = Fetal bovine serum, DMF = N,N-dimethyl formamide, 
ATRA = All-trans retinoic acid, DMSO = Dimethyl sulfoxide, GM-CSF = 
Granulocyte Macrophage-colony stimulating factor) 
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2.3.3 Morphological studies and nuclear characteristics 
 105 cells were prepared for microscopy using a cytospin. Rapid Romanowsky 
staining was used to visualise nuclear morphology and sub-cellular components. Using 
morphological criteria, cells were categorised into three groups in accordance with 
their nuclear, cytoplasmic and granular appearance, as follows: non-differentiated cells 
(mononuclear cells with deep blue cytoplasm and no granules); partially-differentiated 
cells (partially-segmented nucleus with light blue or pink cytoplasm and no granules); 
differentiated cells (polysegmented nucleus with pink cytoplasm, with or without 
granules) (Table 2.4; Figure 2.4).  
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Table 2.4: Morphological criteria for differentiated PLB-985 and KCL-22 
cells 
 Non-differentiated 
cell 
Partially 
differentiated cell 
Differentiated cell 
Nucleus Mononuclear Partially 
segmented nucleus 
or Band form 
Polysegmented 
Cytoplasm Deep blue Light blue/ pink Pink 
Cytoplasmic 
granule 
None None  Appearance of 
granules 
 
 
Figure 2.4: Morphological criteria for differentiated PLB-985 and KCL-
22 cells. The cells are classified into three groups: A) Differentiated cells, B) Band 
form/Segmented/Partially differentiated cells and C) Non-differentiated cells. 
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2.3.4 Cell count and cell viability 
Cell viability was evaluated by flow cytometry using Guava ViaCount® 
reagent (Merck Millipore, USA). This commercial reagent comprises two DNA-
binding dyes: a nuclear stain (membrane permeable) and a viability stain (impermeable 
to live cells). It is capable of distinguishing viable, apoptotic and dead cells, based on 
differential permeabilities of the DNA-binding dyes. Dead cells exhibit high 
fluorescence with the viability stain, while apoptotic cells exhibit medium 
fluorescence and viable cells do not stain with this dye. The nuclear stain shows high 
fluorescence for all three groups of cells. Cell debris is excluded by gating out cells 
that stain negatively with the nuclear dye.  
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2.4 Sub-cloning Mcl-1:EGFP cDNA into pLVX-TetOne-Puro 
system and the transduced PLB-985 cells 
2.4.1 Isolating Mcl-1:EGFP cDNA from the pEGFP-C3 vector 
The Mcl-1 gene was originally cloned into the pEGFP-C3 vector and ligated 
into the pEGFP-C3 vector between the restriction sites, HindIII and BamHI. The Mcl-
1 and EGFP sequences were amplified from the original vector, pEGFP-C3 by PCR, 
using primers that were designed to be used with the linearised pLVX-TetOne-Puro 
vector. The 5΄ end of the primers contained the 15 bases complementary to the specific 
linearisation sites (Bold letters in Table 2.5) on the linearised vector and the 3΄ end of 
the primers must contain sequences of 18 - 25 bases specific to the Mcl-1:EGFP cDNA 
(Table 2.5). Because the pLVX-TetOne-Puro vector did not contain complimentary 
cloning sites, a EcoRI site was engineered into the Mcl-1:EGFP cDNA using the 
primers (Bold and Italic letters in Table 2.5). The GC-content of the primers was 
between 40 – 60%, giving the primers a melting temperature of 58 - 65 oC ± 4 oC. 
Table 2.5: The primers used to obtain the Mcl-1:EGFP sequences for 
cloning into pLVX-TetOne-Puro vector. Restriction sites in the primers are shown 
in Bold and Italic. 
Primers Sequences (5΄3΄) 
Forward CCCTCGTAAAGAATTCATGGTGAGCAAGGGCGAGGAG  
Reverse GAGGTGGTCTGGATCCTCTTGCCACTTGCTTTTCTGGCTA 
2.4.2 Cloning the Mcl-1:EGFP cDNA into the pLVX-TetOne-Puro system using 
In-Fusion HD® (Clontech, USA) 
After amplification, the PCR products contained restriction sites for EcoRI 
(GAATTC) and BamHI (GGATCC) which were essential for the subsequent cloning of 
the Mcl-1:EGFP construct into the pLVX-TetOne-Puro system using In-Fusion HD 
(Clontech, USA). The PCR products were amplified using CloneAmpTM DNA 
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polymerase, and the size of the product (1,937 bp for Mcl-1:EGFP chimera) verified 
on an agarose gel. The PCR products were isolated by gel purification. At the same 
time, the pLVX-TetOne-Puro vector was linearised by double restriction enzyme 
digestion (EcoRI-HF and BamHI-HF) (New England BioLabs (NEB) Inc., USA). 
Using the online programme, Double Digest Finder (From: http://www.neb.com/tools-
and-resources/interactive-tools/double-digest-finder, NEB Inc., USA) the optimal 
restriction endonuclease conditions were determined as: 10 units of each restriction 
enzyme, 1 µg Mcl-1:EGFP PCR product, 5 µL 10X CutSmart® Buffer and dH2O to 
give a total reaction volume of 50 µL. The mixture was incubated at 37 °C for 6 h. The 
linearised vector was verified on an agarose gel and purified (gel purification) for the 
next In-Fusion cloning step on the same day. 
To clone the Mcl-1:EGFP gene (1,937 bp) into the pLVX-TetOne-Puro vector 
(9,227 bp), a 3:1 molar ratio of insert:vector was used, with the minimal amount of 
linearised vector as 10 ng (Figure 2.5). Therefore, the amount of Mcl-1:EGFP DNA 
was 6.3 ng. To set up the In-Fusion cloning reaction, 2 μL of 5X In-Fusion HD Enzyme 
Premix, 10 ng of linearised pLVX-TetOne-Puro vector (9,227 bp) and 6.3 ng of Mcl-
1:EGFP PCR product were mixed with dH2O to a total reaction volume of 10 μL. The 
reaction was incubated at 50 °C for 15 min and immediately placed on ice. After an 
overnight incubation at 4 °C, the reaction mixture was ready to transform competent 
cells. 
 
Figure 2.5: Formula for calculating the amounts of insert and vector for 
efficient ligation 
2.4.3 Transforming competent cells to transfect with the pLVX-TetOne-Puro 
vector 
2.5 μL of the In-Fusion HD cloning reaction was used to transform Stellar 
competent cells (ClonTech, USA). The competent cells were thawed on ice (approx. 
20 - 30 min). 2.5 μL of the ligation mixture was added into 50 μL of competent cells 
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in a 1.5 mL centrifuge tube. Then, the competent cell/In-Fusion cloning reaction 
mixture was placed on ice for 20 - 30 min. The mixture was immediately heated shock 
at 42 oC for 45 s, then was put on ice for 2 min. 500 μL of pre-warmed Super Optimal 
broth with Catabolite repression (SOC) medium was added into the mixture and 
incubated at 37 oC for 45 min with shaking. The transformation mixture was spread 
onto a 10-cm Luria-Bertani (LB) agar plate containing 100 μg/mL ampicillin to select 
for transformants. 
2.4.4 Sequence analyses of the Mcl-1:EGFP in pLVX-TetOne-Puro vector 
 Two primers were designed to cover the junctional area (between the insertion 
and the vector) and the Mcl-1 gene (Figure 5.6). The first primer to cover the junctional 
area was designed to confirm the Mcl-1 in conjunction with EGFP genes in the vector. 
The second primer was designed to sequence the Mcl-1 gene, to confirm the presence 
and the correctness of the Mcl-1 gene in the vector (Table 2.6). After PCR, the products 
were sent for sequencing to Macrogen, Korea. The interpretation of Sanger sequencing 
was described in details in Chapter 5. 
Table 2.6: The primers used to confirm the sequence of the Mcl-1:EGFP 
in pLVX-TetOne-Puro vector   
 Sequence (5΄  3΄) 
Primer to sequence the junctional area TATGCAGACTTTACTCCCT 
Primer to sequence the Mcl-1 gene GAGGTCCCCGACGTCACC 
2.4.5 Production of lentiviral supernatants using Lenti-X Packaging Single Shots 
(VSV-G) (Clontech, USA) 
4 – 5 x 106 Lenti-X 293T cells (a subclone of human embryonic kidney (HEK) 
293T cell line that is highly transfectable and facilitates high-level viral protein 
expression), seeded in 10-cm plate with 8 mL of growth media (90% Dulbecco's 
Modified Eagle's Medium (DMEM) with 10% FBS), were incubated at 37 °C, 5% CO2 
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for 24 h before transfection. 7.0 μg of the lentiviral vector plasmid DNA was diluted 
in 600 μL sterile water, and mixed by vortexing. The diluted DNA was added in a tube 
of Lenti-X Packaging Single Shots (Clontech, USA), and the tube was vortexed at a 
high speed for 20 s. The mixture was incubated for 10 min at room temperature to 
allow the formation of nanoparticle complex, then centrifuged at 500 g for 2 s. The 
nanoparticle complex solution were gently dropped on the Lenti-X 293T cell culture, 
with 80% confluence. The cells were incubated at 37 °C supplied with 5% CO2. After 
4 h, 6 mL of fresh complete growth medium was added and incubated for an additional 
24 - 48 h. At 48 h after the transfection, the lentiviral supernatant was collected, and 
centrifuged at 500 g for 10 min, to remove the cell debris. The lentivirus production 
was now ready to transduce target cells, PLB-985 cells, or stored at –80°C for the 
transduction.  
Before the transduction, the viral titre was determined to adjust the multiplicity 
of infection (MOI) for the proper transduction conditions. The Lenti-X p24 Rapid Titre 
Kit (Clontech, USA) was performed to quantify the viral titre. Briefly, lentiviral (HIV-
1) p24 core protein in packaging cell supernatants is bound to wells of a microtitre 
plate coated with HIV-1 p24 capture antibody. The presence of bound p24 in the wells 
is detected using a biotinylated secondary anti-p24 antibody, a streptavidin-
horseradish peroxidase conjugate, and a color-producing substrate. Quantitation was 
performed by comparing test samples to a p24 standard curve. 
2.4.6 Transduce PLB-985 cells with pLVX-TetOne-Puro vector 
PLB-985 cells, at 70 - 80% confluence, were cultured in RPMI-1640 with 10% 
FBS before the transduction. Polybrene was added to the cell culture to obtain the final 
concentration of 4 μg/mL. The PLB-985 cells were transduced at an MOI of 1-10, and 
make sure that the total volume of viral supernatant, Mcl-1:EGFP in pLVX-TetOne-
Puro lentiviral stock was less than 1/3 the culture medium. The cultures were 
centrifuged at 1,200 g for 90 min at 32 °C to improve transduction efficiency. After 8 
- 24 h, the virus-containing medium was discarded and the fresh growth medium was 
added.  
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2.4.7 Clonal selection of PLB-985 cells transduced with Mcl-1:EGFP in pLVX-
TetOne-Puro vector 
 The transduced PLB-985 cells were cultured in 6 well-plate containing 
complete growth medium supplemented with 0.1 - 1 μg/mL puromycin. The cultures 
were maintained for 2 weeks with the antibiotic replacement every 48 h, the 
puromycin-resistant clones were selected. The clonal selection was performed by a 
serial dilution in a 96 well-plate. 
2.4.8 Confirmation of expression in cells using flow cytometry and fluorescent 
microscopy 
 Approximately 20 clones of transduced PLB-985 cells were added with 100 
ng/mL doxycycline to induce gene expression. Mcl-1 was tagged with EGFP gene, 
therefore, the gene expression was confirmed by the combination of the visualisation 
by a fluorescent microscopy and the flow cytometry detection of a green fluorescence. 
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2.5 Methods: Metabolomics 
2.5.1 Neutrophil Isolation  
The study of neutrophils from healthy control was approved by the University 
of Liverpool Committee on Research Ethics, and the study of neutrophils from RA 
patients was approved by the NRES Committee North West (Greater Manchester 
West, UK). All participants gave written, informed consent. Whole blood was 
collected into lithium-heparin vacutainers (the use of EDTA as an anticoagulant was 
avoided because extra resonance signals can be observed in the NMR spectrum via the 
formation of complexes between EDTA and the Ca2+ and Mg2+ ions that are present 
in plasma) (130), and neutrophils were isolated within 15 min of blood collection. 
HetaSep solution (STEM CELL Technologies, USA) was added to the blood at a ratio 
of 1:5 (i.e. 1 mL HetaSep to 5 mL blood), then mixed and incubated at 37 oC for 30 
min, to aggregate the erythrocytes. The erythrocyte-free phase containing all nucleated 
blood cells was collected, and carefully layered on top of Ficoll-Paque solution (GE 
Healthcare, USA) at a ratio of 1:1, and then centrifuged at 500 g for 30 min. The 
peripheral blood mononuclear cells (PBMC) layer, plasma, and Ficoll-Paque solution, 
were carefully removed, leaving a pellet of polymorphonuclear (PMN) cells (> 97% 
neutrophils). The PMN pellet was resuspended in RPMI-1640 media with 25 mM 
phosphate buffer pH 7.4. Note that the use of HEPES was avoided because it interferes 
with the NMR signal. Ammonium chloride solution (8.02 g NH4Cl (ammonium 
chloride), 0.84 g NaHCO3 (sodium bicarbonate) and 0.37 g EDTA 
(ethylenediaminetetraacetic acid, disodium) in 1 L Millipore H2O) was added to the 
media at a ratio of 1:9 (i.e. 1 mL RPMI-1640 media to 9 mL ammonium chloride) to 
lyse the remaining erythrocytes. The mixture was left at room temperature for 3 min, 
and then centrifuged at 400 g for 3 min. The supernatant was removed, and the PMN 
pellet was then suspended in RPMI-1640 with 25 mM phosphate buffer pH 7.4 for 
further analyses. 
2.5.2 Neutrophil metabolomics in response to stimulation  
 Neutrophils, at 2 – 10 x 106 cells/mL, were divided into two groups: one group 
was incubated with PMA (100 ng/mL), while the other was untreated and served as a 
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control. The cells at baseline were collected first at 0 h (time zero, no additions) and 
then at 5 and 15 min afterwards. All samples were collected as technical triplicates.  
2.5.3 Sample preparation for intracellular metabolite extraction 
After incubation as described above, neutrophils were centrifuged at 1,000 g, 
at room temperature for 2 min. The supernatants were collected and heated at 100 oC 
for 1 min (to inhibit any further reactions), and then snap-frozen in liquid nitrogen. 
The cell pellets were resuspended with cold PBS, then centrifuged at 1,000 g, at room 
temperature for 2 min. The supernatant was discarded, and the pellets were heated at 
100 oC for 1 min (to inhibit any further reactions), and then were snap-frozen in liquid 
nitrogen. All samples were kept at -80 oC prior to intracellular metabolite extraction. 
2.5.4 Intracellular metabolite extraction 
 Ice-cold solvent solution (50% HPLC grade acetonitrile, 50% double distilled 
water (ddH2O)), was prepared freshly each day. 500 µL of the solution was added into 
the pelleted cells. The cell pellets were sonicated on ice (maximum frequency) in 3 x 
30 s bursts (with 30 s off-period in-between to prevent heating). The samples were 
vortexed for 15 s before centrifugation at 12,000 g for 10 min at 4 oC. The supernatants 
were collected and snap-frozen in liquid nitrogen. The samples were lyophilised at -
55 oC overnight. After this step, lyophilised samples were stored at -80 oC prior to 
NMR analyses. 
2.5.5 Extraction at soluble metabolites (lyophilisation) 
On the day of NMR analyses, the lyophilised samples were extracted. 1 mL of 
extraction buffer was prepared from 898 µL 100% D2O, 100 µL 1 mM sodium 
phosphate pH 7.4 in 100% D2O and 1 µL 100 mM Trimethylsilylpropanoic acid 
(TMSP or TSP) (a chemical compound used as an internal reference in NMR) in 100% 
D2O. 200 µL of this solution was added into the lyophilised samples. The samples 
were centrifuged at 12,000 g for 2 min at room temperature. The supernatants were 
collected and then transferred into 3-mm tubes for NMR analyses.  
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2.5.6 Synovial fluid sample preparation 
Synovial fluid (SF) samples from patients with inflammatory arthritis were 
obtained from Dr. Helen L Wright (Institute of Integrative Biology, University of 
Liverpool), and from patients with osteoarthritis from Dr. Mandy Peffers and Dr. 
James Anderson (Institute of Ageing and Chronic Disease, University of Liverpool). 
RA patients fulfilled the 1987 American College of Rheumatology (ACR) criteria for 
RA (131). Non-RA inflammatory arthritis (IA) patients with joint effusions included 
adults (over the age of 18) with gout/crystal arthropathy (n = 4), reactive arthritis (n = 
2), and n = 1 each of Systemic Lupus Erythematosus (SLE), Juvenile Idiopathic 
Arthritis (JIA), Behçets disease, ulcerative colitis, ankylosing spondylitis, palindromic 
arthritis and inflammatory monoarthritis. RA and IA SF was aspirated into heparinised 
tubes and processed within 1 h. Aliquots of whole SF were centrifuged at 2,000 g for 
5 min and cell-free SF was decanted and frozen at -20°C. The SF samples were thawed 
on ice and 100 μL of SF were aliquoted. 20 μL of 1 M sodium phosphate buffer pH 
7.4 in D2O, 80 μL of H2O and 0.5 μL 1.2 M sodium azide (NaN3, as a preservative) 
were added into the samples. The samples were vortexed for 1 min prior to 
centrifugation at room temperature at 13,000 g for 5 min. 200 μL of the supernatants 
were collected and then transferred into 3-mm NMR tubes for further analyses. 
2.5.7 Spectral acquisition, Quality assessment of NMR spectrum, and Spectral 
analyses 
The samples were analysed using an NMR-based metabolomic method using 
a 700 MHz NMR machine (see Chapter 6 for detailed experiments) 
2.5.8 Statistical analyses  
Principal component analysis is the statistical technique to simplify a set of 
observations. In the principal component analysis (PCA), the directions of the original 
variables were identified as the principal components, new variables, using 
mathematical algorithms (an orthogonal transformation) to decrease the 
dimensionality of the data. Each principal component includes different ranges of 
variance in the original variables (see details in Chapter 6).  
Page 86 of 280 
For the statistical analysis, the spectral data in the peak intensity tables, were 
analysed via the Metaboanalyst® online programme which uses R-based statistics. In 
the time-point experiments, e.g. samples collected at different times after PMA 
treatment), a fold-change analysis was selected. For the spectral data of neutrophils 
from healthy controls and patients with disease, e.g. rheumatoid arthritis, either 
ANOVA or T-test with post-hoc analyses were applied with regards to the number of 
different groups: ANOVA for three groups or more, and T-test to compare two groups. 
The p value for the spectral analyses was set at 0.01. 
2.5.9 Experiments to optimise protocols for neutrophil metabolomics 
2.5.9.1 Optimal neutrophil cell number and the number of scans (NS) 
Different total cell numbers of neutrophils (2.5, 3.5 and 9.7 x 106 cells per 
sample), were analysed using an increasing number of scans (NS), i.e. 128, 256, 512, 
1,024 and 2,048. The number of scans is the number of times that a series of pulse-
detect-wait sequences is repeated in NMR analyses. The increased number of scans 
builds up the total signal intensity, and at the same time, decreases the noise (the 
random signals with no metabolomic interpretation). However, the increased number 
of scans also requires the longer duration of NMR analyses, for example 15 min for 
NS of 128 and 4 h for NS of 2,048. The PCA was then performed to determine the 
reproducibility of data spectra in each experiment. 
  2.5.9.2 Quenching neutrophil metabolism: Heating neutrophils prior to 
the snap freezing 
 107 healthy neutrophils were collected either with or without a heating step 
prior to the collection of cell pellet (in Section 2.5.3). The heating step was the brief 
exposure of cell pellet to 100 oC heat for 1 min, immediately before the snap-freezing 
step. The following steps of intracellular extraction and lyophilisation were similarly 
processed. The spectral data analyses were evaluated, in order to detect the similarity 
of data, including the number of detected metabolites, between two groups.   
2.5.9.3 Minimising the centrifugation times and metabolite loss during the 
extraction 
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 Normally, neutrophil suspensions (1 - 2 mL) are centrifuged at 4,000 g for 3 
min. However, in the metabolomic studies, a minimal isolation and processing time 
was required to increase the chances of metabolite collection and decrease the chances 
for metabolite loss. 
 Two cell concentrations, 2.5 x 106 and 107 neutrophils per 1 mL media (RPMI-
1640), were collected and centrifuged at 4,000 g for either 2 or 3 min. The size of the 
pellets was visually compared. 
2.5.10 Experiments to determine any loss of NADP+ during sample preparation 
for NMR 
 Purified NADP+ (Sigma Aldrich, USA) was added into the samples under 
three different conditions. First, 10 μg NADP+ were added into the cell pellets of 9.7 
x 106 neutrophils before the heating steps. The cell pellets then went through the 
intracellular extraction and lyophilisation procedures. Second, 10 μg NADP+ was 
added into the PBS (no cell pellets). The mixture, NADP+ and PBS, was then heat 
shocked, and extracted and lyophilised. Third, 20 μg NADP+, without any processing, 
was analysed as a positive control. 
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CHAPTER 3 MSCs AND DIABETIC WOUND HEALING 
Use of MSCs to accelerate wound healing in diabetic nude mice 
and role of exogenous vitamin C 
3.1 Introduction 
In diabetes mellitus, chronic hyperglycaemia alters the wound 
microenvironment (38), leading to delayed and impaired wound healing. The 
inflammatory response in the diabetic wound is prolonged, therefore, dysregulates the 
wound healing phases in diabetes mellitus. Patients with diabetic wound have 
increases the risk of infections, and sometimes amputations. However, current 
approaches to wound healing fail to recognise the underlying pathophysiology in 
diabetic wounds. New approaches are therefore needed to address the problem of non-
healing of chronic wounds to prevent morbidity and mortality, particularly in diabetic 
patients. 
In this study, we utilised both in vitro and in vivo wound healing models to 
investigate the effects of vitamin C on MSC function during wound healing under 
hyperglycaemic conditions. We identified vitamin C as a factor that enhances MSC 
functions under hyperglycemic conditions, and propose that this small molecule may 
be therapeutically administered simultaneously with MSC treatment, to accelerate 
diabetic wound healing. Our results therefore highlight the beneficial effects of 
administering oral vitamin C to diabetic patients to enhance wound healing.  
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3.2 Aims and objectives 
The aims of the research in this Chapter were to determine the effects of 
hyperglycaemia on the ability of MSCs to generate angiogenic growth factors and to 
determine if the dietary antioxidant, vitamin C had any effect on this function. Another 
aim was to determine if externally applied MSCs would enhance wound healing in 
diabetic or control nude mice and whether orally-administered vitamin C had any 
effect on the properties of the MSCs, in particular in the diabetic mice. The objectives 
therefore were to: 
1. Measure the effects of TGF-β1 on the expression of angiogenic and 
extracellular matrix-producing genes in MSCs incubated under 
normoglycaemia and hyperglycaemia. 
2. To determine the effects of exogenously-added vitamin C on the expression 
of these genes. 
3. To determine if orally-administered vitamin C could accelerate wound 
healing in control and diabetic mice who were also treated with MSCs 
3.2.1 Conceptual framework 
 Figure 3.1: Conceptual framework for the study of MSCs and diabetic 
wound healing  
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3.3 Results 
3.3.1 Upregulated expression of mVEGF-α, mPDGF-BB, mFN-1 and mTNC in 
MSCs cultured in the presence of TGF-β1  
The first experiments conducted aimed to study the potential function of BM-
MSCs incubated under experimental conditions that may be present during the wound 
healing process. Transforming growth factor-β1 (TGF-β1) is recognised as a key 
cytokine orchestrating tissue-healing processes (132), including angiogenesis and 
extracellular matrix production (133). Therefore, mRNA expression of BM-MSCs was 
measured after culture for 24 h in the absence and presence of TGF-β1. 
Eight genes that are key regulators during wound healing were investigated 
using quantitative real time RT-PCR. These genes are associated with either 
angiogenesis: (vascular endothelial growth factor-α (mVEGF-α), angiopoietin-1 
(mANGPT-1), platelet-derived growth factor-BB (mPDGF-BB), hepatocyte growth 
factor-1 (mHGF-1)); or extracellular matrix production (insulin-like growth factor-
1 (mIGF-1), fibronectin-1 (mFN-1), stromal cell-derived factor-1 (mSDF-1), tenascin 
C (mTNC)). It was found that mRNA expression levels of four genes (mVEGF-α, 
mPDGF-BB, mTNC and mFN-1) were upregulated in BM-MSCs in the presence of 
TGF-β1 (Figure 3.2). Increased expression of these genes could potentially play a role 
in wound healing.  
Page 91 of 280 
 
Figure 3.2: Effects of TGF-β on expression of angiogenic and extracellular 
matrix genes in MSCs. MSCs (seeded at 104 cells/well) were incubated in the absence 
(MSCs CON) or presence of TGF-β1 (MSCs+TGF-β1) at 20 ng/mL for 24 h. RNA 
was then isolated and quantitative real time RT-PCR was used to quantify expression 
of eight genes associated with either angiogenesis: vascular endothelial growth 
factor-α (mVEGF-α); angiopoietin-1 (mANGPT-1); platelet-derived growth factor-BB 
(mPDGF-BB); hepatocyte growth factor-1 (mHGF-1); or extracellular matrix 
production: insulin-like growth factor-1 (mIGF-1); fibronectin-1 (mFN-1); stromal 
cell-derived factor-1 (mSDF-1); tenascin C (mTNC). Expression levels were 
normalised to those of the house-keeping gene, glyceraldehyde-3-phosphate 
dehydrogenase (mGADPH). Values presented are means (± SD, n = 3) and * indicates 
a p value ≤ 0.05. BLACK bars = MSCs CON; GREY bars = MSCs+TGF-β1. 
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3.3.2 Decreased mVEGF-α mRNA expression in TGF-β1-treated MSCs cultured 
under high glucose conditions  
As high glucose concentrations can adversely affect MSC proliferation 
(54,134,135), their differentiation capacity and secretion of paracrine factors (135), it 
was investigated whether exposure of cultured MSCs to high glucose concentrations 
could affect expression of these TGF-β1-upregulated genes. MSCs were cultured in 
either normal or high glucose levels to observe any effects of prolonged high glucose 
exposure on expression of these genes. To ensure that the cells had sufficient time to 
become conditioned to the effects of prolonged hyperglycaemia, MSCs were cultured 
in high glucose media (α-MEM, 20% FBS, and 55.56 mmol/L (1,000 mg/dL) D-
glucose) for at least 1 month prior to these experiments. Cell count at day 1, 3 and 5, 
was decreased by ~30% compared to when cells were cultured under normal glucose 
concentrations (data not shown). The decreased cell count could result from either 
increase in apoptosis or decrease in proliferation. Figure 3.3 shows that mRNA 
expression of a key angiogenic cytokine, mVEGF-α, which was upregulated under 
normal glucose conditions by TGF-β1 (Figure 3.3), was significantly decreased in 
MSCs cultured in hyperglycaemic media (Figure 3.3 i, p value ≤ 0.05). 
Hyperglycaemia also partially blocked TGF-β1 upregulation of mPDGF-BB (p value 
= 0.06), but had little effect on TGF-β1 upregulation of mFN-1 or mTNC (Figure 3.3 
ii-iv).  
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Figure 3.3: Effects of high glucose and vitamin C on TGF-β1-regulated 
mRNA expression of MSCs. MSCs CON and MSCs+TGF-β1 were incubated as 
described in the legend to Figure 3.2. All TGF-β1 cultures contained 20 ng/mL of 
TGF-β1. In the vitamin C treatment groups (VitC and VitC+TGF-β1), vitamin C 50 
μg/mL was added into the culture media. MSCs were incubated in either 
normoglycaemic or hyperglycaemic conditions. After 24 h incubation, mRNA 
expression of the 4 genes regulated by TGF-β1 (mVEGF-α, mPDGF-BB, mFN-1 and 
mTNC) was analysed qPCR. Expression levels were normalised to those of the house-
keeping gene, mGADPH. Values presented are means (± SD, n = 3) and * indicates a 
p value ≤ 0.05. Abbreviations; CON = control group (no treatment), TGF-β1 = MSCs 
cultured in the presence of 20 ng/mL of TGF-β1, plus 50 μg/mL of vitamin C (VitC+ 
TGF-β1), and VitC = MSCs cultured in the presence of 50 μg/mL of vitamin C. 
BLACK bars = Normoglycaemia; GREY bars = Hyperglycaemia 
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3.3.3 Vitamin C reverses the hyperglycaemic suppression of TGF-β1 regulation 
of mVEGF-α and mPDGF-BB expression  
To investigate whether vitamin C could reverse the suppressive effects of 
hyperglycaemia on TGF-β1 induced mVEGF-α or mPDGF-BB expression, MSCs 
were incubated in the absence and presence of vitamin C (50 μg/mL), which was added 
to the culture media for at least two weeks before quantifying gene expression levels. 
In human small intestine, oral ascorbic acid is absorbed via active transport (using 
Sodium-Ascorbate Co-Transporters (SVCTs) and Hexose transporters (GLUTs)) and 
simple diffusion, and enter the circulation in form of ascorbic acid (136). The addition 
of vitamin C had little effect on expression levels of mVEGF-α, mPDGF-BB, mFN-1 
and mTNC mRNA of control MSCs incubated under either normoglycaemic or 
hyperglycaemic conditions (Figure 3.3 i-iv). However, vitamin C reversed the 
inhibitory effect of hyperglycaemia on TGF-β1-induced mVEGF-α and mPDGF-BB 
expression (Figure 3.3 i-iv, p ≤ 0.05). In the presence of vitamin C under 
hyperglycaemia, levels of expression of these two genes were equivalent to those 
observed under normoglycaemia. 
3.3.4 Effect of hyperglycaemia on the secretion of angiogenic cytokines into the 
culture medium of MSCs 
In MSCs cultured under prolonged hyperglycaemic conditions, mRNA 
expression of two TGF-β1-regulated angiogenic cytokines (mVEGF-α and mPDGF-
BB) was decreased (Figure 3.3). Therefore, a tubular formation assay by HUVECs was 
used to measure the presence of angiogenic factors secreted into conditoned medium. 
Figure 3.4 shows that HUVEC medium (Figure 3.4 i), but not basal medium (Figure 
3.4 ii) induced tubular formation in HUVECs that may be attributable to the presence 
of angiogenic factors in the former, but not in the latter medium. While conditioned 
medium from MSCs incubated under normoglycaemic and hyperglycaemic conditions 
could both induce tubular formation (measured by area density and tubular length), 
this activity was significantly impaired in conditioned medium from MSCs incubated 
in hyperglycaemic conditions (Figure 3.4 iii, iv, Figure 3.5 A-D). Tubular length 
(Figure 3.5 A), tubular area (Figure 3.5 B), number of branch points (Figure 3.5 C), 
but not thickness (Figure 3.5 D) were all decreased after culture of HUVECs with 
conditioned medium from MSCs cultured under hyperglycaemic conditions. These 
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data strongly suggest that long term culture under hyperglycaemia greatly decreases 
the secretion of angiogenic factors by MSCs.   
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Figure 3.4: Angiogenic effects of conditioned medium from MSCs 
cultured under normoglycaemic and hyperglycaemic conditions. MSCs were 
cultured for 24 h in normoglycaemic (NormoCM) or hyperglycaemic (HyperCM) 
conditions, and conditioned medium was collected. A shows images of HUVECs 
incubated for 6 h in the presence of Endothelial Cell Growth medium (HUVEC 
medium, Lonza, USA) (i), basal (fresh) medium (used as a positive control), (ii) or 
conditioned medium from MSCs cultured for 24 h in normoglycaemic (iii) or 
hyperglycaemic (iv) media.  
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Figure 3.5: The effects of HUVEC medium on tubular formation. The 
measurements of tubular length (A), tubular area (B), number of branch points (C) and 
branch thickness (D) are shown. Values shown are means (n = 3) ± SD and * represents 
a p value of ≤ 0.05. (Abbreviations: HyperCM, Conditioned media derived from 
MSCs cultured under hyperglycaemia; NormoCM, Conditioned media derived from 
MSCs cultured under normoglycaemia).  
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3.3.5 Effects of vitamin C on wound closure  
The effects of vitamin C and MSCs in a wound healing model of normal and 
induced-diabetes mellitus mice were then measured. In these experiments, vitamin C 
was orally administered to synergise the effects of topical MSC treatment in this 
diabetic wound model in vivo. STZ was used to induce diabetes mellitus in BALB/C 
nude mice which was confirmed by measuring tail-venous plasma glucose level (≥ 
11.11 mmol/L (200 mg/dL)) at least twice prior to the wounding experiments. In these 
studies, the wound was stretched by tegaderm to cover 1 cm of normal skin around the 
wound to decrease the possibility of wound contraction, and thus to ensure that closure 
occurred by wound healing as a result of re-epithelialisation. In control (non-diabetic) 
mice (CON), wound healing was observed by 7 days (Figure 3.6; 3.7 A) and was 
approx. 87% complete by 14 days (Figure 3.6; 3.7 B). The rate of wound healing was 
significantly decreased in diabetic mice (DM) after both 7 and 14 days post-wounding 
and the topical administration of MSCs or supplementation of the diet with vitamin C, 
both significantly increased the rate of wound healing in the diabetic mice at both 7 
and 14 days, to levels equivalent to those of healthy mice (CON). By 7 days post 
wounding, the combined effects of MSCs and vitamin C on diabetic mice did not 
enhance healing compared to the effects of MSCs or vitamin C used alone (Figure 3.6; 
3.7 A), but by 14 days the rate of healing in the dual-treated diabetic mice (MSCs plus 
vitamin C) was greater than that observed with either agent alone (Figure 3.6; 3.7 B).  
 Histopathological studies confirmed that wound healing resulted from re-
epithelialiasation rather than wound contraction, in every group of animals (example 
section shown in Figure 3.7 C). 
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Figure 3.6: Vitamin C as adjunct therapy for MSC treatment of diabetic 
wounds in vivo. Wound healing was followed in five study groups of nude mice; 
wounded control (CON; n = 6); wounded diabetes mellitus (DM; n = 12); wounded 
diabetes mellitus treated with MSCs (DM+MSCs; n = 12); wounded diabetes mellitus 
treated with VitC (DM+VitC; n = 6); and wounded diabetes mellitus treated with 
MSCs and VitC (DM+MSCs+VitC; n = 12). Figure shows representative images of 
wounds from each of the five study groups at day 0, 7 and 14.  
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Figure 3.7: The percentage of wound closure. A and B show percentage 
wound closure (calculated as described in Methods) on day 7 and 14, respectively from 
experiments shown in Figure 3.6 above. * indicates a p value of ≤ 0.05. C shows a 
representative histochemical staining of a wound biopsy showing re-epithelialisation, 
confirming wound healing.  
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3.3.6 Measurement of capillary density during wound healing  
The in vitro studies described above (Figure 3.2; 3.3) showed that vitamin C 
treatment enhanced the expression of two angiogenic cytokines (mVEGF-α and 
mPDGF-BB) after TGF-β1 treatment of MSCs cultured in high glucose. Furthermore, 
the experiments in Figure 3.4, 3.5, 3.6 and 3.7 show that vitamin C used as an adjunct 
therapy to MSCs could accelerate wound closure in diabetic nude mice. The effects of 
vitamin C and MSCs on wound microvasculature as the possible underlying 
mechanism of acceleration of wound healing were therefore determined. At day 7 post-
wounding, vitamin C alone treatment that had significantly enhanced the percentage 
of capillary density in the diabetic mice (Figure 3.8; 3.9 A, B). However, by 14 days, 
the highest levels of capillary density were observed in the diabetic mice treated with 
the combination of MSCs plus vitamin C (Figure 3.8; 3.9 C). This high capillary 
density in these animals correlated with the highest rates of wound closure.  
VEGF protein levels in wound tissues were then measured by ELISA. Tissue 
VEGF levels at day 7 in the control, the diabetic mice treated with MSCs and the 
diabetic mice treated with both MSCs and vitamin C were significantly increased when 
compared to the diabetic group alone (Figure 3.9 A, p value ≤ 0.05). This high tissue 
VEGF level at 7 days after wounding might help explain the mechanism regulating the 
high capillary density and rate of wound healing observed under these conditions.  
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Figure 3.8: Effects of vitamin C and MSCs on vascularisation of wounds. 
Capillary vascularity was determined as described in Methods, 7 and 14 days after 
wound healing. Wound healing conditions were as follows: CON, control group; DM, 
diabetic mice; DM+MSCs, diabetic mice + MSCs; DM + VitC, diabetic mice + 
vitamin C supplementation; DM+MSC+VitC, diabetic mice + MSCs + vitamin C 
supplementation. Figure shows representative images day 7 and 14 after initiation of 
the wounds. 
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Figure 3.9: Effects of vitamin C and MSCs on vascularision of wounds. 
Figure shows % of capillary vascularity at day 7 and 14, respectively of the data shown 
in Figure 3.8. * Indicates a p value of ≤ 0.05. 
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3.4 Discussion 
Current therapeutic procedures for the treatment of diabetic wounds largely 
focus upon preventing infections, rather than specifically aiming to promote wound 
healing. It is widely accepted that wound healing is problematic and delayed in 
diabetes mellitus as a result of elevated levels of glucose concentrations that can delay 
wound closure. Hence, new approaches that can accelerate healing of diabetic wounds 
offer the potential for new therapeutic procedures that both prevent infections and 
decrease the risk of amputations in these patients. In this Chapter, I have shown that 
oral vitamin C supplementation can enhance wound healing following topical MSC 
administration in vivo in animal models of diabetes mellitus. This accelerated wound 
healing was associated with enhanced capillary vascularity. These in vitro studies 
indicate that vitamin C can reverse the hyperglycaemia-induced suppression of TGF-
β1 activated expression of angiogenic factors, which may, at least in part, explain the 
in vivo effects observed in diabetic nude mice.  
In this study, we showed that administration of oral vitamin C and/or MSC 
therapy in diabetic wound model using nude mice, resulted in accelerated wound 
closure, that was detected as early as 7 days post-wounding that was associated with 
increased capillary density. In diabetes mellitus, prolonged exposure to 
hyperglycaemic conditions can impair several key cellular functions, including 
angiogenesis, wound healing and proliferation by mechanisms that include both 
oxidative and non-oxidative stresses (54,137). The excessive ROS production in 
diabetes mellitus, implicated by the formation of advanced glycation end-products e.g. 
HbA1c (glycated haemoglobin) can potentially contribute to those dysregulated 
cellular functions (138). For instance, impaired endothelial progenitor cell (EPC) 
proliferation from diabetic patients correlated with the level of HbA1c (higher HbA1c 
level, less EPC proliferation) (139).  
Previous studies have demonstrated the promising potential benefits of MSC 
treatment in normal cutaneous wound healing that is likely to be associated with MSC 
paracrine signalling which could provide a mechanism that is responsible for new 
vessel formation and resulting wound repair (50,51,61). Similar to other progenitor 
cells, MSCs are regulated by and contribute to signals within their environment that 
can regulate processes involved in homeostasis and proliferation. In diabetes mellitus, 
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MSCs are affected by prolonged exposure to hyperglycaemic conditions, which can 
impair several key functions, including angiogenesis, wound healing and proliferation 
by mechanisms that include both oxidative and non-oxidative stresses (54,137). 
Vitamin C was previously shown to be deficient in diabetic patients (140) and an 
impaired vitamin C metabolism was observed in an animal experimental model e.g. 
STZ-induced diabetic rat (141,142). The oxidised form of vitamin C is transported into 
a variety of mammalian cells via a facilitative glucose transporter, mediated by 
members of the Glucose Transporter (GLUT) protein family (143). Consequently, 
high blood glucose levels can competitively inhibit vitamin C transport into 
mesenchymal cell types (such as fibroblasts) that would normally be participating in 
wound healing, thereby interfering with their cellular functions (144). In previous 
studies, the systemic administration of vitamin C has been shown to improve 
endothelial-dependent vasodilation in diabetic patients, but not in non-diabetic patients 
(145). Given the systemic and intracellular deficiencies of vitamin C that occur in 
diabetic patients, the effects of high glucose on mesenchymal cells may be responsible 
for impaired MSC function and therapeutic benefit in diabetic wounds.  
In our wound model, the wound closure effects were validated as the 
consequences of each therapeutic agent, either single or combinations. Therefore, the 
wound closure in diabetes mellitus was measured in comparison with the control, non-
diabetic wound, to demonstrate the delayed wound healing in diabetes mellitus. 
Moreover, the histopathological studies were perform to confirm the re-
epithelialisation, not wound contraction, as the healing process. 
In the studies shown in this Chapter, therefore, it was hypothesised that oral 
vitamin C supplementation would reverse the hyperglycaemia-induced changes in 
vitamin C metabolism and hence impairment of mesenchymal cell function. This 
hypothesis was based on the fact that that oral vitamin C supplementation may restore 
systemic vitamin C levels and consequently, improve the functions of both exogenous 
and endogenous MSCs. The results show that vitamin C, used as an adjunct to MSC 
therapy, can promote wound closure in vivo and promote vascularisation, and these in 
vitro experiments showed that it could restore the hyperglycaemia-induced 
suppression of expression of angiogenic cytokines by MSCs, which would enhance 
angiogenesis in vivo. It would be interesting to investigate whether vitamin C can 
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modulate the expression of other cytokines in addition to those involved in angiogenic 
pathways or which exert effects other than paracrine effects to facilitate wound healing 
e.g. in the regulation of inflammation. 
Moreover, our diabetic wound model may facilitate the further experiments to 
confirm the hypothesis regarding the possible mechanism of stem cells and vitamin C 
on diabetic wound healing. If the effects of vitamin C are due to its antioxidant effects, 
then other antioxidants may be administered instead of oral vitamin C, and the wound 
closure effects compared. It would also be interesting to determine the effects of other 
antioxidants on gene expression of MSCs in vitro under normoglycaemia and 
hyperglycaemia. This would confirm whether the mechanism of action of vitamin C 
resulted from either its antioxidative activity or other unique properties of vitamin C.  
Given the clinical importance of effective diabetic wound care in the face of 
an ever-increasing rise in the worldwide incidence of diabetes mellitus, these results 
open up new avenues to further explore the use of oral vitamin C in diabetic wound 
treatment. Oral vitamin C is a safe and simple supplement, and if these results are 
replicated in human diabetic patients, the accelerated wound closure time will 
minimise the risks of infection and amputations that are higher in these patients.    
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CHAPTER 4. WISKOTT-ALDRICH SYNDROME (WAS) 
AND PROPERTIES OF WAS NEUTROPHILS 
4.1 WAS and neutrophil defects 
The Wiskott-Aldrich syndrome (WAS) gene encodes the WAS protein (WASp) 
that regulates the actin cytoskeleton in haematopoietic cells. Therefore, the potential 
roles of WASp on neutrophil functions, including cell migration and others, have been 
widely studied, but not yet entirely understood. It would therefore be predicted that 
defective WASp expression would adversely affect neutrophil function and 
differentiation and two types of mutation in this gene have been observed: loss-of-
function mutations in Wiskott-Aldrich syndrome (WAS) and gain-of-function 
mutations in X-linked neutropaenia (XLN), respectively. While WAS patients suffer 
from eczema, microthrombocytopaenia and are prone to infection and bloody 
diarrhoea, they have normal neutrophil counts. In contrast, the distinct pathological 
findings of XLN are low neutrophil counts, susceptibility to infection and 
predisposition to myelodysplasia in the absence of thrombocytopaenia and T-cell 
immunodeficiency. XLN results from an activating mutation in the WAS gene, giving 
rise to a constitutively-active protein (100,146). Neutropaenia is associated with 
haematopoietic maturation arrest at the promyelocyte/myelocyte stage in the bone 
marrow. In normal haematopoietic cells, WASp is ubiquitously expressed from early 
progenitors onwards. WASp function is regulated via an autoinhibitory mechanism. 
The activating mutation compromises normal auto-inhibition of WASp, leading to an 
unregulated activation of the actin-related protein 2/3 (Arp2/3) complex, and increased 
actin polymerising activity (147). Unregulated actin polymerisation by abnormal 
WASp causes defects of mitosis and cytokinesis, resulted in disrupted myelopoiesis 
(147). There are very few instances in which activating and inactivating mutations in 
genes encoding signal molecules cause such distinct hereditary disorders. 
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4.2 Modelling neutrophil defects in genetic disease 
Currently, the two main types of models for used to study human neutrophil-
associated diseases are the use of haematopoietic progenitor cells (or CD34+ cells), 
which can be differentiated in vitro, and peripheral blood neutrophils, which are 
terminally-differentiated. However, neutrophils derived from these sources are 
extremely limited in their usefulness for studies of development and understanding of 
disease mechanisms, due to their short half life in vitro, limited proliferation and low 
abundance. The percentage of CD34+ cells present in different sources is as follows: 
peripheral blood (0.15%), bone marrow (1.68%) and cord blood (0.83%) (148). The 
ability of CD34+ cells to expand and proliferate in vitro is problematic and very 
limited. For these reasons, genetic studies on human neutrophils are extremely 
restricted. Due to the distinct haematopoietic processes in animals, most of the clinical 
or cellular characteristics of human diseases cannot be reproduced exactly in animal 
models (149). In inherited diseases, the same genetic mutation can result in different 
clinical phenotypes and severity in different animal models. For example, the mutation 
of ADAMTS13 (150) gene encoding von Willebrand factor-cleaving protease in 
humans results in congenital thrombotic thrombocytopaenic purpura in human, but 
normal platelet counts in mice. Therefore, the use of animal models for human 
haematopoietic diseases is of limited benefit. In addition, genetic manipulations to 
study the role of specific genes affecting clinical features are difficult, particularly with 
regard to the events regulating human haematopoiesis. The use and limitations of 
cultured cell lines that can be induced in vitro to differentiate into mature blood cells 
(e.g. neutrophils) is discussed in Chapter 5. 
However, neutrophil precursors can proliferate from iPSCs and then be 
induced to differentiate into mature cells in vitro (129,151). The major advantages of 
iPSC technology result from the opportunity to generate disease- or patient-specific 
iPSCs through the reprogramming of somatic cells from patients with specific 
diseases. However, major considerations for the use of iPSCs as disease models of 
genetic neutrophil defects include the development of effective methods for 
differentiating iPSCs into mature neutrophils, and to ensure that the properties of 
iPSC-derived neutrophils (iPSC-Neu) match those of mature, peripheral blood 
neutrophils (106). Furthermore, while both genetic and environmental factors may 
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contribute to disease mechanisms, only genetic factors can be effectively manipulated 
when iPSCs are used as a disease model. Recently, iPSC-derived neutrophils have 
been used as a disease model in NADPH oxidase-deficient neutrophils in chronic 
granulomatous disease (128). This model was able to validate iPSC-derived 
neutrophils with oxidase deficiency, which mirrored the phenotype of the mature, 
circulating cells.  
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4.3 iPSC as a disease model for WAS neutrophils 
 One of the major roles of WASp is to regulate the actin cytoskeleton in 
haematologic cells. Therefore, in WAS, the absence of WASp may interfere either the 
movement or the functions of haematologic cells that require cytoskeletal re-
arrangements, and thus contribute to the clinical characteristics of WAS patients, 
including bleeding and infection. In WAS patients with the loss-of-function mutation 
of the WAS gene, neutrophil counts are normal, but the major cause of death is from 
bacterial infections. Therefore, WAS neutrophils have been studied to determine their 
functions, in particular chemotaxis (movement of neutrophils in response to 
chemoattractants) as cellular migration is highly dependent on the WASp. However, 
the clinical data from WAS neutrophils remains controversial (89). For example, some 
studies demonstrated chemotactic defects of WAS neutrophils in response to C5a, a 
potent chemotactic agent derived from complement component C5 (95). In these 
studies, all patients had experienced major bacterial infections, and one of them died 
of overwhelming pneumococcal meningitis. In contrast, chemotaxis of WAS 
neutrophils was reported to be normal in response to the chemoattractant, fMLP. 
Interestingly, in peripheral blood neutrophils isolated from XLN patients, neutrophil 
functions, including NADPH-oxidase activation by Fcγ or fMLP receptor ligation, and 
phagocytosis of opsonised bacteria, were reported to be markedly impaired (98). Thus, 
the activating mutation of WAS, resulting in active WASp, also affects neutrophil 
functions.  
  In previous studies, the effects of WASp on neutrophil chemotaxis capability 
are variable from patient to patient. The generation of haematopoietic stem cells (HSC) 
from iPSCs of patients, offers a promising approach to model disease pathology (152). 
However, the differentiated cells must be characterised as morphologically mature 
neutrophils with the same functional properties as the mature cells from the original 
patients. The first steps of this research were to study the effects of WASp on mature 
neutrophil functions in patients attending Chulalongkorn Hospital. Once this was 
achieved, neutrophils derived from WAS-iPSCs could be characterised to demonstrate 
similar defects to neutrophils isolated from WAS patient’s peripheral blood (WAS 
neutrophils). 
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 Thus, this study aimed to determine if neutrophil chemotaxis was defective in 
WAS patients attending Chulalongkorn University Hospital, and further demonstrate 
if similar defects were observed in WAS-iPSC-derived neutrophils, in order to validate 
the usefulness of WAS-iPSCs as a model of human disease.   
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4.4 Aims and objectives 
 The aims of the research in this Chapter were to explore the chemotactic 
functions of WAS peripheral blood neutrophils, which might be responsible for the 
clinical manifestation of proneness to bacterial infection. Another aim was to 
demonstrate the capability of WAS-iPSC-derived neutrophils to differentiate towards 
mature neutrophils, as detected by morphological criteria. The objectives therefore 
were to: 
 1. To measure the chemotactic function of WAS peripheral blood neutrophils. 
 2. To determine if the morphology of corrected WAS-iPSC-derived 
neutrophils after differentiation in vitro. For these experiments, WAS-iPSCs were 
genetically modified in vitro to correct their genetic defect by re-introducing the WAS 
gene. 
4.4.1 Conceptual framework  
 
Figure 4.1: Conceptual framework for the study of Wiskott-Aldrich 
syndrome (WAS) and properties of WAS neutrophils 
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4.5 Experiments using WAS patient peripheral blood neutrophils 
4.5.1 Functional studies  
 Chemotaxis of WAS neutrophils was studied and compared with that of 
healthy controls. Briefly, in this chemotaxis study, neutrophils migrated through the 
3-μm-sized pores towards the chemoattractant, in this case fMLP, which is a 
formylated oligopeptide that is similar to the N-formyl oligopeptides released from 
bacteria. It is a chemoattractant for neutrophils and activates them by binding to 
specific G-protein coupled receptors on their cell surface (153). Using a 24 well-plate 
assay, 3-μm-pore-sized hanging inserts separated the well into upper and lower 
compartments, and the fMLP was added into the lower compartment. 106 cells/200 μL 
were added into the upper chamber, and were allowed to migrate for 120 min. In order 
for the cells to migrate towards the chemoattractant, the cells must first adhere to the 
membrane, undergo actin remodeling, and migrate through the pores that are of a 
smaller diameter than the cell. The chemotaxis study through the transwell migration 
is therefore suitable to evaluate the functions of the neutrophil actin cytoskeleton that 
is reported to be regulated by WASp.  
Neutrophils were isolated from the patient’s whole blood on three separated 
occasions (n = 3). The control neutrophils were isolated from 7 different healthy 
individuals (n = 7). In the chemotaxis assay, the percentage of migrating neutrophils 
were calculated (see Section 2.2.6). The results revealed defective chemotaxis activity, 
in response to fMLP, in WAS neutrophils (mean ± SD, 27.23% ± 7.53, n = 3) in 
comparison to the healthy controls (90.0% ± 7.52, n = 7, p ≤ 0.05) (Figure 4.2). 
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 Figure 4.2: Impaired chemotaxis activity of WAS neutrophils. WAS 
neutrophils shown impaired chemotaxis activity in response to fMLP, a 
chemoattractant, when compared to the healthy controls. Without fMLP, the migration 
of both WAS and healthy neutrophils were minimal (2.0% and 0.8% respectively) and 
resulted from a random movement. In the presence of a chemoattractant, fMLP, the 
migration of WAS neutrophils (27.23% ± 7.53, n = 3) was significantly lower when 
compared to healthy neutrophils (90.0% ± 7.52, n = 7) (mean ± SD, * indicates p ≤ 
0.05). 
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4.6 Experiments with WAS-iPSC-derived neutrophils 
4.6.1 Preliminary data with WAS-iPSCs 
 These preliminary results were obtained by Stem Cell and Cell Therapy 
Research Unit, and Medical Genetics and Metabolism Unit, Department of Paediatrics, 
Faculty of Medicine, Chulalongkorn University. They are presented here to show 
“proof of principle” of the experimental approach used in my studies.  
 This research was designed to study the role of WASp in haematopoiesis and 
thrombopoiesis. WAS-iPSCs were derived from a patient’s dermal fibroblasts, by 
reprogramming using retrovirus transfection techniques. WAS-iPSCs demonstrated 
the ability to generate most types of haematopoietic colonies. In addition, further 
culture of iPSC-derived haematopoietic progenitors (CD34+, CD45+) revealed 
decreased number of macrophage colonies when compared with the wild-type iPSCs 
(WT- iPSCs), which produced smaller-sized colonies (Figure 4.3).  
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Figure 4.3: Haematopoietic stem cell (HSC) differentiation of WAS-iPSCs. 
(A) Schematic diagram of the in vitro haematopoietic stem cell differentiation 
protocol, or iPS-sac formation protocol. Cells were cultured for 7 days under hypoxia 
(5% O2) followed by 7 days under normoxia (20% O2) over the OP9 feeder cells. iPS-
sac. (B) Western blot analysis showing WASp expression in haematopoietic stem cells 
(HSCs) derived from WT-iPSCs but not in fibroblasts, iPSCs, or HSCs from WAS-
iPSCs. Peripheral blood mononuclear cells (PBMCs) expressing WASp were used as 
a positive control. (C) Phase contrast photomicrographs of iPS-sacs generated from 
WT-iPSCs and WAS-iPSCs on day 14; magnification 4X and 10X. iPS-sac was a 
VEGF-promoted structures that concentrate haematopoietic progenitors. The sac-like 
structures consisted of multiple cysts demarcated by cellular monolayers that retained 
some of the properties of endothelial cells. (Abbreviations: HSCs = Haematopoietic 
stem cells, iPSCs = induced pluripotent stem cells, WT = Wild type, WAS = Wiskott-
Aldrich syndrome, IMDM = Iscove's Modified Dulbecco's Media, FBS = Fetal bovine 
serum, VEGF = Vascular endothelial growth factor). 
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4.6.2 Terminal differentiation of mature neutrophils from WAS-iPSCs 
 Following the protocols developed in published studies (129), iPSCs were 
differentiated into haematopoietic stem cells (HSCs) using the iPS-sac formation 
method (see Chapter 2). HSCs developed inside the sac-like structure, the so called 
iPS-sac. Using flow cytometry analyses, the progenitor cells derived from the iPS-sac 
at 14 days after differentiation stained positive for CD34 and CD45, the 
haematopoietic surface markers. 
Once haematopoietic stem cells (HSCs) were derived from the iPS-sac, they 
were further cultured in neutrophil differentiation media. In this differentiation media, 
the key cytokine, e.g. G-CSF, was added into the media to direct the differentiation 
towards mature neutrophils. 
At 14 days after incubation in terminal differentiation media, the cells were 
collected to evaluate the morphology of iPSC-derived neutrophils. Using a cytospin, 
the cells on the slide were stained with Giemsa and the morphology was assessed. 
iPSC-derived neutrophils were morphologically similar to mature neutrophils from 
peripheral blood (Figure 4.4).   
For comparison, the morphology of CD34+-derived neutrophils and mature 
neutrophils isolated from the blood of healthy volunteers, is shown in Figure 4.4. Of 
note, the differentiated cells, both from CD34+ cells and from the iPSCs, have the 
distinctive multi-lobe nucleus that defines a mature neutrophil. The iPSC-derived 
neutrophil also has a very distinctive granular cytoplasm, which again is also seen in 
mature neutrophils. This granular cytoplasm represents the development of granules, 
small membrane-bound organelles containing a variety of proteins required for 
effective neutrophil function. 
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Figure 4.4: iPSC-derived neutrophils. WAS-iPSCs with genetic correction 
(Corrected WAS-iPSCs) were differentiated into neutrophils via iPS-sac formation 
method. At day 15 after differentiation, the morphology of cells was visualised using 
Giemsa stain. The positive control was neutrophils derived from human CD 34+ cells 
(CD 34 is a haematopoietic progenitor and stem cell marker.). The morphology was 
compared with peripheral blood mature neutrophils. (Abbreviations: Corrected WAS-
iPSC-derived neutrophils = Neutrophils derived from WAS-iPSCs with genetic 
correction)  
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4.7 Discussion and limitations 
 The initial aim of the research described in this Chapter was to culture iPSCs 
from fibroblasts derived from a patient with Wiskott-Aldrich syndrome, characterise 
and then correct the genetic defect, and then to differentiate these iPSCs into mature 
neutrophils. The aim of this approach was to correct the functional defect in the mature 
neutrophils of these patients. This would provide the basis for considering the use of 
this approach to develop a new therapeutic approach for this genetic defect by the re-
introduction of genetically corrected stem cells back into the patient. As (a) the stem 
cells were derived from somatic cells and (b) the stem cells would be re-introduced 
back into the same patient, there would not be the same ethical considerations and 
concerns as there are currently with the use of embryonic stem cells. Furthermore, as 
the patient’s own cells would be corrected and then re-introduced, there would be no 
issues over tissue compatibility and the need for tissue matching or immune-
suppression of the graft. Such an approach could, theoretically be applied to any 
human disease that results from a genetic defect that affects any type of leukocyte.  
 The initial parts of this approach have been achieved. First, these experiments 
confirmed that the WAS neutrophils had a defect in their rates of chemotaxis, which 
is reportedly due to the WASp playing a role in regulation of cytoskeletal re-
arrangements (154,155). The actin cytoskeleton is composed of the network of 
polymerised actin filaments. The polymerisation actin is initiated by three classes of 
actin nucleator: the Arp2/3 complex; the formin family and the Spire, cordon-bleu, and 
leiomodin family. The unique activity of the Arp2/3 to form branched actin network 
is regulated by the WASp and other members of the WAS family (154). Therefore, 
defective WASp would prevent the actin branching and hence formation of the 
cytoskeleton and cytoskeletal re-arrangements during processes such as chemotaxis. It 
was also shown in this thesis that iPSCs could be isolated from fibroblasts from these 
patients and their genetic defect was identified and then corrected experimentally. 
Third, these iPSCs could be cultured in vitro and then differentiated into cells that 
acquired the features of mature, blood neutrophils, namely a multi-lobed nucleus and 
a granular cytoplasm.   
 The clinical manifestation of the WAS loss-of-function mutation, presents with 
normal neutrophil counts, while in the WAS gain-of-function mutation, the clinical 
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phenotype results in X-linked neutropaenia (94,96). Furthermore, in both forms of the 
disease, the patients suffer from increased susceptibility to bacterial infections that is 
often fatal (94,96). The patient studied in this thesis had the loss of function mutation, 
and in agreement with previous observations had normal neutrophil counts. However, 
it was shown here that this patient had a chemotatic defect in their neutrophils, which 
could at least in part explain the clinical manifestation of a proneness to infection. 
Neutrophils are cells of innate immunity, and the first barrier (after the penetration of 
endothelial or epithelial barriers), to protect our body from bacterial infections. 
However, their role in host defense requires them to move from the blood into the site 
of infection, usually transmigrating across membrane barriers. Chemotactic defects in 
WAS neutrophils as a result of impaired actin cytoskeleton re-arrangements as a result 
of WAS loss-of-function mutation would prevent their transmigration to the site of 
infection (156). As phagocytosis of bacteria also requires actin cytoskeletal re-
arrangements, it would be predicted that this defect would also impair this important 
step in control of infections. Defective WASp expression therefore affects a number 
of neutrophil functions associated with control of infections. The first step of these 
studies was therefore to validate WAS-iPSC-derived cells as a neutrophil model, and 
carry out functional studies of iPSC-derived neutrophils which were expected to 
demonstrate the same defects as in neutrophils from WAS patients.  
 As the role of WASp is in the regulation of the specific actin nucleator, Arp2/3 
protein, the absence of WASp, resulting from the WAS loss-of-function mutation, 
could interfere with the branch formation of actin cytoskeleton. It would be interesting 
to use the iPSC technology to observe the effects of loss-of-function mutation of WAS 
on the actin cytoskeleton either in resting state or during chemotaxis via the live 
imaging technology after specific staining on the actin. For example, phalloidin 
staining could be used to detect such changes in actin polymerisation during activation 
of WAS neutrophils or in neutrophils derived after differentiation of WAS-iPSCs.  
However, it was not possible for me to continue these studies with iPSC-
derived WAS neutrophils and to fully characterise their functions. This was partly due 
to technical reasons and partly due to changes in the organisation of my laboratory 
training. The next steps would be to determine the functional properties of both normal 
(healthy) and WAS neutrophils derived from differentiated iPSCs and determine if 
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they were both similar to those of mature neutrophils from healthy controls and WAS 
patients. In future functional studies, WAS iPSC-derived neutrophils should 
demonstrate chemotactic defects similar to the WAS neutrophils, which would 
confirm the use of WAS iPSCs as a model of disease. Furthermore, the chemotactic 
function is expected to be restored in the corrected WAS iPSC-derived neutrophils. 
Other neutrophil functions that require cytoskeletal re-arrangements such as 
phagocytosis could also be measured. 
The numbers of cells derived from these iPSCs was relatively low (only a tens 
of cells) and so these assays would be based on microscopic techniques using specific 
stains or immuno-histochemistry or immuno-fluorescence. Some functional assays, 
such as phagocytosis and chemotaxis could also be performed by microscope-based 
assays. It would then be possible to determine if normal neutrophil function was 
restored in the WAS-defect corrected iPSCs that were differentiated into mature 
neutrophils.  
In summary, the limited data in this Chapter show that it is feasible to isolate 
iPSCs from healthy control and patients with specific genetic defects and differentiate 
them in vitro into neutrophils. It is notable that the mature cells after differentiation 
show the characteristic granular cytoplasm and multi-lobed nucleus of mature, 
bloodstream cells. These characteristics are not always visible in other types of 
“neutrophil-like” myeloid cells that have been induced to differentiate in vitro (see 
Chapter 5). The preliminary data shown in this Chapter demonstrate clear “proof of 
principle” that this approach should be further developed as it offers great potential to 
both understand and then treat genetic diseases associated with impaired neutrophil 
function and increased morbidity and mortality form infections.  
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CHAPTER 5. PLB-985 CELLS 
5.1 The myeloid cell line, PLB-985, as a model for neutrophil 
differentiation and understanding of human genetic conditions 
 Neutrophils are the major immune cells that are responsible for the clearance 
of bacterial and fungal infections (74), but neutrophil dysfunctions also contribute to 
several diseases including autoimmune diseases (157–159). However, the usefulness 
of peripheral blood mature neutrophils to model a particular disease is limited due to 
their short lifespan and inability to proliferate. Moreover, transfection of neutrophils 
is not possible, as the cells cannot survive long enough for clonal selection and the 
transfection protocols often perturb neutrophil function and induce apoptosis. Thus, it 
is impossible to study a particular gene of interest in human neutrophils by transfection 
methods and there have been few reports to reproducibly demonstrate this, in spite of 
many attempts (160).  
 Because of the difficulties in transfecting primary immune cells, alternative 
approaches have used animal models to characterise the functions of particular genes, 
particularly using gene “knock-outs” or “knock-ins” in mice. However, because of the 
distinct haematopoietic processes in animals, and different structural and functional 
properties of key genes and proteins in humans and mice, many of the clinical or 
cellular characteristics of human diseases cannot be reproduced exactly in these animal 
models (13). Therefore, the use of animal models for the study of human 
haematopoietic diseases is of limited usefulness. One alternative approach (other than 
the use of stem cells, described in Chapters 3 and 4 of this thesis), is the differentiation 
of human myeloid cell lines towards neutrophils. This approach uses myeloid cells 
isolated from human patients with malignant disease, and so the cells retain their 
proliferative potential, but can be induced to differentiate after suitable culture in vitro. 
However, there are a number of limitations to this approach, including the efficiency 
of differentiation methods and the properties of the differentiated cells. Many studies, 
have shown that such differentiated cells demonstrate only partial characteristics of 
mature neutrophils, including morphology of the nucleus, appearance of cytoplasmic 
granules, cell surface CD markers, and some functional capacities, in comparison to 
mature neutrophils (161). Therefore, the differentiated cells are generally considered 
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as “neutrophil-like” cells, but not fully-differentiated neutrophils. However, these cells 
do have many experimental advantages over other systems to study the effects of gene 
modifications. For example, the cultured cells are usually easy to maintain and 
proliferate in vitro, and do not require any specialised facilities other than standard 
tissue culture equipment. Second, they are relatively cheap to maintain in culture and 
do not require any expensive growth factors (other than those in serum) to be 
maintained. Third, they only adhere very weakly in tissue culture flasks, therefore not 
requiring trypsin treatment to isolate them, which can perturb the cell membrane and 
damage cell surface receptor expression. Fourth, they can be grown in large volumes. 
Fifth, there are few ethical issues to consider when manipulating the expression of 
particular genes and/or testing the effects of new inhibitors or potential drugs. Such 
cell lines are therefore widely used by many neutrophil biologists worldwide, and it is 
generally accepted that results obtained with differentiated “neutrophil-like” cell lines 
can give important insights into the functional and molecular properties of mature 
neutrophils.  
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5.2 Human myeloid cell lines as models of neutrophil function 
 There are several myeloid cell lines with potential to differentiate into 
neutrophil-like cells, with HL-60 and PLB-985 cells being the most commonly-used. 
Although studies of neutrophil-like cells using these cell lines have contributed many 
important insights into neutrophil biology, challenges remain in determining if the 
functional and molecular characteristics of such differentiated neutrophil-like cells 
completely match those of mature, peripheral blood neutrophils. In some cases, the 
differentiated cells do not possess all of these properties.  
 HL-60 cells were originally isolated from the peripheral blood of a patient with 
acute promyelocytic leukaemia, and the cells are at the promyelocyte stage of 
development with marked karyotypic abnormalities (45X, -5, -8, -16, -X, where 45X 
means an individual has 44 autosomes and a single X-chromosome (a normal 
individual has 44 autosomes with 2 sex chromosomes (either XX (female) or XY 
(male): -5, -8, -16, -X mean a deletion of chromosome 5, 8, 16 and one X 
chromosome.) (162). In previous studies, the cells can be induced into neutrophil-like 
cells (163) with some functional characteristics similar to mature neutrophils, for 
example, response to chemoattractants, including fMLP (3), and phagocytosis of 
certain microorganisms, including Escherichia coli Strain C1845 (164). However, 
despite their leukaemic origins, these cells have karyotypic abnormalities and limited 
capability to differentiate towards terminal mature neutrophils. 
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5.3 PLB-985 differentiated cells 
 The PLB-985 cell line was originally isolated from the peripheral blood of an 
acute nonlymphocytic leukaemia (ANLL) patient with no chromosomal 
translocations, and the cells have the potential to differentiate towards either 
neutrophils or monocytes. From DNA fingerprinting, PLB-985 cells are considered a 
subclone of the HL-60 line, despite being described as isolated years apart and from 
different patients (165). Previous studies revealed that PLB-985-differentiated cells 
could demonstrate the capability to degranulate cell compartments, which is a similar 
property to the terminal differentiated neutrophils in the peripheral blood (3). 
Therefore, PLB-985 cells can potentially be used as a model of neutrophil function, 
with the capacity to alter the expression of key genes (“knock-ins” or “knock-outs”) 
and determine their effects on function. Currently our laboratory is optimising the 
protocols to induce the differentiation of the cells towards the mature neutrophils and 
to characterise their functional properties. 
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5.4 Myeloid Cell Leukaemia 1(Mcl-1) gene and neutrophils 
 One of the most characteristic properties of human neutrophils is their high rate 
of spontaneous apoptosis (166). This poses a particular problem when attempting to 
differentiate cells lines into mature neutrophils: as cell lines acquire the properties of 
mature neutrophils, they will also acquire the property of spontaneous apoptosis. Thus, 
very soon after differentiation they will die by apoptosis. Much research has focused 
on understanding the molecular mechanisms that control neutrophil survival and 
apoptosis, and it has been shown that Mcl-1 is the major survival protein (166,167). 
Mcl-1 (Myeloid Cell Leukaemia 1) is an anti-apoptotic protein of the B-cell lymphoma 
2 (Bcl-2) family, which are a group of proteins with roles in both the intrinsic and 
extrinsic apoptosis pathways, ultimately regulating mitochondrial integrity (1). The 
members of this protein family are identified by having one or more motifs of sequence 
homology to the eponymous Bcl-2 protein, or Bcl-2 homology (BH) domains, in their 
protein structure. Mcl-1 contains 3 putative BH domains, but a unique characteristic 
of Mcl-1 is the presence of regulatory residues and motifs, or PEST sequences (proline 
(P), glutamic acid (E), serine (S), and threonine (T)) in the N-terminal domain. This 
region of the protein, which is unique within the Bcl-2 family, includes sites for 
ubiquitination, cleavage and phosphorylation, which alter the protein’s stability, 
localisation, dimerisation and function (168).   
The altered expression of Bcl-2 family members, usually over-expression of 
the protective anti-apoptotic proteins, is a common feature of ANLL and other 
leukaemias, in particular chemoresistant clones (169). Among the anti-apoptotic Bcl-
2 family members, Mcl-1 is reported to be critical in the survival of ANLL cells, as 
deletion of the Mcl-1 gene, but not Bcl-XL, resulted in ANLL cell death (170). 
However, Mcl-1 expression in mature neutrophils is more dynamic. Neutrophils 
constitutively undergo apoptosis such that their normal lifespan is between 8 - 20 h, 
but this can be extended in response to a variety of agents (171). Mcl-1 protein 
normally has a short half life in neutrophils, with a high rate of turnover due to its 
PEST motifs, which target the protein for rapid proteolysis via ubiquitination. In 
neutrophils, the role of Mcl-1 is to block the pro-apoptotic actions of Bak (and/or Bim) 
at the outer mitochondrial membrane and thus delay neutrophil apoptosis (167).  
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As mature neutrophils do not express Bcl-2 or Bcl-X (171), differentiated PLB-
985 cells should become less dependent on these two proteins and more dependent on 
Mcl-1 for their survival. However, as stated above, because of the short half life of 
neutrophils, fully differentiated PLB-985 cells should also undergo spontaneous 
apoptosis. Therefore, one way to extend the lifespan of fully differentiated PLB-985 
cells may be to over-express Mcl-1. The aim of this Chapter, therefore, was to generate 
PLB-985 clones stably transfected with an inducible Mcl-1:EGFP gene, to determine 
the sub-cellular localisation of this protein and assess if its inducible expression could 
prolong the lifespan of fully differentiated cells. If the survival of PLB-985 cells 
differentiated into mature neutrophils could be extended experimentally, then this 
would allow for a more useful experimental system to study the effects of genetic 
manipulations on the function of mature neutrophils. 
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5.5 pLVX-TetOne-Puro system, and the study of Mcl-1 gene in 
neutrophil model 
 For these experiments, the pLVX-TetOne-Puro system (Clontech, USA) which 
is one of the Tet-One systems, was used. This vector allows for inducible gene 
expression within mammalian cells and contains all the necessary components for 
inducible expression in a single lentiviral vector. After transducing the cells with 
lentivirus, the cells will express the Tet-On 3G transactivator protein and contain the 
cloned gene of interest (GOI) under the tight control of a TRE3G promoter (PTRE3GS). 
When doxycycline (Dox) is present in the cell culture, this antibiotic binds to the Tet-
On 3G protein to induce a conformational change to allow the protein to bind to the 
tet operator sequences in the PTRE3GS promoter, initiating the transcription of the GOI. 
Therefore, in order to maintain inducible GOI expression, the cell culture medium 
should be replenished with doxycycline every 48 h.  
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5.6 KCL-22 versus PLB-985 as cell lines suitable for 
differentiation into mature neutrophils 
During a recent Ph.D. project (172), another myelogenous leukaemic cell line, 
namely KCL-22, was studied and characterised for its ability to resist apoptosis. The 
KCL-22 cell line is originally derived from the pleural effusion of a patient with 
chronic myelogenous leukaemia in blast crisis. Chromosome analysis revealed a 
female karyotype with double Philadelphia chromosomes (genetic abnormality in 
chromosome 22 due to reciprocal translocation of genetic material between 
chromosome 9 and 22, to result in a fusion gene called BCR-ABL1, a constitutively 
active tyrosine kinase) and additional chromosome abnormalities (173).  
It was reported in this thesis (172) that KCL-22 cells (a CML cell line) do not 
express Bcl-2 but they do express Mcl-1. This suggests that they may represent 
immature cells committed to the neutrophil lineage. Therefore, preliminary 
experiments were also performed to determine if KCL-22 cells could differentiate in 
vitro to acquire the properties of mature neutrophils. The ability of these cells to 
differentiate was compared to that of PLB-985 cells. 
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5.7 Aim and objectives 
 The aims of this Chapter are to determine the efficiency of differentiation of 
PLB-985 cells into mature neutrophils and to develop stably-transfected cell lines 
expressing Mcl-1:EGFP. The objectives therefore were to: 
 1. To compare the efficiency of differentiation of PLB-985 cells with that of 
 CML cell line, KCL-22 
 2. To clone Mcl-1:EGFP into an inducible lentiviral expression vector to 
 establish transfected PLB-985 cell line 
 3. To differentiate PLB-985 cells into neutrophil-like cells 
5.7.1 Conceptual framework   
 
Figure 5.1: Conceptual framework for the study of myeloid cell line, PLB-
985, as a model for neutrophil differentiation and understanding of human 
genetic conditions  
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5.8 Results   
5.8.1 Differentiation of PLB-985 cells and KCL-22 cells into neutrophils 
PLB-985 cells and KCL-22 cells are myelogenous leukaemic cell lines that 
have the potential differentiate into neutrophils. The differentiation capability of KCL-
22 cells into neutrophils were studied in comparison with PLB-985 cells, as previous 
work in this laboratory showed that KCL-22 cells are more neutrophil-like in terms of 
the expression of Bcl-2 family protein (172). This suggests that KCL-22 cells are more 
mature along the neutrophil differentiation pathway than PLB-985 cells, as mature 
neutrophils do not express Bcl-2 or Bcl-XL. At either day 5 or 7 of culture in 
differentiation media (see Methods), the cells were collected and cytospins were 
stained with Rapid Romanowsky stain (30 s in methanol for a fixation, 20 s in an 
anionic dye, Eosin Y, and 30 s in a cationic dye, Azure B). The cell morphology was 
evaluated using the criteria in Table 2.4 and Figure 2.4. One hundred cells were 
randomly counted, and the percentage of cell differentiation at different stages were 
evaluated. The cell viability was assessed using ViaCount® reagent and flow 
cytometry. 
In PLB-985 cell experiments, the cells were collected every day at 08.30 (also 
time zero) and 18.30 to closely observe the time of differentiation. At timepoint 18.30 
on day 3 of the differentiation, approx. 30% of cells were differentiated into the poly-
segmented cells (Table 5.1). During day 4 and 5 of the differentiation, the number of 
the differentiated cells increased, with the more mature nuclear morphology of 
differentiated cells, including increased appearance of a hypersegmented (4 – 5 
segments) nucleus similar to that found in mature neutrophils. 
As a control, PLB-985 cells were also cultured in the maintenance culture 
medium in parallel. The morphological characteristics of non-differentiated PLB-985 
cells, including mononuclear appearance with deep blue cytoplasm, were unchanged 
throughout the experiments. In the study of cell viability, the percentages of viable 
cells were > 90% until day 4 of the experiments. However, the cell viability in both 
differentiation and control (no differentiation) studies revealed similar trends during 5 
days of the experiments (Figure 5.3). The percentages of differentiated cells at day 5 
were as follows: differentiated cells (67.5%), band form/segmented/partially 
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differentiated cells (22.35%), and non-differentiated cells (10.15%). (Table 5.1; Figure 
5.2) 
Table 5.1: The percentages of PLB-985 cell differentiation. Cytospins were 
obtained at the time-points indicated and the percentages of fully-, partial- and non-
differentiated cells was calculated. Fields of cells were selected at random and for each 
field, at least 100 cells were counted and compared. Three cytospins were prepared at 
each time-point.  
Differentiation 
day (and time) 
Percentages of 
differentiated cells  
Percentages of 
band form/ 
segmented/ 
partially 
differentiated cells 
Percentages of 
non-differentiated 
cells  
1 The differentiated cells were rarely observed. 
2 The differentiated cells were rarely observed. 
3 (8.30) The differentiated cells were rarely observed. 
3 (18.30) 30.1 25 44.9 
4 (8.30) 31.7 42.0 26.3 
4 (18.30) 54.7 29.9 15.4 
5 (8.30) 61.5 27.6 10.9 
5 (18.30) 67.5 22.4 10.1 
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Figure 5.2: The catergorisation of PLB-985 cell differentiation. The images 
shown were obtained from the PLB-985 cells at day 5 (18.30) of culture in 
differentiation medium. Each circle was used to label the cells at the different stages 
of the differentiation (see Table 2.4; Figure 2.4). A BLUE circle was used to identify 
the differentiated cells. A YELLOW circle was used to label the band form/ 
segmented/partially differentiated cells. A RED circle was used to label the non-
differentiated cells. 
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Figure 5.3: The percentage of viable cells during culture of PLB-985 cells 
in maintenance medium or differentiation medium. The BLUE line indicates the 
PLB-985 cells in the differentiation medium, the RED line indicates the PLB-985 cells 
in the maintenance medium as a negative control. During the first four days of the 
experiments, the percentages of viable cells were more than 90% in both groups, but, 
the % viable cells were significantly decreased to approx. 70% at the final day of the 
experiment. 
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For KCL-22 cells, the cells were poorly differentiated into neutrophil-like cells 
when the PLB-985 cell differentiation protocol was applied (see Section 2.3.1;2.3.2) 
(Figure 5.4). Therefore, the differentiation time was increased (from 5 to 7 days) and 
the potential differentiating and survival agents were added into the differentiating 
media including GM-CSF, dimethyl sulfoxide (DMSO) and human AB serum. 
However, these differentiating and survival agents did not seem to improve the 
differentiation efficiency of KCL-22 cells. However, interesting findings were found 
in the differentiation media 3 (with the addition of 5 ng/mL GM-CSF) and 4 (with 
human AB serum instead of FBS). The nuclear morphology observed after incubation 
in these two conditions changed into the partially-segmented forms at as early as day 
2 differentiation (27% in differentiation media 3 and 45% in differentiation media 4). 
However, these morphological changes in the nucleus could not be maintained and 
these neutrophil-like cells could not be observed in the following days of culture 
(Figure 5.5).  
In conclusion, using the current protocols that have been optimised for 
differentiation of PLB-985 cells were not efficient for differentiation of KCL-22 cells 
after day 5 incubation. Despite the previous study in our lab (172) suggesting the 
possible origin of KCL-22 cells as immature neutrophil lineage, the current available 
protocols could not differentiate the cells into the stage of the neutrophil-like cells. 
Therefore, the PLB-985 cells were selected for the further studies as a model for 
neutrophil study. 
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 Figure 5.4: KCL-22 cells cultured in differentiation medium. The PLB-985 
differentiation protocol was applied to KCL-22 cells, however, at day 5, no KCL-22 
cells were differentiated into neutrophil-like cells. 
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 Figure 5.5: The KCL-22 cells in differentiation media 3 and 4 during the 
first 3 days of culture. The differentiation media were described in Table 2.3 (in 
Chapter 2). Briefly, in differentiation medium 3, 5 ng/mL GM-CSF was added to the 
differentiation medium 1 (similar to PLB-985 cell differentiation medium), and in 
differentiation medium 4, human AB serum replaced FBS. Unlike for the other 
differentiation media, the KCL-22 cells in these 2 media were partially differentiated 
at as early as day 2. However, no differentiation could be observed in the following 
days.   
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5.8.2 The generation of Mcl-1:EGFP in pLVX-TetOne-Puro vector 
One of the main objectives of the work in this Chapter was to generate 
transfected clones of PLB-985 cells that could be induced to express a Mcl-1:EGFP 
chimeric protein. Such chimeric proteins (and mutants thereof) have been useful to 
probe structure/function relationships of key residues in this anti-apoptotic protein and 
to visualise the location of this protein by confocal microscopy (168,174,175). Cloning 
of this gene under the control of an inducible promoter will enable the role of this 
protein to be explored in differentiated cells that are normally subject to high rates of 
apoptosis.  
The Mcl-1 gene was originally cloned in pEGFP-C3 (Clontech, USA), in which 
Mcl-1 gene is located next to EGFP gene (Figure 5.6). The Mcl-1 gene was ligated 
into the pEGFP-C3 vector between the restriction sites, HindIII and BamHI. The first 
aim was to sub-clone this chimeric cDNA into the new inducible expression vector 
(pLVX-TetOne-Puro) to allow for the transfection of the PLB-985 cells.   
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Figure 5.6: Restriction maps of Mcl-1:EGFP in the original pEGFPC3 (A) 
and after sub-cloning in pLVX-TetOne-Puro (B).  
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5.8.3 Sequence analyses of the Mcl-1:EGFP cDNA in the pLVX-TetOne-Puro 
vector 
 The sequence of the new expression vector containing the Mcl-1:EGFP cDNA 
was confirmed to determine whether the gene was correctly inserted into the vector, 
and whether the sequence of the insert gene, Mcl-1:EGFP, was correct. Sanger 
sequencing, the method of DNA sequencing based on the selective incorporation of 
chain-terminating dideoxynucleotides by DNA polymerase, was performed by 
Macrogen Korea to determine the nucleotide sequence in the insert cDNA. The Sanger 
sequencing results were provided as coloured chromatographic peaks. The first step in 
the analysis was to ensure the quality of the peaks, and then the sequences were studied 
in comparison with the original sequences of Mcl-1 and EGFP from the database 
(Figure 5.7; 5.8). The Basic Local Alignment Search Tool (BLAST), National Center 
for Biotechnology Information (NCBI), USA, was used to compare the nucleotide 
sequences (the sequencing results) to those deposited in sequence databases.  
The sequencing results obtained from using the primer covering the junctional 
area, between Mcl-1 and EGFP, were first analysed. The results were matched with 
the original sequence from the database, however, towards the end, the nucleotide 
sequences were mismatched, from 7G in the database to 8G in the sequencing results 
(Figure 5.8). The Sanger sequencing results were re-evaluated and revealed the low-
quality of sequencing data at that area. Therefore, the sequencing results from the 
primer to cover the Mcl-1 gene were analysed, and these revealed perfectly matched 
sequences. As a consequence, the Mcl-1:EGFP in the pLVX-TetOne-Puro vector was 
successfully cloned and hence used in the subsequent experiments. 
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Figure 5.7: The mapping sequence of a Mcl-1:EGFP cDNA in the pLVX-
TetOne-Puro vector. The PINK and GREEN arrows indicate the Mcl-1 and EGFP 
insertions, respectively. (i) The DNA segment that was sequenced by the primer 
designed for covering the Mcl-1 gene and the insertion site. (ii) The DNA segment that 
was sequenced by the primer designed for covering the junction between Mcl-1 and 
EGFP genes. 
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 Figure 5.8: The sequencing results of Mcl-1:EGFP cDNA in the pLVX-
TetOne-Puro vector. (A, B) The Sanger sequencing results of the primer designed to 
cover the junctional area between Mcl-1 and EGFP in the vector. (C) The comparison 
of the nucleotide sequences and the database sequences using Basic Local Alignment 
Search Tool (BLAST) online programme. 
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5.8.4 The PLB-985 cell transduced with Mcl-1:EGFP in pLVX-TetOne-Puro 
vector   
 The PLB-985 cells were then transduced with Mcl-1:EGFP in pLVX-TetOne-
Puro vector and transformants were selected by the addition of puromycin antibiotics. 
However, it was possible that some colonies arose from more than one transformed 
PLB-985 cell, and some transformed cells were transfected with more than one copy 
of the vector. Therefore, clonal selection was performed to ensure that only clones 
containing a single copy of the vector were used in subsequent studies. The serial 
dilution method was used, and 16 individual clones of the transduced PLB-985 cells 
were derived.  
 Experiments were then conducted to induce the expression of Mcl-1:EGFP 
chimeric gene by the addition of 100 ng/mL doxycycline, and to allow the protein 
expression (measured after 24 h in the presence of the antibiotic). As the Mcl-1 gene 
was tagged by EGFP, the Mcl-1 protein expression should be observed by the 
fluorescence of the EGFP, using either flow cytometry or the fluorescence microscopy 
to visualise the green fluorescence. Initially, flow cytometry was performed. However, 
the data was inconsistent. In one experiments, green fluorescence was detected in all 
16 clones, but in subsequent experiment to confirm the expression prior to the 
fluorescence microscopy, the flow cytometry failed to detect the green fluorescence in 
all 16 clones despite multiple attempts. Therefore, further experiments should be 
conducted to directly confirm the presence of the vector in the cells, rather than indirect 
confirmation based on the puromycin resistant properties on the PLB cells. 
Additionally, re-cloning the transformants using alternative methods, including the 
fluorescence activated cell sorting (FACs) could improve the confidence in obtaining 
single clones. 
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5.9 Discussion 
 Despite the recognised role of neutrophils as the major innate immune cells in 
eliminating bacteria and fungi during infections, and the importance of neutrophil 
dysfunctions in the underlying pathologies of many diseases (159), the use of the 
peripheral blood neutrophils to study and model the disease is limited partly due to 
their short life span. Moreover, the transduction of neutrophils to genetically modify 
their function, is rarely successful. Therefore, myeloid leukaemic cell lines are still the 
main resource to model human neutrophil function in vitro.  
 In this thesis, the two myeloid leukaemic cell lines, PLB-985 and KCL-22 
cells, were compared, to determine their efficiency to differentiate into neutrophil-like 
cells, in these experiments determined by the appearance of a polymorphic nucleus. 
This was performed to select which line would be more suitable to establish the 
transfected Mcl-1:EGFP in an inducible lentiviral expression vector. However, the 
differentiation protocol used, containing all-trans retinoic acid and N,N-dimethyl 
formamide as differentiating agents, was first developed for PLB-985 cells. Using this 
protocol and medium, it was shown that the percentage of differentiated cells at day 5 
was as high as 67.5% and the nuclear morphology of the differentiated cells was also 
similar to that of mature neutrophils (Table 5.1). Ongoing studies in our lab are explore 
other characteristics and functional properties of differentiated PLB-985 cells, in 
comparison with those of peripheral blood neutrophils. 
 A previous study in our lab reported (172) that KCL-22 cells (a CML cell line) 
did not express Bcl-2 but they do express Mcl-1, suggesting that these immature cells 
are committed to the neutrophil lineage. It was postulated, therefore, that it would be 
relatively easy to fully differentiate these cells into neutrophils, as they already 
displayed some of the molecular properties of mature cells. While different medium 
supplements were tested, the percentages of differentiated cells were significantly 
lower compared to those obtained after differentiation of PLB-985 cells. However, in 
differentiation media 3 and 4, the cells began to develop into partially differentiated 
cells, but not fully differentiated to neutrophil-like cells, as seen by a change in the 
morphology of their nuclei. These nuclear changes, however, could be observed as 
early as day 2, compared to the day 3 in PLB-985 cells, but differentiated cells were 
not seen in later days of incubation. This could be because only a small population of 
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cells underwent differentiation, and these differentiated cells that were observed after 
the first few days in culture then underwent apoptosis. Further experiments, employing 
more systematic changes to the composition of the differentiating media should be 
conducted in future to determine if differentiation efficiency can be improved and there 
is any experimental advantages in using KCL-22 cells as models for neutrophil 
differentiation. 
 It was concluded that rather than attempting this systematic attempt to improve 
the differentiation conditions for KCL-22 cells, to instead use PLB-985 cells as a 
neutrophil-like cell line for the transfection experiments. PLB-985 cells were therefore 
transduced with the Mcl-1:EGFP cDNA cloned into an inducible lentiviral expression 
vector to establish transfected PLB-985 cell lines. The expression system has two 
particular advantages for studying the role of Mcl-1 expression on the survival of 
differentiated PLB-985 cells. First, the system can allow for the controlled, inducible 
expression of Mcl-1 by the addition of the doxycycline. Therefore, the Mcl-1 
expression could be “turned on” (in the presence of doxycycline) and “turned off” (in 
the absence of doxycycline) at any particular stages of PLB-985 cell differentiation, 
and the effects of these changes on differentiation, function and apoptosis determined. 
Second, the Mcl-1 was tagged with EGFP, and so EGFP expression could be used as 
an easily-measured reporter for expression of Mcl-1. 
 In the first step of this approach, the PLB-985 cells were transduced with the 
Mcl-1:EGFP in the inducible lentiviral expression vector, and the sequence was 
confirmed. Also, initial analyses using flow cytometry confirmed EGFP expression in 
all clones. However, following isolation of single clones, expression of EGFP could 
not be re-induced in all clones obtained. The possible explanations to this failure to 
detect expression of the EGFP reporter could be as follows: 
1. Failure of the doxycycline to induce expression. It was first assumed that the 
doxycycline stock had degraded and lost activity, and so a new batch was used. 
However, this new batch also failed to induce expression of the reporter. 
2. The initial results on the mixed cell populations was in fact a false positive of 
the green fluorescent detection by flow cytometry. While care was taken to set 
up the flow cytometer correctly, it may be that the initial experiments actually 
detected endogenous fluorescence rather than EGFP fluorescence.  
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3. PLB-985 cells are myeloid leukaemic cells that multiply at a high rate. 
Therefore, it is possible that they were cultured for too long were limited in a 
particular nutrient, and because of this they either failed to express the 
exogenous gene or in the initial experiments, the stressed cells expressed a high 
level of endogenous fluorescence. 
4.  It is possible that either the lentivirus was excised from the genome or became 
dysfunctional during the cell cloning procedures, or that the cloning procedure 
only selected non-transformed cells.    
However, the parallel experiments being conducted in this laboratory on PLB-
985 differentiation into neutrophils is extremely promising and the differentiated cells 
display many of the properties of mature neutrophils including a multi-lobed nucleus. 
Therefore, although the experiments in this Chapter did not reach a conclusion, they 
should be followed up. In particular, more work should be done to isolate transfected 
PLB-985 cells with Mcl-1:EGFP and to confirm inducible expression of this protein. 
This would appear to be a useful avenue to fully exploit the usefulness of this 
neutrophil like cell model.  
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CHAPTER 6 METABOLOMICS 
6.1 Post-genomic technologies 
Recent developments in post-genomics technologies have provided 
unprecedented information on the fine details of the components of living cells and 
tissues. Advances in next-generation sequencing in the early 2000s and the 
development of new sequencing platforms greatly decreased both the times and costs 
of DNA sequencing and as a consequence there has been an unparalleled acquisition 
of knowledge and information about the genomes and transcriptomes of a wide variety 
of tissues and species. Advances in proteomics technologies have also developed 
greatly during this period, but high-throughput, non-biased methodologies based on 
chromatography and mass spectrometry have been more difficult to develop. 
However, advances in this field of post-genomics biology have been considerable, and 
both approaches generate vast amounts of data that has necessitated the parallel 
development of software and algorithms to capture, record and interpret the data that 
are generated. 
A criticism of transcriptome studies sometimes raised is that the transcriptome 
only provides the potential templates for proteins that may, or may not be translated. 
Quite often, it is necessary to confirm that a change in expression of a protein in a cell 
type or tissue corresponds with a change in the level of a transcript (176). However, 
even such a dual measurement (of a gene and a protein) is insufficient to measure the 
activity of a gene product within a cell. The activity of a protein, say an enzyme, is 
dependent on the total amount of enzyme expressed and its activity, which may be 
reversibly regulated by post-translational modifications (for example reversible 
phosphorylation), but also by other control mechanisms such as allosteric control 
(binding of an activator or inhibitor) or by the concentrations of substrates or products. 
Changes in the concentrations of substrates or products can result in either positive or 
negative feedback control mechanisms. For these reasons, there is a need to measure 
the total concentrations of metabolites in a cell or tissue to gain a full understanding 
of the biological functions of that cell or tissue. 
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6.2 Metabolomics 
Metabolomics is the quantitative study of the complement of metabolites 
produced or present within a biological system. Currently, there are the two major 
metabolomic analytical platforms: nuclear magnetic resonance (NMR) spectroscopy 
and mass spectrometry. 
NMR spectroscopy is an analytical chemistry technique using the application 
of an external magnetic field and complex radio frequency ‘pulses’ to observe the 
resonance or chemical shift from each atom of a particular nucleus (typically 1H). Once 
the external magnetic field is applied, the protons in a molecule align themselves either 
with or against the magnetic field, thus creating an energy difference between two 
states, of lower and higher energy transition states. The NMR spectrum is observed 
when the radiation applied matches with these energy differences. In this manner, a 
spectrum is produced with multiple signals arising from each molecule. The location 
of each signal is recorded as the chemical shift, which is a measure of how different in 
chemical environment (or how shielded) the 1H is compared to the reference 
compound signal. The chemical environment of each 1H is affected by 
electronegativity, chemical bonds, charged nuclei, hydrophobic interactions etc. The 
unit of chemical shift is parts per million (ppm). Apart from the external magnetic 
field, the molecules already contain their own magnetic environment due to the 
movement of electrons around the protons, thus shielding the effect of the external 
magnetic field (called diamagnetic shielding). Thus, the protons in electron dense 
environments are enormously shielded, and therefore will require a lower frequency 
to exhibit resonance because the energy difference is smaller. The ppm will be smaller 
and located farther towards the right side hand of the spectrum (towards null ppm), 
and vice versa. 
Mass spectrometry metabolomics is an analytical technique that requires the 
chemical molecules to be ionised and sorted according to their mass-to-charge ratios 
(177). To enhance the information on the chemical properties of metabolites, other 
separation techniques, for example liquid or gas chromatography, are often applied 
prior to the samples becoming introduced into the spectrometer (178). This pre-step 
requires more time for sample preparation, which may increase the chance of 
metabolite losses, for example as a result of breakdown or instability. Therefore, the 
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complexity of mass spectral data is decreased due to this metabolite separation step 
and also processing times are increased. There also needs to be some selection of the 
type of separation step required in order that a particular set of metabolites are 
introduced into the spectrometer. Nevertheless, the technique provides abundant 
information of low-molecular mass metabolites (< 1,500 Da).  
Table 6.1 Comparison of two major metabolomics analytical platforms 
(nuclear magnetic resonance (NMR) spectroscopy metabolomics and mass 
spectrometry (MS) metabolomics) 
 NMR Spectroscopy 
Metabolomics 
Mass Spectrometry 
Metabolomics 
Preparation 
process and time 
Less time, non-destructive More time, derivitisation 
required 
Detected 
metabolites 
Untargeted, metabolic 
fingerprinting 
Targeted, metabolic profiling 
Analyses Quantitative analyses, 
pattern comparison 
Quantitative analyses, 
metabolite libraries 
Sensitivity Only medium to high 
abundance metabolites 
High sensitivity 
Considerations True “omics” data Not true “omics” data 
Advantages Metabolic pathway analyses Identify specific metabolites 
 
 
Page 152 of 280 
6.3 NMR spectroscopy for neutrophil metabolomics  
It was decided to use the NMR methodology to study neutrophil metabolomics, 
as this technique allows quantitative analyses of untargeted metabolomic profiles, 
while MS metabolomics is more suitable when specific metabolites are being targeted. 
Briefly, NMR spectroscopy exploits the magnetic properties of certain atomic nuclei, 
to determine their chemical and physical properties. Any molecules containing the 
atomic nucleus of interest, 1H in this case, will be detected. Therefore, as the 1H 
nucleus is abundantly present in many metabolites, 1H-NMR spectroscopy is highly 
suitable for use as a metabolic profiling technique in biological samples. However, 
there are no published reports of the use of this technique in the study of neutrophil 
function. Therefore, for this study, NMR protocols for the identification and 
quantitation of metabolomic profiles of human neutrophils have been developed for 
the first time. 
In biofluid NMR, there are two preferential pulse sequences, where the 
observed peak intensities are edited, for metabolomic profiling (130). First, the 1D 
Nuclear Overhauser Effect Spectroscopy with pre-saturation (NOESYpresat) 
approach provides adequate suppression of the solvent (water) resonance. The NOESY 
spectrum is high sensitivity and therefore suitable for identifying specific metabolites 
present in low quantities. Second, the 1D Carr-Purcell-Meiboom-Gill (CPMG) 
sequence allows for magnetic filtering for metabolites of low molecular weight (less 
than 1,000 Da) and macromolecular species in the sample (e.g. proteins, lipoproteins) 
from the spectrum, without any physical manipulation of the sample required. With 
the higher discrimination power, the CPMG spectrum provides more distinct peaks 
which allows the comparison of spectral peaks in each samples (179).   
NMR spectra of biofluids and pattern recognition methods in metabolomics 
have enabled the identification and quantitation of metabolites in different biological 
samples, thus providing highly informative data about the functional state of living 
organisms, including humans. 
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6.4 Neutrophil metabolomics 
Neutrophils are innate immune cells that kill invading microbes mainly 
through the phagocytosis and production of reactive oxygen species (ROS). These 
reactions are activated in the matter of seconds, and so analysis of samples taken after 
suitable experimental time-points are an important consideration when planning 
metabolomic experiments to detect changes in neutrophil function. For example, one 
of the hallmarks of neutrophil function is the activation of the normally dormant 
NADPH oxidase during phagocytosis or other forms of activation, which can result in 
large but transient changes in the NADP+/NADPH ratio very rapidly after cell 
stimulation (Figure 6.1). This activation occurs rapidly, is sustained for several 
minutes and then declines. This is likely to be accompanied by transient and rapidly 
changing profiles of other metabolites. 
 Figure 6.1: The chemical equation of NADPH oxidase reaction in 
neutrophils 
The first aim of this study was to establish the optimal methods to study 
changes in the neutrophil metabolomic profile during various forms of in vivo or in 
vitro activation. Therefore, it was necessary to establish protocols to optimise sample 
preparation, extractions and analysis methods that minimise the chemical and physical 
degradation of metabolites due to their natural diversity, instability and high turnover 
rate. This protocol development is necessary because this study represents the first 
time that metabolomic profiling of neutrophils has been attempted in this way. In NMR 
metabolomics, there is no excessive preparation time required, thus increasing the 
potential to detect any transient metabolites in neutrophils, provided that they can be 
extracted appropriately.  
Therefore, the first experiments in this study were to optimise the extraction 
and analysis procedures and to compare the metabolomic profiles obtained with 
spectra of known standards. Once this was established, it could then be possible to 
determine how the metabolome of neutrophils changes over time during activation in 
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vitro (e.g. using fMLP, PMA) or following priming by cytokines (e.g. GM-CSF, TNF). 
Once this was established, it would then be possible to identify the metabolome of 
neutrophils activated in vivo, for example in patients with rheumatoid arthritis.  
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6.5 Conceptual framework 
 
Figure 6.2: Conceptual framework for optimising protocols and analytical 
methods for neutrophil NMR metabolomics 
Definition of terms used in this Chapter 
- Spectrum/Spectra/Spectral, define the whole range of peaks in the NMR sample. 
- Peak, defines the specific peak in the spectrum. 
- Metabolic, is used to specify anything related to specific metabolites. 
- Metabolomics, is used to specify anything related to the metabolomic study. 
- NMR, is used when the technique of NMR analyses was being focused. 
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6.6 Preliminary spectral analyses and the generation of a pattern 
file for neutrophil NMR metabolomics 
 In metabolomics, the metabolites are recognised by their specific spectral 
patterns. Chenomx Profiler® software (version 8.2 standard) is used to detect the 
specific spectral pattern in the NMR data, interpret these patterns and then provide 
identification of the metabolites. Pattern files are therefore generated by the use of the 
Chenomx Profiler® software (version 8.2 standard) and the NMR spectra visualised 
by the Bruker TopSpin® software, to provide lists of molecules (pattern files).  
 To create the pattern files, the NMR spectral data of a sample that was assumed 
to contain the highest number of metabolites was analysed. As circulating blood 
neutrophils are in a resting state in healthy individuals, blood neutrophils from a 
healthy control were stimulated in vitro before extraction and analysis. As this 
approach had not been applied to human neutrophils previously, intracellular 
concentrations of metabolites detected by this technique were not known. Therefore, 
the initial experiments used a sample of 107 healthy control neutrophils stimulated for 
10 min with phorbol-12-miristate-13-acetate (PMA), which induces a very large 
respiratory burst via activation of the NADPH oxidase and activates many intracellular 
kinase systems including protein kinase C. Samples were analysed using the NOESY 
pulse sequence technique (to detect low quantity metabolites) and the number of scans 
was set at 16,384, which required 12 h processing time. This first experiment was 
performed in this way to ensure capture of as many metabolites as possible in order to 
generate the pattern files. In general, the NMR spectra are analysed after 32 scans for 
NOESY pulse sequence analysis, which normally requires only 5 min processing time.   
For the next step, the selected spectrum was opened simultaneously in two 
software packages, Chenomx Profiler® (version 8.2 standard) and TopSpin®. 
Chenomx Profiler® is an automated metabolite analyses appraisal software, in which 
the metabolite patterns were recognised. Bruker TopSpin® is an acquisition and 
processing of NMR spectra software package, where the peaks was selected and 
identified. Using reference standards of known metabolites, these approaches were 
used to create the pattern files for neutrophil metabolomics that included the details of 
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the peak location (ppm) with range, and the possible metabolites identified by the 
peaks (Figure 6.3) (see Supplementary data: The neutrophil pattern file).   
 
 Figure 6.3: An example of the pattern file of human neutrophils. The 
descriptions in lines 1 to 4 described the details of spectral samples, which were from 
the experiments of 107 healthy human neutrophils, and the author. The number of items 
(line 7) was the number of spectral peaks identified in the pattern file, which was 1056 
for this sample from human neutrophils in this study. From lines 8 to 26, examples of 
the spectral peak information, in terms of the ppm range and the possible metabolites 
identified (from a peak identification) by Chenomx Profiler® software (version 8.2 
standard). The spectral peaks that are unable to be identified by the software were 
labelled as UNKNOWN. 
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6.7 Spectral and statistical analyses using Chenomx Profiler® 
software (version 8.2 standard) and Metaboanalyst programme 
For further and more detailed analyses, the spectral data were interpreted into 
a “bucket table” via Amix® software (Figure 6.4). The bucket table describes the 
spectral data in terms of the peak intensity with identification (possible metabolites), 
defined by the pattern file.  
Statistical analyses were then performed using an online programme, 
Metaboanalyst® (From: http://www.metaboanalyst.ca/), which uses the R package of 
statistical computing software. The experimental data in the bucket table, or a peak 
intensity table format, was first normalised by median centering. This normalisation 
of data is to make the samples comparable (Figure 6.5). In addition, Pareto scaling was 
applied to make the variables in the data more similar in scale, so that the statistical 
differences were not influenced by the larger variables, or the larger spectral peaks. 
This allows for the application of some linear analysis methods, including principal 
component analysis (PCA). Pareto scaling is obtained from mean-centered data and is 
divided by the square root of the standard deviation of each variable. 
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Figure 6.4: The bucket table of metabolites from healthy neutrophils. The 
figure demonstrates the bucket table, which describes the spectral peaks in terms of 
the peak intensity (from the spectral data) and identification (from the pattern file, see 
Figure 6.3; Supplementary data: The neutrophil pattern file). 
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Figure 6.5: Normalisation of the data and the data scaling. The original 
spectral data (left) was normalised by median and the application of Pareto scaling to 
the normalised and scaled spectral data (right), which allowed the comparison 
between samples. The box and whisker plots represented the normalisation of each 
metabolomic spectrum. 
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After the statistical analyses, the spectral peaks that showed significant 
differences were listed. The statistical analyses methods were selected for each 
experimental design. Briefly, fold change analysis was selected in the time-point 
experiments, e.g. PMA treatment. For the spectral data of neutrophils from healthy 
controls and patients with disease, e.g. rheumatoid arthritis, either ANOVA or T-test 
with post-hoc analyses were applied with regards to the number of different groups. 
The p value for the spectral analyses was set at 0.01 because the NMR metabolomics 
has the sensitivity to measure very small metabolomic changes. Once the list of 
significant peaks identified as possible metabolites was obtained, the retrospective 
check with the original spectrum via Bruker TopSpin® and Chenomx Profiler® 
(version 8.2 standard) software was performed to confirm the possible metabolites. 
6.7.1 Principal Component Analysis (180) 
 As the high-dimensional characteristics of NMR metabolomic data limit 
simple exploration of the data, principal component analysis (PCA), a complex 
mathematical algorithm including linear algebra, can decrease the dimensionality of 
the data but still retain all of the variations. The decrease is accomplished by 
identifying directions as new variables, called principal components, which are the 
linear combinations of the original variables: the variation in the data is still maximal. 
By using few components, values for thousands of variables can be represented by 
relatively few numbers. The visual assessment of similarities and differences between 
samples then becomes possible. However, in two- or three-dimensional visualisation, 
much information will be missing, and so different combinations of components are 
required for visualisation in a data set. 
6.7.2 Pathway analyses 
 Metabolic pathway analysis was carried out on those metabolites that showed 
a significant increase/decrease between samples (e.g. +/- PMA, disease versus healthy) 
using Metaboanalyst® Pathway Analyses software. The metabolite data were input 
either as a list of compound names or other compound labels (including Human 
Metabolome Database (HMDB) or Kyoto Encyclopaedia of Genes and Genomes 
(KEGG)). HMDB is the online database for small molecule metabolites found in 
human samples (181–183). KEGG is the database resource for understanding high-
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level functions and utilities of the biological system. The KEGG compound contains 
the small molecules database. The first step was to standardise the metabolite data into 
matched compounds with identified HMDB or KEGG reference numbers. However, 
the programme allows for the manual selection of the metabolites from the 
approximate matched compounds. Metabolites for which no match could be found 
were not included into the pathway analysis. In the next step, a pathway library, 
categorised by sample species, was selected. In homo sapiens (human), there were 80 
pathways available in the programme. The algorithms for pathway enrichment 
analysis, or the over-representation analysis, test if metabolites involved in a particular 
pathway are enriched compared to random hits (or represented more than expected by 
chance). The hypergeometric test was selected. 
 The pathway topology analysis was used to estimate the node importance. It is 
well-known that changes in more important positions of a network would impact more 
severely on the pathway than changes in marginal or relatively isolated positions. 
There are two well-established node centrality measures to estimate node importance: 
degree centrality and betweenness centrality. The degree centrality measure focuses 
more on local connectivities, while the betweenness centrality measure focuses more 
on global network topology. The relative betweenness centrality was selected in the 
study. The impacted metabolic pathways were then analysed in correlation with the 
biomedical background of patient samples and experimental design.   
 
 
 
 
Page 163 of 280 
6.8 Optimising protocols for NMR metabolomic analyses of 
human neutrophils: challenges and advantages  
 Sample collection, preparation, storage and analysis can all affect the 
metabolomic profiles obtained, and therefore, highly consistent preparation and 
analysis procedures are required. No established protocols have yet been developed 
for the measurement of the metabolomic profiles of human neutrophils. The first 
objective was to optimise these procedures in view of the challenges and potential 
advantages of different protocols.  
6.8.1 Optimising sample preparation protocols  
6.8.1.1 Optimal neutrophil cell number and the number of scans (NS) 
Aim: To determine the minimum cell number that could provide full NMR spectrum 
coverage. 
Objectives:  
1. Intracellular metabolite extraction of neutrophils with different total number 
of cells 
2. NMR spectrum coverage to be identified by Chenomx Profiler® software 
(version 8.2 standard) 
This cell number optimisation was necessary because the total numbers of 
neutrophils that can obtained from the blood or inflammatory fluid of a patient or donor 
can be low. For clinical samples, particularly from paediatric patients, the total number 
of neutrophils that can be obtained from a single blood sample may be as low as 2 x 
106 cells. Therefore, the first step was to determine the minimum number of 
neutrophils required to detect the highest possible number of distinct NMR spectra of 
metabolites and to generate reproducible spectral patterns.  
In the first experiments, data obtained from three different cell numbers (i.e. 
2.5, 3.5 and 9.7 x 106 cells) were analysed using five different number of scans (NS) 
(i.e. 128, 256, 512, 1,024 and 2,048). Samples were prepared as described in Chapter 
2.5. In a 3D-scores plot, each colour indicates each NS and one point indicates one 
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sample. In Figure 6.6 A, B, the DEEP BLUE, LIGHT BLUE and PINK points 
represent the analyses after the number of scans of 512, 1,024 and 2,048, respectively. 
In the plot, the clustering of the points in these three colours, aka NS, was observed in 
two different locations. For each location, the cell numbers of 3.5 and 9.7 x 106 were 
represented in the points in each locations (Figure 6.6 A, B). Therefore, the number of 
scans and the number of cells affected the analyses of the spectral data. A cell number 
of 3.5 x 106 demonstrated similarity of the data at the NS of 512 (Figure 6.7 C). When 
the lower number of cells (2.5 x 106) were analysed, a higher NS, at least 1,024, was 
required to produce the similar results (Figure 6.7 D). Moreover, at the highest cell 
number (9.7 x 106), the points from the NS of 128 and 256 also produced a less 
compacted grouping of points (GREEN) (Figure 6.7 A, B). On the contrary, the data 
obtained at a cell number of 2.5 x 106 were scattered, even at the high NS of 2,048 
(Figure 6.7 E).  
In conclusion, the higher total number of neutrophils is recommended for all 
future experiments, as the results revealed good technical replication even at the low 
number of scans, which means a shorter short processing time. From this study, a 
number of total neutrophils at least 3.5 x 106 cells are required, with the optimal 
number of scans at 512.  
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Figure 6.6: The principal component analysis of the data from three 
different neutrophil cell numbers (2.5, 3.5 and 9.7 x 106 cells) after five different 
numbers of scans (NS) (128, 256, 512, 1,024 and 2,048). (A) Comparison of principal 
component 1 (PC1) (53.3%) and principal component 2 (PC2) (21%), two clusters of 
points were observed, marked in a RED circle and RED square. In the RED circle, 
the clustering contained the points represented the data of 9.7 x 106 cells at every NS. 
The looser sub-clustering of points (GREEN points) represented the NS of 256. In (B) 
the RED square depicts another clustering of points that contained the points 
representing the data of 3.5 x 106 cells at the highest number of scans, but excluding 
NS of 128 and 256. (Abbreviations: NS = Number of scans, G1, G2, G3, G4 and G5 
= The number of scans at 128, 256, 512, 1,024 and 2,048, respectively. The samples 
were technical triplicates). 
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Figure 6.7: Principal component analysis of the data of three different cell 
numbers (2.5, 3.5 and 9.7 x 106 cells) at each number of scans (NS). The number 
of scans ranged from 128 (A), 256 (B), 512 (C), 1,024 (D) and 2,048 (E). 
(Abbreviations: S = Sample, G1, G2 and G3 = Total cell number of 2.5, 3.5 and 9.7 
x 106 cells, respectively. The samples were technical triplicates.)  
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6.8.1.2 Quenching neutrophil metabolism: Heating neutrophils prior to 
the snap freezing 
Aim: To detect the metabolites present in resting and stimulated neutrophils from 
healthy controls. 
Objectives:  
1. To stabilise all metabolites and metabolic enzymes in neutrophils 
2. To prevent unwanted cellular reactions that could alter the concentrations of 
these metabolites 
Neutrophils are normally in a resting state in the circulation, but can be 
activated either intentionally (e.g. through a PMA treatment, that activates the signal 
transduction enzyme protein kinase C (PKC)) or unintentionally (through the process 
of neutrophil isolation or rough handling/sample processing). Samples were heated to 
100 oC for 1 min in order to denature metabolic enzymes (which could be released 
during extraction) and hence stabilise all metabolites and protect them from further 
cellular reactions. 
In these experiments, the total cell number of cells (106) was incubated with 
PMA (0.1 µg/mL). 10 min after treatment, heat shock was applied to one sample while 
another sample was extracted without the heat shock treatment. The objectives of the 
study were to assess whether the heat shock could stabilise all the metabolites either 
at their resting state or in the activated state. After extraction, the number of 
metabolites and the similarity of the data within the two groups, with and without heat 
shock, were evaluated. In Figure 6.8, the spectrum representing PMA-treated 
neutrophils (BLUE) that were subject to the heat shock demonstrated an overall higher 
level of metabolites than the RED spectrum that represented the samples extracted 
without the heat shock. In conclusion, the heat shock could enhance the detection of 
metabolites in the neutrophil extracts, and should be applied in all further experiments. 
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Figure 6.8: Effect of heat shock on extraction of neutrophil metabolites. 
106 neutrophils were activated with PMA (0.1 µg/mL) prior to metabolomic extraction. 
The RED spectrum represented the PMA-treated neutrophils without the heat shock, 
while the BLUE spectrum represented the PMA-treated neutrophils without this heat 
shock treatment.  
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 6.8.1.3 Minimising the processing times and metabolite loss during 
extraction 
Aim: To decrease the processing time and procedures in order to minimise metabolic 
changes following extraction  
Objectives: 
1. To decrease the number of washing steps in neutrophil isolation in order to 
prevent cell loss and minimise perturbations to cellular metabolism   
2. To minimise the centrifugation time but still recover all of the cells 
As the total number of cells and number of scans were crucial factors in 
neutrophil metabolomics (Section 6.8.1.1), the optimal process to minimise cell loss 
or perturbation during the neutrophil isolation and metabolite extraction procedures 
were investigated. During the isolation process, all of the washing steps were 
decreased as appropriate without comprising the numbers of cells collected. Therefore, 
the washing step after centrifugation in Ficoll-Paque reagent was eliminated. In a 
normal preparation, the cell pellets would be washed with RPMI-1640 medium to 
remove all the Ficoll-Paque residue. For these and subsequent experiments, the 
polymorphonuclear (PMN) pellets were resuspended in RPMI-1640 media with 
phosphate buffer, and the ammonium chloride was added to lyse the RBCs as 
described in Chapter 2.5. After centrifugation, the cell pellets were collected and re-
suspended in RPMI-1640/phosphate buffer. The cell suspension was counted and 
immediately aliquoted into triplicate samples.   
In order to investigate the effect of washing steps, the neutrophil suspensions 
were equally distributed into two tubes, at the concentration of 3.5 x 106 cells/mL for 
3 mL. Both tubes were centrifuged at 500 g for 3 min. In one tube (washed sample), 
the media was discarded and 3 mL RPMI-1640 media with phosphate buffer was 
added. After the red blood cell lysis step, the cell pellet was resuspended and 
recounted. The cell concentration was decreased to 3 x 106 cells/mL. In another tube 
(non-washed sample), the only difference is that, after the Ficoll-Paque centrifugation, 
the media was not discarded and used to resuspend the cell pellet again. The cell 
suspensions were then aliqouted into three tubes for the technical replicates. The 
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aliquoted cell suspensions were centrifuged, and the cell pellets were collected. The 
NMR spectra were visibly different, and more metabolites could be detected in the 
non-washed sample (Figure 6.9). Moreover, the possible contamination of the spectra 
by of Ficoll-Paque was not observed in the spectra. Therefore, in subsequent 
experiments in this thesis, the washing step after centrifugation in Ficoll-Paque was 
not performed. 
For some experiments, including after PMA treatment, the cells had to be 
collected at defined time-points, and so optimising the minimal processing time, in 
terms of washing and centrifugation without cell loss, was necessary. Therefore, in 
these experiments, the numbers of cells recovered in cell pellets after different 
centrifugation times were compared. In these experiments, the neutrophil suspensions 
were centrifuged at 1,000 g for 2 and 3 min, and cell recovery was equivalent. 
Therefore, in the further metabolomic experiments, a centrifugation time at 1,000 g for 
2 min was applied.  
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Figure 6.9: Experiment to determine the effects of decreasing the number 
of washing steps on neutrophil metabolites. i) Three technical-replicate spectra 
derived from the neutrophils undergoing the isolation process without the washing 
step after the centrifugation in Ficoll-Paque. ii) Three technical-replicate spectra 
derived from the neutrophils undergoing the isolation process with the washing step. 
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 6.8.1.4 Minimising contaminants that may be introduced into neutrophil 
extracts 
Aim: To detect the NMR metabolomics and their changes in response to different 
stimulants, without interference from contaminating molecules introduced during the 
extraction/isolation process  
Objectives: 
1. The avoidance of all contaminating external metabolites, for example, 
alcohol and buffers (HEPES) 
2. The avoidance of HEPES in RPMI-1640 media 
3. The use of 25 mM phosphate buffer pH 7.4 in RPMI-1640 media 
 NMR metabolomics has the potential to detect intracellular metabolites at very 
low levels, for example as low as 500 ng of pure compound (184). However, these low 
quantity metabolites are detected as low intensity peaks, which can be easily obscured 
by the presence of high concentration metabolites, which can commonly be 
contaminants or introduced by external interference, e.g. specific foods or drinks taken 
by the patients prior to blood withdrawal.  
 As the NMR technique is a very sensitive tool, all possible contaminants, 
including chemicals and disinfectants used in cell preparation/isolation, were 
considered and then eliminated as far as possible. In a preliminary study in healthy 
volunteers, those with a 48 h history of no alcohol consumption or medications were 
included in the study. The possible contaminants from the isolation/extraction 
procedures were reviewed thoroughly. In the isolation of neutrophils, RPMI-1640 
media with HEPES buffer was initially used, in order to maintain the pH of the media 
around 7.2 - 7.5, which is a normal requirement of cell culture to maintain viable 
human neutrophils. Moreover, altered pH of the samples could influence the chemical 
shifts of the NMR spectrum (185). However, it was found that residual HEPES in the 
neutrophil extracts (from the RPMI-1640 medium) provided undesirable, multiple 
high peaks, in the NMR spectra (Figure 6.10). Therefore, in all subsequent 
experiments, 25 mM phosphate buffer was added into the media in place of HEPES, 
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to maintain the pH at 7.4. The colour of the phenol red, a pH indicator in the media, 
was observed and visually compared to when HEPES was used, and no differences 
were observed (data not shown). The colour of the media with HEPES buffer and pH 
7.4 phosphate buffer appeared to have the similar pink/red colour, which indicated a 
similar pH of both media. As the phosphate buffer provide only a clear distinct peak 
in NMR metabolomics with much less interfere to the overall NMR spectrum, 
phosphate buffer was used in all subsequent neutrophil NMR metabolomic 
experiments.  
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 Figure 6.10: The interference peaks of HEPES. The BLUE spectrum 
represented the neutrophil metabolomics when the HEPES-containing media was used 
during the isolation of neutrophils. In the BLACK circle, the multiple peaks of HEPES 
were present. The RED spectrum represented the neutrophil metabolomics when the 
HEPES was removed. 
6.8.2 Optimising the NMR analyses to detect low level metabolites 
Aim: To optimise protocol for the detection of low quantity metabolite 
Objectives: 
1. To determine if metabolites such as NADP+ are lost during the extraction 
protocols 
2. Refine the sensitivity of the parameter sets for NMR spectral analyses to 
detect NADP+ 
 Neutrophils are aggressive, bacteria-killing immune cells, and possess 
sophisticated mechanisms for the phagocytosis and killing of bacteria. These include 
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the generation of reactive oxygen metabolites via the NADPH oxidase which is rapidly 
activated during cell stimulation (186). Therefore, there are dynamic changes in the 
concentrations and ratios of NADPH and NADP+ during neutrophil activation. 
However, in the preliminary studies above using 107 neutrophils after PMA treatment, 
the spectral peaks representing NADP+ and NADPH were barely detectable (Figure 
6.11). Therefore, experiments were performed in order to determine whether the 
detection of the spectral peaks could be enhanced by increasing sensitivity of the NMR 
spectral analyses. For this, more sensitive parameter sets for NMR spectral analyses, 
NOESY, were applied for samples collected and processed after different incubation 
times. The study revealed the presence of more prominent NADP+ and NADPH 
spectral peaks at the number of scans of 4,096, using NOESY parameter sets (Figure 
6.11C). Usually, 32 scans is the default setting for NOESY parameter sets (Figure 
6.11B). Using this approach, the metabolites of interest were present in the sample, 
however, at low levels.   
In conclusion, the current protocol of intracellular neutrophil extraction was 
able to stabilise some highly active metabolites, including NADP+, in neutrophils. 
However, it may be that the low intensity of the spectral peaks are the result of high 
turnover rate of this molecule. Therefore, in subsequent experiments, higher sensitivity 
NMR analyses was applied in order to study specific metabolic pathways. Also, further 
experiments were performed to determine whether or not NADP+ was lost during the 
intracellular extraction of neutrophils (see Section 6.9.2)  
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 Figure 6.11: NADP+ peak identification using Chenomx Profiler® 
software (version 8.2 standard). The NMR spectral data of the sample of 107 
neutrophils after PMA treatment were analysed by the same parameter sets, NOESY, 
at different numbers of scans: 32 in (B) and 4,096 in (C). (B, C) The NADP metabolite 
was identified in two different NMR spectrum. (A) In Chenomx Profiler® software, 
there are three different coloured spectral lines; two profiler spectra (RED and 
BLACK) and one compound spectrum (BLUE). The BLACK line indicates the NMR 
spectrum of neutrophil sample. The BLUE line indicates the predicted compound 
(NADP+) spectrum by Chenomx Profiler® software (version 8.2 standard). The RED 
line indicates the sum line of metabolic compounds at that location (ppm). At the left 
upper corners, all peak locations of NADP+ metabolite were informed in ppm, the 
GREEN digits indicated in the spectral peaks (BLACK line) at that location (ppm) 
were matched with the predicted spectral peaks (BLUE line). (B) The neutrophil 
samples were analysed by NOESY parameter sets at NS of 32 (5 min processing time). 
The NADP+ spectral peaks were barely evident. (C) The same sample was re-analysed 
by NOESY parameter sets at NS of 4,096 (6 h processing time) and then prominent 
NADP+ spectral peaks were observed. 
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6.9 Special considerations in neutrophil NMR analyses 
6.9.1 Contaminants or unidentified metabolites in neutrophil extracts 
As the NMR technique is very sensitive, it is possible that contaminants, 
including chemicals in buffers and disinfectants, appear in extracts and are included in 
the NMR spectra. It is clearly necessary to identify and then eliminate such 
contaminants. In the neutrophil experiments for metabolomics, HEPES was avoided, 
as it produces an NMR spectrum that interferes with the neutrophil signals (Figure 
6.9). However, as the pH of samples can influence the chemical shifts of the NMR 
spectrum, phosphate buffer was added to maintain the pH to around 7.2 and 7.5.  
6.9.2 High turnover rate metabolites  
Neutrophils are dynamic cells whose activity is highly regulated in order to 
eliminate infection, and at the same time, to control inflammation. Therefore, 
neutrophil metabolites are expected to turnover at a high rate. However, as NMR 
metabolomic analysis provides a snapshot at a single point in time, it is necessary to 
distinguish metabolites that are present either at a steady low level and those which 
are transiently generated at high levels, but have a high turnover rate. During the initial 
analysis of neutrophils metabolomic spectral data, some specific metabolites, 
including NAD+, NADH, NADP+ and NADPH, were detected at low levels, which 
was counter-intuitive considering the reported importance of these molecules in 
neutrophil metabolism (187). There are a number of potential reasons for this 
observation: these metabolites may be highly unstable; they might be degraded by 
neutrophil intracellular enzymes or chemicals during the extraction process; the 
metabolites might have a high turnover rate or finally, they may genuinely be present 
in neutrophils at lower levels than those that were anticipated. 
 To exclude the possibility of metabolite loss during the extraction procedure, 
the specific spectra for NAD+, NADH, NADP+ and NADPH were analysed in 
different cell types using similar extraction techniques to those used for the neutrophil 
metabolite. Extracts were made from the cell line, PLB-985 (myeloid leukaemic cell 
line). The peaks of NAD+ and NADP+ were readily clearly observed these samples 
(data not shown). Therefore, additional experiments were designed to determine if 
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NADP+ was lost during the extraction protocol. For these experiments, purified 
NADP+ (Sigma Aldrich, USA) was added into the samples under three different 
conditions: with cell pellets (9.7 x 106 neutrophils) which then went through the 
extraction (to detect any loss from the intracellular enzymes and the extraction 
process); in PBS without cell pellets and undergoing the extraction process (to detect 
any loss during the extraction process); NADP+ alone without any extraction process 
(a positive control) (Table 6.2). The data in Figure 6.12 shows that NADP+ was not 
significantly lost during the extraction process, as the amounts of NADP+, determined 
by the height of the peak (in the RED circle), were similar in the control groups and 
the other two groups (processed with and without cells). The final amount of NADP+ 
after the extraction process, either in the presence or the absence of neutrophils, was 
similar. The NADP+ was unlikely to be degraded by the released intracellular enzymes 
and metabolites during the extraction process.  
In conclusion, the very low levels of NADP+ detected in neutrophil extracts 
might be explained by the presence of only low levels of this metabolite in the cells, 
rather than technical/extraction errors. This suggests that the steady-state levels of 
NADP+, which is involved in neutrophils in producing toxic oxygen radicals, are low 
and likely to be as a result of its high-turnover rate. The analyses also reflect one 
limitation of NMR metabolomics as it only measures steady state levels of molecules 
at a single time-point i.e. a snapshot of the metabolites at the time of sampling. 
Therefore, to overcome this limitation, neutrophils were stimulated (by PMA) and 
samples were collected as a time-point series following activation. 
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Table 6.2: Experiments to determine loss of NADP+ during sample 
preparation for NMR. 
Conditions Amount of 
NADP+ (μg) 
The step of NADP+ 
addition 
Objectives 
NADP+ control 20 No processing A positive control 
NADP+ with no 
cells 
10 Before the heating step 
and prior to 
intracellular extraction 
To detect any loss from 
the extraction process 
NADP+ added 
to the cell 
pellets 
10 Before the heating step 
and prior to 
intracellular extraction 
To detect any loss from 
the intracellular 
enzymes and the 
extraction process 
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Figure 6.12 No significant loss of NADP+ signals during the extraction 
process. The peaks of NADP+ was observed in all three experimental conditions: 
NADP+ control (20 μg) (GREEN), NADP+ (10 μg) was added into the PBS which 
then went through the extraction process (RED), and NADP+ (10 μg) which was 
added into the cell pellets and which then went through the extraction process (BLUE). 
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6.10 The current optimised protocol for NMR analyses of human 
neutrophils  
All of these preliminary experiments were performed to optimise the 
extraction/analysis of neutrophil metabolites, and the optimised protocol is fully 
described in Chapter 2.5 (Methods: Metabolomics).  
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6.11 NMR Metabolomics of healthy human neutrophils  
 Neutrophils were isolated from the whole blood of healthy volunteers (see 
protocol in Chapter 2.5). After RBC lysis, the neutrophils in media (RPMI-1640 media 
with 25 mM phosphate buffer) were equally aliquoted into three tubes for technical 
replicates. From this step onwards, all technical triplicates were separately extracted 
and analysed by NMR.  
 The NMR spectra of 11 healthy controls were analysed to identify the 
similarities in the healthy group (Figure 6.14). The baseline neutrophil metabolites 
were found to be highly variable (n = 11) (Figure 6.14) with abnormally distinct peaks 
present in some samples (RED circle, Figure 6.14). In this study, Chenomx Profiler® 
software (version 8.2 standard) was used to identify the metabolites from NMR 
spectra, and 338 metabolites were positively identified by the software. Notably, 
Figure 6.13 demonstrates the peaks of two distinct compounds: H2O (left label), the 
major spectral interference which is dramatically suppressed but still prominent (as 
H2O is the major source of intracellular 
1H.), and TSP (right label), the internal 
reference. These peaks were present in all neutrophil metabolomic samples. 
Approximately 30% of the overall peaks could not be attributed to specific 
metabolites, including the contaminants/unidentified metabolites. To distinguish 
between the contaminants and the unidentified metabolites, the analytical criteria (see 
Table 6.3) were created based on the fact that all metabolites in the cells should not be 
substantially different from other intracellular metabolites and the technically 
triplicated samples could produce similar spectra. Therefore, the peaks were visualised 
one by one, and in all three replicates. The possible characteristics of the contaminant 
peaks included the high intensity peaks that were observed in some, but not all, 
triplicates or samples (Figure 6.13; 6.14) or the peaks that were extremely high in 
comparison to other metabolites.  
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Table 6.3: The criteria to distinguish between an unidentified metabolite 
and a contaminant.  
Criteria Likely to be an 
unidentified metabolite 
Likely to be a 
contaminant 
Reproducibility in all 
triplicates 
Yes No 
Reproducibility in all 
samples 
Yes No 
The distinct peak e.g. 
singlet or doublet peaks 
Yes No 
Abnormally high peak 
intensity (comparable to 
H2O) 
No Yes 
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Figure 6.13: The spectral data of healthy neutrophils. The spectral data of 
healthy neutrophils (n = 11) were visualised by Bruker TopSpin® software. The 
BLACK square marked the peaks of two distinct compounds: H2O (left label), the 
major spectral interference which was dramatically suppressed but still prominent, 
and TSP (right label), the internal reference.        
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 Figure 6.14: Neutrophil metabolomics of healthy individuals (n=11, 
measured in triplicate). (A) The shape and height of peaks vary between samples and 
(B) the abnormally high peaks were observed in some samples, which may represent 
contaminants or unidentified metabolites (in RED circle).
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Table 6.4: Common metabolites in healthy neutrophils. The total number 
of metabolites detected by Chenomx Profiler® software (version 8.2 standard) was 
338 (the total metabolite pattern available in Chenomx Profiler® software), and of 
these 89 were reproducibly detected in human healthy neutrophils. (n=11, each with 3 
technical replicates) 
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6.12 NMR metabolomics of human neutrophils in response to 
PMA 
Phorbol-12-myristate-13-acetate (PMA), a phorbol ester, directly stimulates 
protein kinase C (PKC) in neutrophils, which then activates the NADPH oxidase 
through redistribution and activation of PKC and subsequent phosphorylation of 
several proteins, including p47phox, the cytosolic NADPH-oxidase component (188). 
Following PMA treatment, neutrophils become highly activated and many metabolic 
pathways are stimulated, including the production of superoxide anions. The PMA-
induced neutrophil NADPH-oxidase activation is very rapid but transient. For 
example, the maximal superoxide production is observed at 5 - 8 min after treatment, 
is sustained for around 15 min and then gradual declines to baseline levels (188).  
Because of its ability to rapidly and extensively (but transiently) activate 
neutrophils, PMA was chosen as the agonist to initially characterise the metabolomic 
changes following activation, and to establish the kinetics of these responses. In these 
experiments, the metabolomic changes in neutrophils were evaluated at 5 and 15 min 
after PMA treatment.  
The experiments were performed on three different preparations of neutrophils, 
with total cell numbers of: 4 x 106 (experiment G1); 4 x 106 (experiment G2); 3.6 x 106 
(experiment G3), and using the NS of 256. Each sample was analysed in triplicate (3 
technical repeats). The data at baseline were quite scattered (Figure 6.15), presumably 
that in the un-activated cells, levels of metabolites were quite low and this low 
signal:noise ratio led to apparent scattering of data. However, when all three 
experiments were analysed using PCA, a consistent pattern of neutrophil 
metabolomics in response to PMA was observed.  
At 5 min after the PMA treatment, two distinct metabolomic responses were 
observed (Figure 6.15A). The points of the triplicated samples at each time-point 
became more clustered, meaning that the triplicated data became more similar, 
compared to the wider scatter of the pre-treatment samples that were more disperse 
and therefore not very similar to each other. Second, the triplicated points representing 
the neutrophil spectral data at 5 min after the PMA treatment (GxPMA5) of each of 
the three preparations of neutrophils (BLUE points in RED circle, YELLOW points 
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in YELLOW circle and RED points in BLUE circle) tended to move towards the 
same area. There are two possible explanations for these two observations of 
neutrophil metabolomics in response to PMA. 
The first explanation is the technical limitation of the NMR metabolomics to 
detect the low level metabolites present in resting neutrophils (see Section 6.8.2). 
Therefore, the triplicated data did not generate very similar spectral data and the signal 
to noise ratio was low. Based on the experimental study to optimise the number of 
cells required for neutrophil NMR metabolomics, the number of cells significantly 
impacted the interpretation of the spectral data, and also the confidence level in the 
comparison study (see Section 6.12; 6.13). This study suggested that when the number 
of neutrophils was 3.5 x 106 cells, the number of scans should be at least 512 to allow 
the comparison study between groups. However, in the current experiments of 
neutrophil metabolomics in response to PMA treatment, the NS of 256 was applied. 
However, 5 min after treatment with PMA resulted in the generation of higher levels 
of metabolites, therefore providing the higher peak intensity, and a greater signal to 
noise ratio. The high peak intensity, could possibly compensate for or overcome the 
limitation of the NMR approach when low numbers of cells were used.  
A second explanation may be the similarity of neutrophil metabolomics in 
response to the PMA treatment, despite the significantly different baseline spectra (or 
at resting state) (see Section 6.11). Due to the fact that PMA is a strong protein kinase 
C activator, high levels of similar metabolites are likely to be produced in neutrophils 
in response to this treatment. These cellular responses should be similar in neutrophils 
from healthy controls, and provide the similar patterns of metabolomic profiles in 
response 5 min after activation with this agent. 
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Figure 6.15: Neutrophil metabolomic changes in response to PMA 
treatment. In PCA, the 3D scores plots of PC 1 (48.8%) and PC 2 (22.4%) in (A), and 
PC 2 (22.4%) and PC 3 (14.3%) in (B) are presented. (Abbreviations are: G1NoPMA0 
= preparation 1, no PMA added at time zero; G3PMA5 = preparation 3 PMA added 
for 5 min etc.) 
!
!
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 In the subsequent analyses (Figure 6.16), neutrophil metabolomics at baseline 
(NoPMA0 group), 5 min after the PMA treatment (PMA5 group) and 15 min after the 
PMA treatment (PMA15 group) were compared. In PCA, the principal components 
that represented the variables of neutrophil metabolomics in three different states of 
response (NoPMA0, PMA5 and PMA15 groups) were clearly different from each 
other (Figure 6.16). The neutrophil metabolomic profiles at 5 and 15 min were 
different from the profiles at resting state (or baseline). Therefore, in the next steps, 
the metabolites that were significantly changed in response to the PMA treatment were 
investigated. 
 The principal component analysis allowed for the preliminary visualisation of 
the spectral data of neutrophil metabolomics in response to the PMA treatment. This 
allowed for visual distinctions of the similarities and differences of the spectral data at 
each time-point, (NoPMA0, PMA5 and PMA15). The neutrophil metabolomics at the 
baseline were highly variable from one healthy individual to another, and within the 
technical replicates. However, the PMA treatment was likely to activate similar sets of 
metabolites in neutrophils (see Section 6.12). However, as the objectives of the study 
were to detect changes in metabolites in response to the PMA treatment, the fold 
change analysis of the spectra at either 5 or 10 min after PMA treatment were 
compared to the spectra at baseline. The fold change threshold was 2.  
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 Figure 6.16: The PCA of the neutrophil metabolites in response to PMA 
treatment. In each experiment, the three groups of neutrophils, NoPMA0 (in RED 
circle), PMA5 (in GREEN circle) and PMA10 (in BLUE circle), were grouped and 
compared. (Abbreviations: NoPMA0 = neutrophil metabolomics at baseline, PMA5 
= neutrophil metabolomics at 5 min after PMA treatment, PMA10 = neutrophil 
metabolomics at 10 min after PMA treatment. A, B and C represent three different 
preparations of neutrophils, with three technical replicates at each time-point.) 
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 Using the online programme Metaboanalyst®, the fold change analysis in each 
study group (PMA5 and NoPMA0: PMA15 and NoPMA0) was performed. Three lists 
of spectral peaks were obtained for each study group (n=3 for: PMA5 and NoPMA0; 
PMA15 and NoPMA0). In the PMA5 and NoPMA0 comparison, the number of 
spectral peaks that were changed ≥ two fold in the PMA5 group compared to NoPMA0 
group, were 29, 129 and 24 for experiments 1, 2 and 3 respectively. In the PMA15 and 
NoPMA0 comparison, the number of spectral peaks that were changed ≥ two fold 
compared to NoPMA0 group, were 60, 219 and 39 for experiments 1, 2 and 3, 
respectively. The spectral peaks were then selected for further analyses if they were 
detected in at least 2 out of 3 experiments. In the comparison study between the PMA5 
and NoPMA0, 43 metabolites were identified as changed spectral peaks (Table 6.5), 
however, only 7 metabolites were confirmed to change ≥ two fold in the PMA5 group 
compared to NoPMA0 (Table 6.6). For the comparison study between PMA15 and 
NoPMA0, 40 metabolites were identified as changed spectral peaks (Table 6.7), and 7 
metabolites were confirmed to change ≥ two fold in the PMA15 group compared to 
NoPMA0 (Table 6.8). To confirm identity of the metabolites represented by the 
spectral peaks, manual appraisal of possible metabolites was performed. 
The spectral peaks were manually appraised using Chenomx Profiler® and 
Bruker TopSpin® software by applying the following criteria. First, the peaks 
representing the specific metabolites were defined as either the distinct or the non-
distinct peaks. The distinct peak means either a spectral peak represented only one 
dominant metabolite or a spectral peak absolutely matched with the metabolite peak 
(from Chenomx Profiler® software). In general, the distinct peaks usually locate in the 
area represented by the specific chemical structure, for example, aromatic rings and 
methyl groups. If the spectral peak was the distinct peak of the metabolites, then that 
identified metabolite was likely to change. Second, if the spectral peak was slightly 
matched with the metabolite peak, then the other peaks that represented that metabolite 
would be reviewed and if other distinct peaks representing that metabolite was not 
changed, then that metabolite was less likely to have changed. 
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Table 6.5: The manual appraisal of possible metabolites. All 43 identified 
metabolites that were different by ≥ 2 fold in the PMA5 group compared to the 
NoPMA0 group, were appraised one by one. Only 7 metabolites were subsequently 
confirmed to be significantly different (Table 6.6).  
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Table 6.6: The list of changed identified metabolites between PMA5 and 
NoPMA0 groups. Seven identified metabolites were confirmed visually to be 
different. The threshold of the fold change analysis was 2. 
Compound Names HMDB PubChem KEGG 
Betaine HMDB00043 247 C00719 
Dimethylamine HMDB00087 674 C00543 
Formic acid HMDB00142 284 C00058 
3-Methylhistidine HMDB12897 64961 C20157 
D-Glucose HMDB00122 5793 C00031 
Methylguanidine HMDB01522 10111 C02294 
(Abbreviations: HMDB = Human Metabolome Database, KEGG = Kyoto 
Encyclopedia of Genes and Genomes, PubChem = PubChem project of National 
Center for Biotechnology Information (NCBI)) 
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Table 6.7: The manual appraisal of possible metabolites. All 39 identified 
metabolites that were different by ≥ 2 fold in the PMA15 group compared to the 
NoPMA0 group, were appraised one by one. Only 7 metabolites were subsequently 
confirmed to be significantly different (Table 6.8).  
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Table 6.8: The list of changed identified metabolites between PMA15 and 
NoPMA0 groups. Seven identified metabolites were confirmed visually to be 
different. The threshold of the fold change analysis was 2. 
Compound Names HMDB PubChem KEGG 
Dimethylamine HMDB00087 674 C00543 
3-Methylhistidine HMDB00479 64969 C01152 
D-Glucose HMDB00122 5793 C00031 
Glucose 6-phosphate HMDB01401 5958 C00092 
Oxypurinol HMDB00786 4644 C07599 
Succinylacetone HMDB00635 5312 NA 
Taurine HMDB00251 1123 C00245 
(Abbreviations: HMDB = Human Metabolome Database, KEGG = Kyoto 
Encyclopedia of Genes and Genomes, PubChem = PubChem project of National 
Center for Biotechnology Information (NCBI), USA, NA = not available) 
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6.13 The study of neutrophil NMR metabolomics in health and 
rheumatoid arthritis 
 Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease that 
primarily affects the synovium of joints (see Section 6.14). Evidence suggests that 
neutrophils (158) contribute to the pathophysiology of RA through the release of 
cytotoxic and immunoregulatory molecules (75). In the affected joints, neutrophils are 
the majority of immune cells deposited in the synovium (189) and constitute up to 
~90% of immune cells in synovial fluid. Moreover, the peripheral blood neutrophils 
from RA patients have an activated phenotype including delayed apoptosis, increased 
capacity to produce reactive oxygen species, active gene expression and membrane 
expression of high-affinity Fcγ receptors (FcγR) (190,191). This study, therefore, 
aimed to use NMR metabolomics to characterise the distinct phenotype of RA 
neutrophils.  
 RA neutrophils were freshly isolated from whole blood as described in section 
2.5. The demographic data of the patients and the healthy controls were described in 
Table 6.9. The number of cells in each sample varied due to the total number derived 
from the whole blood, and were technically triplicated. All the healthy controls and 
the rheumatoid arthritis patients were Caucasian. The mean age was 34.75 ± 14.38 
years old for healthy controls, and 63.25 ± 11.02 years old for rheumatoid arthritis 
patients. 
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Table 6.9: The clinical data of the healthy and the RA neutrophils  
Samples Sex Age Total cell 
number 
Duration 
from the 
diagnosis 
Remarks (e.g. time 
from diagnosis, 
special medications) 
Healthy1 Male 55 3.6 x 106 - - 
Healthy2 Male 35 4 x 106 - - 
Healthy3 Male 24 4 x 106 - - 
Healthy4 Female 25 8.5 x 106 - - 
RA1 Male 47 7 x 106 6 months Methotrexate 
RA2 Female 69 4.5 x 106 3 months Methotrexate, 
Sulfasalazine and 
Hydroxychloriquine 
RA3 Male 66 10 x 106 6 months Methotrexate and 
Hydroxychloriquine 
RA4 Male 71 8.5 x 106 15 years Rituximab. Active 
disease. 
(Note: Rituximab is a biological therapy for severe rheumatoid arthritis. It is a 
monoclonal antibody against the protein CD20, which is primarily found on the 
surface of B cells. RA4 patient was later excluded from the study analysis to the fact 
that this drug was used and that the patient had a long and difficult clinical history.) 
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In the first experiments, the principal component analyses were performed to 
visualise the spectral data of the two groups. In the 3D scores plot, the principal 
components of the two groups, RA and healthy neutrophils, were likely to be 
distinguished from each other. However, the RA4 sample represented by three 
GREEN points in the BLUE circle was clustered at the same area as the healthy 
samples (Figure 6.17). Therefore, the clinical data of the RA4 sample was reviewed 
and revealed the significantly different clinical history of this patient from the others. 
RA4 patient’s disease was active and the biological medication, Rituximab, was 
prescribed at the time of the neutrophil collection. Rituximab is a monoclonal antibody 
against the protein CD20, which is primarily found on the surface of immune system 
B cells, and therefore destroys B cells. Moreover, in a previous study of NMR-based 
serum metabolomics of the RA patients (192), the serum metabolomics in the patients 
receiving biological treatment revealed the distinct metabolomics spectrum from either 
the healthy control or the pre-treatment RA patients. Due to the significant difference 
in clinical background, which highly modulates the neutrophil phenotype, sample RA4 
was excluded from further analyses.  
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 Figure 6.17: PCA of neutrophil NMR metabolomics in healthy controls 
and RA patients. The healthy neutrophil group (n = 4) was represented by the RED 
points, while the RA neutrophil group (n = 4) was represented by the GREEN points. 
However, one RA sample (the GREEN points in the BLUE circle) was excluded from 
the further study due to the significant difference in clinical background. 
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For the further analyses, the number of RA samples was 3, while the healthy 
controls were 4. The principal component analyses revealed the two distinct groups of 
samples, RA and healthy neutrophils (Figure 6.17; 6.18). Therefore, at a first step, the 
common metabolites in RA neutrophils were listed and then compared with those in 
healthy controls. To define the common metabolites, the same criteria of metabolites 
present in ≥ 50% of samples (in this case, 2 out of 3) was applied. As a result, 97 
metabolites were found in common between all 3 RA samples (see Table 6.10), while 
89 common metabolites were identified in the 4 healthy controls (see Table 6.11). The 
comparison of the metabolites revealed 17 metabolites were present in RA neutrophils 
but absent in healthy neutrophils, and 12 metabolites were present vice versa (Table 
6.12).  
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Table 6.10: Common metabolites in RA neutrophils. The total number of 
metabolites detected by Chenomx Profiler® software (version 8.2 standard) was 338 
(the total metabolite pattern available in Chenomx Profiler® software), and of these 
97 were reproducibly detected in human RA neutrophils. (n = 3, each with 3 technical 
replicates) 
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Table 6.11: Common metabolites (n = 17) present in RA neutrophils, but 
not present in healthy neutrophils. The total number of metabolites identified by 
Chenomx Profiler® software (version 8.2 standard) was 338 (the total metabolite 
pattern available in Chenomx Profiler® software). 
 
Table 6.12: Common metabolites (n = 12) present in healthy neutrophils, 
but not present in RA neutrophils. The total number of metabolites identified by 
Chenomx Profiler® software (version 8.2 standard) was 338 (the total metabolite 
pattern available in Chenomx Profiler® software). 
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 Figure 6.18: The PCA of the healthy and rheumatoid arthritis (RA) 
neutrophils. The principal components of the healthy neutrophil NMR spectra (n = 4) 
were displayed in PINK circle, while the principal components of the RA neutrophil 
samples (n = 3) were displayed in GREEN circle. All samples were technically 
triplicated. 
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Using the online programme Metaboanalyst®, the statistical analyses of the 
metabolomic spectra between two groups, RA and healthy neutrophils, were 
performed. The fold change analysis, at the threshold of 2, revealed that 68 spectral 
peaks were ≥ 2 fold different in healthy compared to the RA group. Among 68 spectral 
peaks, 57 metabolites were identified. However, to confirm identity of the metabolites 
represented by the spectral peaks, manual appraisal of possible metabolites was 
performed (Table 6.13). Only 14 metabolites were changed at least 2 folds in the 
healthy group when compared to the RA group (Table 6.14).  
The pathway analyses were performed using those 14 metabolites (Figure 6.19; 
Table 6.15). Using the pathway analyses in the Metaboanalyst® programme, the 
metabolites were analysed through pathway analysis algorithms (Hypergeometric test 
for an over representation analysis and Pathway topology analysis for a pathway 
impact value). The pathways involved in the metabolomic changes were listed in Table 
6.15. The most impacted pathway is phenylalanine metabolism.  
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Table 6.13: The manual appraisal of possible metabolites. All 57 identified 
metabolites that were different by ≥ 2 fold in the healthy group compared to the RA 
group, were appraised one by one. Only 14 metabolites were subsequently confirmed 
to be significantly different (Table 6.14).  
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Table 6.14: The list of changed identified metabolites between RA and 
healthy neutrophils. Fourteen identified metabolites were confirmed visually to be 
different. The threshold of the fold change analysis was 2. 
Compound Names HMDB PubChem KEGG 
3-Hydroxymethylglutaric 
acid HMDB00355 1662 C03761 
3-Hydroxyisovaleric acid HMDB00754 69362 NA 
5-Aminolevulinic acid HMDB01149 137 C00430 
Formic acid HMDB00142 284 C00058 
D-Glucose HMDB00122 5793 C00031 
Glucose 1-phosphate HMDB01586 439165 C00103 
Glucose 6-phosphate HMDB01401 5958 C00092 
L-Glutamine HMDB00641 5961 C00064 
Glutathione HMDB00125 124886 C00051 
Isocitric acid HMDB00193 1198 C00311 
Methanol HMDB01875 887 C00132 
L-Acetylcarnitine HMDB00201 1 C02571 
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Compound Names HMDB PubChem KEGG 
Taurine HMDB00251 1123 C00245 
Trimethylamine N-oxide HMDB00925 1145 C01104 
(Abbreviations: HMDB = Human Metabolome Database, KEGG = Kyoto 
Encyclopedia of Genes and Genomes, PubChem = PubChem project of National 
Center for Biotechnology Information (NCBI), USA) 
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Figure 6.19: Pathway analysis. In the overview of pathway analysis (left), 
each point represented the impacted pathway, for example phenylalanine metabolism 
(the labelled red point at the right upper of the graph). The x axis represents the 
pathway impact (implies the contribution of the changed metabolites to that pathway, 
for example the node (more impacted) or the end product (less impacted)), and the y 
axis is the p value (implies the number of changed metabolites in that pathway). The 
methane metabolism pathway was demonstrated (right), where the RED boxes 
represented the changed metabolites and the BLUE boxes represented the other 
unchanged metabolites. The methane metabolism pathway that was highly impacted 
by metabolomic changes in synovial fluid from RA and IA (non-RA inflammatory 
arthritis). 
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Table 6.15: List of the pathway names that impacted by the changed 
metabolites. (The threshold of the fold change analysis was 2.) 
Pathway Name Total Hits P Impact 
Methane 
metabolism 34 3 0.000669 0.16384 
Nitrogen 
metabolism 39 3 0.001006 0 
Starch and sucrose 
metabolism 50 3 0.002084 0.15505 
Glycolysis or 
Gluconeogenesis 31 2 0.011465 0 
Galactose 
metabolism 41 2 0.019612 0.03137 
Glyoxylate and 
dicarboxylate 
metabolism 50 2 0.028507 0.16853 
D-Glutamine and 
D-glutamate 
metabolism 11 1 0.057949 0.02674 
Amino sugar and 
nucleotide sugar 
metabolism 88 2 0.079377 0.08797 
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Pathway Name Total Hits P Impact 
Citrate cycle (TCA 
cycle) 20 1 0.10304 0.05826 
Taurine and 
hypotaurine 
metabolism 20 1 0.10304 0.33094 
Alanine, aspartate 
and glutamate 
metabolism 24 1 0.12243 0.20703 
Pentose phosphate 
pathway 32 1 0.16006 0 
Pyruvate 
metabolism 32 1 0.16006 0 
Glutathione 
metabolism 38 1 0.1873 0.23743 
Inositol phosphate 
metabolism 39 1 0.19176 0 
Primary bile acid 
biosynthesis 47 1 0.22663 0.00822 
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Pathway Name Total Hits P Impact 
Glycine, serine and 
threonine 
metabolism 48 1 0.23089 0 
 (Abbreviations: Total is the total number of compounds in the pathway. Hits 
is the number of the actually matched metabolites. “p” is the p value calculated from 
the enrichment analysis. Impact is the pathway impact value calculated from pathway 
topology analysis.)   
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6.14 NMR metabolomics of synovial fluid 
Synovial fluid is the viscous fluid secreted from the cells lining the synovium 
of joints, which include fibroblasts and fibroblast-like synoviocytes (193). The role of 
synovial fluid is to protect the joints by decreasing the friction between two articular 
cartilage surfaces during movement or joint loading. Synovial fluid also provides the 
nutrients and lubrication for the joints (194). As synovial fluid is normally an 
ultrafiltrate of plasma plus hyaluronic acid (the carbohydrate lubricant), its 
biochemical properties are similar in physiologic conditions. However, in joint 
diseases, the physiologic conditions of synovial fluid are disturbed and the volume and 
composition of synovial fluid changes. Identifying the metabolites in such fluids could 
help identify the biological functions that are perturbed in these joints and identify 
biomarkers to identify efficacy of drug treatments. 
The synovial fluid samples used in this study were obtained from patients with 
inflammatory joint diseases and have increased amounts of proteins, cells (including 
inflammatory cells), cytokines and metabolic enzymes. These components will 
potentially interfere with the synovial fluid NMR metabolomic study, as they could 
obscure the peaks of low-quantity metabolites. Therefore, the preparation steps for 
synovial fluid were different from those used for extraction of intracellular neutrophil 
metabolites. In particular, it was necessary to remove the proteins and some large 
molecules in the diseased synovial fluids. Moreover, the internal reference, for 
example TSP, could not added into the synovial fluid, as TSP-protein complexes will 
be formed.  
Despite the fact that the extraction procedures were altered, the analytical 
processes for synovial fluid NMR metabolomics were similar those used for 
neutrophils: the preliminary spectral analyses, the creation of a pattern file (see 
Supplementary data: The synovial fluid pattern file), and the spectral and statistical 
analyses were all similar. 
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6.15 The study of synovial fluid NMR metabolomics in 
rheumatoid arthritis 
In rheumatoid arthritis (RA), the underlying pathology is immune-mediated 
inflammatory joint disease (193). The RA joints are marked by inflammation of the 
synovium and destruction of articular cartilage and bones. The RA synovium becomes 
hyperplastic with infiltration by a variety of immunocompetent cells (activated 
neutrophils in particular). Therefore, RA synovial fluid components are enriched with 
cytokines, inflammatory mediators and proteolytic enzymes that degrade the 
extracellular matrix (195). 
  According to the European League Against Rheumatism (EULAR) RA 
classification criteria (196), there are no definite diagnosis criteria for RA. However, 
the classification criteria (Table 6.16) is recommended to facilitate clinical diagnosis, 
where the definite diagnosis is likely if the score is ≥ 6. Interestingly, although the 
synovial fluid analyses and profiles are essential in the diagnosis of joint disease, they 
are not included in the classification criteria. RA has a distinct pathophysiology 
leading to joint inflammation and destruction, but the current simple synovial analyses 
cannot distinguish between RA and other inflammatory joint diseases.  
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Table 6.16: The 2010 classification criteria of rheumatoid arthritis of 
European League Against Rheumatism (EULAR) 
Criteria Score 
JOINTS DISTRIBUTION (0 - 5) 
1 large joint 0 
2 - 10 large joints  1 
1 - 3 small joints (large joints not counted) 2 
4 - 10 small joints (large joints not counted) 3 
> 10 joints (at least one small joint) 5 
SEROLOGY (0 - 3) 
Negative RF AND negative ACPA 0 
Low positive RF OR low positive ACPA 2 
High positive RF OR high positive ACPA 3 
SYMPTOM DURATION (0 - 1) 
< 6 weeks 0 
≥ 6 weeks 1 
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ACUTE PHASE REACTANTS (0-1) 
Normal CRP AND normal ESR 0 
Abnormal CRP OR abnormal ESR 1 
(Abbreviations: RF = rheumatoid factor, ACPA = Anti-Citrullinated protein 
antibody, CRP = C-reactive protein, ESR = Erythrocyte sedimentation rate) 
NMR metabolomics was therefore used to characterise the metabolomic 
patterns of synovial fluid in rheumatoid arthritis, which may have 
diagnostic/prognostic values. Moreover, the study of metabolomic changes and 
pathway analyses could possibly shed new insights into the understanding in RA 
pathology within joints. 
The synovial fluid samples were as follows: 14 synovial fluid samples from 
RA and 14 from other inflammatory joint diseases (non-RA inflammatory arthritis, 
IA) (gout/crystal arthropathy (n = 4), reactive arthritis (n = 3) and n = 1 each of SLE, 
JIA, Behçets disease, ulcerative colitis, ankylosing spondylitis, palindromic arthritis 
and inflammatory monoarthritis). Spectral data of synovial fluids from RA and IA 
were visualised using Bruker Topspin® software. The spectral alignments were 
observed, because for these for synovial fluid NMR data, there was no internal 
reference (TSP could not be added into the samples.). The spectra had to be aligned in 
order to compare them with the bucket table data of both groups, RA and IA. Two 
statistical analyses, unpaired T-Test and ANOVA, were performed and the results 
were compared. 
A) Unpaired T-Test 
Using Amix® software, the spectral data of RA and IA synovial fluids were 
interpreted into the bucket table with peak intensity value. The statistical analyses were 
performed via the online programme, Metaboanalyst®. The unpaired T-test analysis 
was selected for the comparison of two groups, RA and IA. The p value was at 0.01.  
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As a consequence, 36 spectral peaks were identified that were significantly 
different between RA and IA (non-RA inflammatory arthritis) groups. However, only 
22 identified metabolites were related to the significantly changed spectral peaks 
(Table 6.17). In the next step, the peaks at the locations were visualised individually 
to confirm that they represented the specific metabolites. When analysing spectral 
patterns, one spectral peak may represent either the specific metabolites (the so called 
“distinct peaks”), or the summation of several metabolites (the so called “non-distinct 
peaks”). The changes in the distinct peaks were more likely to be interpreted as the 
changes in concentrations of the identified metabolites, rather than from other 
unspecified metabolites. For example, the spectral peaks of phenylalanine comprises 
17 peaks in total, of which 5 are distinct peaks and 12 are non-distinct peaks. The 
spectral peaks were significantly different in 8 out of the 17 peaks, including 2 distinct 
peaks and 6 non-distinct peaks. Therefore, phenylalanine was likely to be confirmed 
as a significantly changed metabolite when compared between RA and IA groups. All 
22 possible metabolites were appraised one by one, and only 15 metabolites were 
subsequently confirmed to be significantly different (Table 6.18). 
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Table 6.17: The manual appraisal of possible metabolites. All 22 identified 
metabolites that were significantly different between two groups, RA and IA synovial 
fluids, were appraised one by one. Only 15 metabolites were subsequently confirmed 
to be significantly different.  
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 Table 6.18: List of significantly changed, identified metabolites between 
RA and IA (non-RA inflammatory arthritis) (n=15). The identified metabolites that 
the spectra were confirmed visually to be significantly different. The statistical 
analysis was an unpaired T-Test with p value of 0.01. 
Compound Names HMDB PubChem KEGG 
3-hydroxy-3-
methylglutarate HMDB00355 1662 C03761 
3-hydroxybutyrate HMDB00357 441 C01089 
3-hydroxyglutarate HMDB00428 181976 NA 
3-phenyllactate HMDB00779 3848 C01479 
3-phenylpropionate HMDB00764 107 C05629 
Acetate HMDB00042 176 C00033 
Fucose HMDB00174 17106 C01019 
Glutamine HMDB00641 5961 C00064 
Kynurenine HMDB00684 161166 C00328 
Lactate HMDB00190 107689 C00186 
Lysine HMDB00182 5962 C00047 
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Compound Names HMDB PubChem KEGG 
Myo-inositol HMDB00211 NA C00137 
Phenylalanine HMDB00159 6140 C00079 
Succinate HMDB00254 1110 C00042 
Valine HMDB00883 6287 C00183 
 (Abbreviations: HMDB = Human Metabolome Database, KEGG = Kyoto 
Encyclopedia of Genes and Genomes, PubChem = PubChem project of National 
Center for Biotechnology Information (NCBI), USA, NA = not available) 
B) ANOVA 
Using Amix® software, the spectral data of RA and IA synovial fluids were 
interpreted into the bucket table with peak intensity value. The statistical analyses were 
performed via the online programme, Metaboanalyst®. ANOVA with Fisher’s LSD 
post hoc analysis was selected for the comparison of more than two groups (e.g. for 
further comparison with fluids from different degenerative joint diseases such as 
osteoarthritis), with unpaired data. The p value was at 0.01.  
As a consequence, 18 spectral peaks were that were significantly different 
between RA and IA (non-RA inflammatory arthritis) groups. However, only 8 
identified metabolites, (3-phenyllactate, 2-phenylpropionate, 3-phenylpropionate, 5-
aminolevulinate, biotin, glutamine, kynurenine and phenylalanine), were related to the 
significantly changed spectral peaks. In the next step, the peaks at the locations were 
visualised individually to confirm that they represented the specific metabolites. When 
analysing spectral patterns, one spectral peak may represent either the specific 
metabolites (the so called “distinct peaks”), or the summation of several metabolites 
(the so called “non-distinct peaks”). The changes in the distinct peaks were more likely 
to be interpreted as the changes in concentrations of the identified metabolites, rather 
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than from other unspecified metabolites. For example, the spectral peaks of 
phenylalanine comprises 17 peaks in total, which are 5 distinct peaks and 12 non-
distinct peaks. The spectral peaks were significantly different in 8 out of the 17 peaks, 
including 2 distinct peaks and 6 non-distinct peaks. Therefore, phenylalanine was 
likely to be confirmed as a significantly changed metabolite when compared between 
RA and IA groups. All 8 possible metabolites were appraised one by one, and only 4 
metabolites, 3-phenyllactate, 3-phenylpropionate, kynurenine and phenylalanine, were 
subsequently confirmed to be significantly different (Table 6.19).  
Table 6.19: List of metabolites in synovial fluid that were significantly 
different between RA and other inflammatory joint disease (non-RA 
inflammatory arthritis (IA)) (n = 4). Statistical analyses method is ANOVA with 
Fisher’s LSD post hoc, p value = 0.01.  
Compound Names HMDB PubChem KEGG 
3-Phenyllactate HMDB00779 3848 C01479 
3-Phenylpropionate HMDB00764 107 C05629 
Kynurenine HMDB00684 161166 C00328 
Phenylalanine HMDB00159 6140 C00079 
(Abbreviations: HMDB = Human Metabolome Database, KEGG = Kyoto 
Encyclopedia of Genes and Genomes, PubChem = PubChem project of National 
Center for Biotechnology Information (NCBI), USA) 
When the spectral peaks were analysed using two statistical analyses methods, 
T-Test and ANOVA, the number of the changed metabolites was different. However, 
the identified metabolites (n = 5) by ANOVA with Fisher’s LSD post hoc were the 
subset of the results of the T-Test (n = 14). In order to study the metabolomic changes 
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in rheumatoid arthritis, each metabolites were appraised in correlation with the biology 
(See Discussion). 
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6.16 Discussion 
The aim of this chapter was to develop protocols for the study of human 
neutrophils using 1H NMR metabolomics and then apply the protocols to study 
changes of neutrophil metabolism in disease. Protocols were developed to take into 
account the low levels of metabolites in human neutrophils, and to develop optimal 
conditions for the detection of metabolites such as NADP+ which have high rates of 
turn-over during activation of neutrophils. 
In order to optimise protocols for neutrophil metabolomics, it was necessary to 
study both unactivated (freshly isolated healthy control) and activated neutrophils. It 
was decided to use PMA as the activating factor for in vitro optimisation experiments. 
PMA is an analogue of diacylglycerol, which rapidly activates protein kinase C, 
generating a respiratory burst through activation of the NADPH oxidase (197). It is 
used experimentally to activate ROS production (via the respiratory burst) from 
primed and unprimed neutrophils, and is a potent activator of neutrophil extracellular 
trap formation (NETosis) (158). The experiments demonstrated a dynamic regulation 
of glucose levels in response to PMA; after 5 min incubation, glucose levels were 
significantly higher, and after 15 min glucose levels were significantly lower. This 
could represent a rapid import of glucose at 5 min (to support the rapid increase in 
metabolic activity in response to PMA) followed by exhaustion of glucose by 15 min. 
Alternatively, these intracellular increases in glucose could result from the 
mobilisation of glycogen stores of neutrophils. A significant change was also observed 
in the levels of glucose-6-phosphate. This metabolite, in conjunction with NADP+, is 
a substrate for glucose-6-phosphate dehydrogenase to produce NADPH via the hexose 
monophosphate shunt (197). A number of inhibitors of ROS levels were also increased 
by PMA-stimulation, including methyl-guanidine and taurine. These metabolites are 
scavengers of H2O2 and HOCl, both of which are produced during the neutrophil 
respiratory burst (198,199), and the in increased levels of these anti-oxidants by PMA-
treatment may represent a form of feedback inhibition of ROS production. 
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Table 6.20: Key metabolites changed in response to PMA treatment 
Metabolites At 5 min At 15 min Pathways Implications 
Glucose ↑ ↓ Glucose 
metabolism 
The rapid increase of 
metabolic activity in 
response to PMA. 
Glucose-6-
phosphate 
↓ ↑ Hexose 
monophosphate 
shunt 
The metabolite, in 
conjunction with 
NADP+, is a 
substrate for 
glucose-6-phosphate 
dehydrogenase to 
produce NADPH. 
Methylguani
dine, 
Taurine 
↔ ↓ Neutrophil 
respiratory burst 
Inhibitors of reactive 
oxygen species 
(ROS). 
Once protocols for NMR neutrophil metabolomics had been optimised, the 
next step was to study neutrophils activated in vivo by inflammation, in this case 
neutrophils from patients with rheumatoid arthritis. Rheumatoid arthritis (RA) 
neutrophils have previously been shown to circulate in the blood stream in an activated 
form, and have dynamic changes in gene expression compared to healthy control 
neutrophils (191). Indeed, transcriptomic analysis of RA neutrophils can be used to 
stratify patients into responders and non-responders to anti-TNF therapy (200). My 
hypothesis therefore was that the metabolome of RA neutrophils would be 
significantly different to that of healthy control neutrophils. PCA analysis was able to 
discriminate between RA and healthy control neutrophil samples, and it was 
determined that 43 metabolites were present in significantly different levels between 
RA and healthy (present in one but not the other group, or present at significantly 
different levels). A number of the metabolites that were identified in RA neutrophils 
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may be attributed to known mechanisms of disease. Methylamine (present in RA and 
not healthy neutrophils) is a by-product of the activation of protein arginine deiminase 
4 (PAD4). PAD4, an enzyme which plays a key role in the chemical modification of 
arginine to citrulline, has been identified in a genome-wide association study (GWAS) 
as a susceptibility gene for the development of RA (201). Citrullination of histones by 
PAD4 is a key regulator of gene expression; the replacement of positively charged 
arginines with negatively charged citrullines leads to chromatin decondensation within 
the nucleus, which is important for the initiation of gene expression (202). RA 
neutrophils exhibit higher levels of citrullinated histones, especially histone H2A, H3 
and H4. Citrullination of histones is a key component of NETosis (202), allowing 
decondensation of chromatin prior to DNA release, and in RA, a number of 
hypercitrullinated proteins can be found within synovial joints, including vimentin and 
aggrecan (203). A hallmark of severe RA is the presence of serum anti-citrullinated 
peptide antibodies (ACPA), and the hypothesis is that citrullination of peptides via 
PAD4 by neutrophils, followed by exposure of citrullinated peptides in NETs to cells 
of the adaptive immune system, is a key step in the development of ACPA in early RA 
pathology (204). Also elevated in RA neutrophils was ornithine. This metabolite has 
previously been identified in serum from RA patients and from patients with 
periodontal disease (205). Interestingly, it has been shown that patients with 
periodontal disease have increased PAD4 activity due to the presence of pathogens 
such as Porphyromonas gingivalis, leading to increased protein citrullination (206). 
Incidence of periodontal disease is higher in RA compared to the healthy population 
(205).  
Another key metabolite elevated in RA was myo-inositol. Synthesis of inositol 
metabolites is a key pathway regulating the activation of neutrophils, which occurs 
downstream of G-protein activation of phospholipase C (PLC). PLC hydrolyses 
phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol 1,4,5-triphosphate 
(Ins 1,4,5-P3), which induces the release of calcium from intracellular stores, and the 
release of diacylglycerol (DAG) from the plasma membrane, both of which activate 
protein kinase C (PKC) (197,207) leading to rapid activation of cell signalling, 
NADPH oxidase assembly and the respiratory burst. Neutrophils from patients with 
RA show evidence of activation in vivo and do not require priming to generate a 
respiratory burst (159). In addition, reports of increased levels of spontaneous NETosis 
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(204) in RA neutrophils would support the evidence that the NADPH oxidase is 
already assembled and active in RA neutrophils. 
A number of metabolites implicated in the production of inflammatory 
mediators were found to be elevated in RA neutrophils. Kynurenine is a metabolite of 
tryptophan metabolism, and is a vasodilator implicated in systemic inflammation 
(208). Tryptophan metabolism has previously been reported to be elevated in both RA 
serum and synovial fluid (209–212), and was identified in my analysis of RA and IA 
synovial fluid as being elevated in RA. N-acetylcystine (a precursor of L-cystine) and 
glutamate were also elevated in RA neutrophils. These metabolites are part of the 
glutathione synthesis pathway (glutathione was also elevated in RA). Activation of 
this pathway leads to the activation of leukotriene synthesis (197). Leukotrienes are 
eicosanoid inflammatory mediators, produced by neutrophils via the oxidation of 
arachidonic acid. Leukotriene B4 is a potent neutrophil chemoattractant and can 
promote neutrophil adherence via upregulation of CD11b (MAC-1) (213). 
This study identified a number of metabolites, elevated in RA neutrophils and 
RA synovial fluid, that are implicated in ketosis, including 2-hydroxyisovalerate, 
pyruvate, 3-hydroxy-3-methyl glutarate, 3-hydroxybutarate and 3-hydroxyglutarate. 
Ketosis has previously been reported as a metabolic pathway elevated in RA serum 
and synovial fluid, and been attributed to the limited energy source caused by low 
oxygen conditions in pathogenically challenged tissues. Whilst this may indeed be the 
case, another possibility to consider is the fasting state of donors (RA and healthy) at 
the time of sample collection. Ketosis can occur via a shift in metabolism during 
glucose limitation: in the absence of glucose e.g. via dietary limitation or decreased 
mobilisation of glycogen stores, (or during oxygen limitation) metabolism of stored 
lipids is stimulated to increase the supply of acetyl CoA. If this molecule cannot be 
further metabolised in the citric acid cycle (e.g. because of decreased levels of 
intermediates or oxygen limitation), then excess acetyl CoA is converted to ketone 
bodies such as acetoacetate, acetate and hydroxybutyrate. Therefore, if a donor had 
not eaten breakfast on the day of sample donation this could significantly alter the 
metabolite profile of biofluids and cells including neutrophils. Information on fasting 
state were not recorded as part of this study, and should be a consideration for the 
design of follow-on studies.  
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Table 6.21: Key metabolites changed in RA neutrophils 
Metabolites Relative level in 
RA compare to 
healthy control 
Pathways Implications 
Methylamine ↑ The activation 
of protein 
arginine 
deiminase 4 
(PAD4). 
PAD4, an enzyme 
which plays a key 
role in the chemical 
modification of 
arginine to citrulline, 
and has been 
identified in GWAS 
studies as a 
susceptibility gene 
for the development 
of RA. 
Ornithine ↑ Unknown Previously identified 
in serum from RA 
patients and from 
patients with 
periodontal disease, 
which the incidence 
is higher in RA 
patients. 
Myo-inositol ↑ Synthesis of 
inositol 
metabolites 
A key pathway 
regulating the 
activation of 
neutrophils, which 
occurs downstream 
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Metabolites Relative level in 
RA compare to 
healthy control 
Pathways Implications 
of G-protein 
activation of 
phospholipase C 
(PLC). 
Kynurenine ↑ Tryptophan 
metabolism 
A vasodilator 
implicated in 
systemic 
inflammation. 
N-acetylcystine,             
Glutamate 
↑ The 
glutathione 
synthesis 
pathway 
Activation of this 
pathway leads to the 
activation of 
leukotriene 
synthesis, an 
eicosanoid 
inflammatory 
mediator, produced 
by neutrophils. 
2-
Hydroxyisovalerate
, pyruvate,                   
3-Hydroxy-3-
methyl glutarate,                   
3-Hydroxybutarate, 
3-Hydroxyglutarate 
↑ Ketosis The limited energy 
source caused by 
low oxygen 
conditions in 
pathogenically 
challenged tissues. 
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To date, metabolomic studies in RA have focused on biofluids, including urine, 
serum and synovial fluid (210), and the potential of metabolomics to identify 
biomarkers to predict response to therapy. 3-hydroxybutyrate, a key metabolite in 
ketosis, was identified by a number of studies as being elevated in RA serum (214). 
Levels of this metabolite were significantly decreased following successful treatment 
with the anti-TNF drug etanercept (214). These studies have also reported increased 
activation of the tricarboxylic (TCA) cycle and amino acid metabolism in RA biofluids 
(210). A number of lipid metabolites have been previously reported to be lower in RA 
biofluids, with a possible explanation being lipids as a source of energy within the 
hypoxic joint (215). These previous studies were confirmed by my analysis of RA 
synovial fluid. Alteration of lipid metabolism is associated with changes in membrane 
composition/permeability, gene expression and protein distribution and function, as 
well as in cellular functions such as cell growth, proliferation, differentiation, survival, 
apoptosis and chemotaxis, implicated in the RA disease process (216). Metabolomic 
analysis of urine from RA patients prior to commencement of anti-TNF therapy 
identified the upregulation of histamine, glutamine, phenylacetic acid, xanthine, 
xanthurenic acid and creatinine, and downregulation of ethanolamine, p-
hydroxyphenylpyruvic acid and phosphocreatine as biomarkers of a good response to 
therapy (217). Serum biomarkers can also distinguish responders and non-responders 
to methotrexate (211). A number of metabolites and metabolic pathways have been 
shown to correlate with markers of inflammation such as C-reactive protein (CRP), 
including arginine metabolism (arginine and ornithine), tryptophan metabolism 
(serotonin and tryptophan) and branched-chain amino acids (isoleucine, leucine and 
valine) (209). 
The results in this Chapter show that this approach of NMR metabolomics has 
great potential to identify functional changes in neutrophils activated in vitro or in vivo 
during inflammatory activation of these cells. The metabolomic changes identified 
map well with the known and predicted changes in function of these cells and further 
work is now needed to perform these analyses on neutrophils stimulated in vitro with 
a wider range of agonists. It will also be necessary to study the metabolomic profiles 
of RA neutrophils, including a larger patient cohort to identify disease heterogeneity 
and also during the course of their treatment to determine if changes in these 
metabolomic profiles correlate with disease improvement of resistance to therapy. 
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This new approach has great potential to further study neutrophil function, both 
in vivo in inflammatory/metabolic disorders and after in vitro activation. For example, 
transcriptomic analyses (176) have shown great differences in mRNA profiles of 
neutrophils from patients with rheumatoid arthritis, compared to healthy controls. 
These transcriptomic changes would be predicted to result in changes in the function 
and hence metabolic activity of RA neutrophils. Indeed, the pilot experiments 
described in this Chapter show that RA neutrophils have quite a distinct metabolomic 
profile to those of control neutrophils. These metabolomic changes are likely to reflect 
altered cell signalling processes and/or altered cellular composition of neutrophils as 
a result of disease. The above-mentioned transcriptomic studies have also revealed 
considerable neutrophil heterogeneity in different RA patents (200,218) and this may 
be reflected in their different responsiveness to anti-inflammatory drugs. It would be 
interesting, therefore, to undertake a larger scale study of the neutrophil metabolome 
in different RA patients, both before and post therapy, and to determine if changes in 
the metabolome can be used to identify different disease sub-types and/or differential 
responses to therapy. If so, then neutrophil metabolomics may serve as a useful 
prognostic indicator of likely response to therapy. 
Another potential use of this approach would be to compare the metabolomic 
profiles of WAS patients (Chapter 4) with those of healthy controls. An altered actin 
cytoskeleton in these patients may also be reflected by an altered metabolome, 
particularly in cells activated to undergo cytoskeletal re-arrangements. If so, then a 
metabolomic profile of WAS-corrected neutrophils could be a useful indicator of the 
success of genetic correction of stem cells in these patients. 
Furthermore, this technique could also be applied to confirm the efficiency of 
differentiation of iPSCs into different types of mature blood cells. It is predicted that 
different types of mature blood cells (neutrophils, eosinophils, mononuclear 
phagocytes, lymphocytes) would have different resting and activated metabolomic 
profiles. Therefore, determining the metabolomic profiles of iPSCs that have been 
induced to differentiate into different types of blood cells could be a useful molecular 
“fingerprint” to evaluate the efficiency and specificity of differentiation of these cells.  
 
Page 235 of 280 
CHAPTER 7 GENERAL DISCUSSION AND FUTURE WORK 
 This thesis describes a number of technologies that can be applied to study the 
molecular basis of human disease and to determine the how particular cellular 
processes are regulated in a number of human conditions. Stem cell technologies have 
great potential for either the study of human biological processes or the development 
of new therapeutic approaches. In this thesis, two stem cell technologies, mesenchymal 
stem cells (MSCs) and induced pluripotent stem cells (iPSCs) have been explored to 
understand the molecular basis of human disease. First, the potential role of MSCs, in 
combination with oral vitamin C, as a new diabetic wound therapy have been studied 
both in vivo, using a diabetic nude mouse model, and in vitro, using proliferation and 
tubular formation assays and by measuring the expression of angiogenic growth 
factors after in vitro culture of MSCs. Second, the iPSC technology was used to model 
neutrophil functions due to impaired signalling via Wiskott-Aldrich syndrome protein 
(WASp). The morphology of mature blood neutrophils were compared with those of 
iPSC-derived neutrophils and differentiated myeloid cell lines. Additionally, the new 
technique, NMR metabolomics, was used to study the function of neutrophils activated 
in vitro or in vivo and identify altered neutrophil metabolism in human diseases, e.g. 
rheumatoid arthritis. 
 In the MSC experiments, the potential of mesenchymal stem cells (MSCs) and 
vitamin C supplementation in the treatment of diabetic wounds using the diabetic nude 
mouse model was investigated. The main findings of my study in this part of the thesis 
were as follows: 
1. Upregulated expression of mVEGF-α, mPDGF-BB, mFN-1 and mTNC in 
MSCs cultured in the presence of TGF-β1 
2. Decreased mVEGF-α and mPDGF-BB mRNA expression in TGF-β1-treated 
MSCs cultured under high glucose conditions and vitamin C reversal of the 
hyperglycaemic suppression of TGF-β1 regulation of mVEGF-α and mPDGF-
BB expression. 
3. Effect of hyperglycaemia on the secretion of angiogenic cytokines into the 
culture medium of MSCs, which resulted in the impaired tubular formation 
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4. Vitamin C as adjunct therapy for MSC treatment of diabetic wounds in vivo 
accelerated the wound closure, which was likely due to effects of increasing 
capillary vascularisation. 
 This study showed that vitamin C supplementation could reverse the effects of 
hyperglycemia on MSC function, and opens the possibility that oral vitamin C could 
be used as an adjunct therapy. The current therapeutic approaches for diabetic wound 
treatment is not specific to the underlying pathology of the disease. In this thesis, the 
vitamin C supplement could potentiate the angiogenic effects of both intrinsic (natural) 
factors and extrinsic (topical application) mesenchymal stem cells (MSCs). Moreover, 
the serum vitamin C level in diabetic patients is generally low due to the high renal 
excretion rate. Oral vitamin C supplement is safe and therefore should be considered 
as an adjunct therapy in patients with diabetic wound. However, in my study, the only 
in vivo experiment was in diabetic nude mice, and so clinical trials should be conducted 
in future to determine the effects of topical MSCs with vitamin C supplement in the 
treatment of diabetic wounds. Vitamin C is considered a safe and cheap option to 
enhance wound healing.  
 In the study on Wiskott-Aldrich syndrome (WAS) and properties of WAS 
neutrophils, the potential role of genetically-corrected, induced pluripotent stem cells 
(iPSCs) for the treatment of Wiskott-Aldrich syndrome was the original aim of the 
study. The study originally aimed to isolate iPSCs from a WAS patient, identify and 
experimentally correct the genetic defect and determine if neutrophils-derived in vitro 
from these genetically-corrected iPSCs had restored, normal neutrophil function. 
However, because of changes in my training programme, only preliminary 
experiments were obtained and only neutrophil function from WAS patients was 
measured. It was also demonstrated that iPSCs from WAS fibroblasts could be 
successfully cultures and then differentiated into neutrophil-like cells. Nevertheless, 
interesting results were obtained a “proof of principle” experiments showed that this 
approach should be further explored in future studies. The main findings of my study 
in this part were as follows: 
1. WAS neutrophils demonstrated impaired chemotaxis activity in response to 
fMLP, when compared to the healthy neutrophils 
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2. The differentiation of corrected-WAS-iPSCs into neutrophils via iPS-sac 
formation could generate the morphologically mature neutrophils. 
 Clearly, these preliminary data justify further work on this system. In the 
present study blood neutrophils isolated from the WAS patient revealed marked 
chemotactic defects, in response to fMLP. This would appear to confirm a functional 
defect in these neutrophils as a consequence of the genetic defect. Further work should 
include determination if this is a generic chemotactic defect or just restricted to 
responses to fMLP. For example, chemotaxis in response to agents such as IL-8, C5a 
could be performed. Also, further functional assays such as phagocytosis and 
respiratory burst activation should be conducted as these, particularly the former 
function, are dependent on the function of the cytoskeleton, which is reported to be the 
major defect in these patients. Other approaches that should be taken include 
functional characterisation of the in vitro differentiated neutrophils derived from the 
WAS iPSCs and whether these cells have impaired chemotaxis. It would also be 
necessary to assess if the neutrophils derived from the genetically-corrected iPSCs 
have restored chemotaxis activity. In the preliminary study, the differentiation of 
iPSCs to neutrophils provided the morphologically mature neutrophils, however, as 
the number of iPSC-derived neutrophils were limited. Future studies aimed at 
increasing the number of iPSC-derived neutrophils are required so that these functions 
can be fully evaluated.  
 In the PLB-985 study, the aims were to develop a cell-line model of neutrophil 
differentiation and to produce a set of transfected clones expressing EGFP-tagged 
Myeloid Cell Leukaemia-1 (Mcl-1), an anti-apoptotic protein that plays a key role in 
regulating neutrophil survival. The efficiency of the differentiation was compared in 
two myeloid leukaemic cell lines, PLB-985 and KCL-22 cells. The latter was chosen 
because a previous Ph.D. project in this laboratory indicated that this chronic myeloid 
leukaemia cell line had a number of molecular properties, such as an absence of Bcl-2 
expression, that were characteristic of mature neutrophils. This suggested that they 
were committed to the neutrophil lineage, and hence perhaps easier to differentiate in 
vitro into neutrophil-like cells. However, these experiments revealed that the KCL-22 
cells did not differentiate into neutrophil-like cells as well as the PLB-985 cells, 
although time did not permit a thorough study to optimise the differentiation media for 
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the KCL-22 cells. In these experiments both cell lines were cultured in similar media. 
As a consequence, the PLB-985 cell line was selected to transfect and produce 
transfected clones expressing a Mcl-1:EGFP in pLVX-TetOne-Puro system (an 
inducible expression system with antibiotic). The main findings of this part of the study 
were as follows: 
1. The efficiency of differentiation of PLB-985 cells was higher, in terms of the 
percentage of the differentiated cells at day 5, when compared to KCL-22 cells. 
2. The establishment of the transduced PLB-985 cells with a Mcl-1:EGFP in 
pLVX-TetOne-Puro system 
 While the KCL-22 cells could be induced into neutrophil-like cells, there were 
quite wide fluctuations in the percentages of differentiated cells obtained. The reasons 
for this are unknown at present. Also, as mentioned above, a thorough and systematic 
investigation of the culture conditions was not performed, partly because of time 
limitations and partly because another project in this laboratory had spent considerable 
time optimising the differentiation protocols for PLB-985 cells. A major problem in 
these experiments is that terminally-differentiated neutrophils have a very short half 
life because they undergo constitutive apoptosis. Therefore, once differentiated in 
culture, they will die within a day or so unless precautions are taken (e.g. addition of 
apoptosis-delaying agents such as pro-inflammatory cytokines). Therefore, this part of 
the thesis was to produce a set of a transfected clones expressing a Mcl-1:EGFP in 
pLVX-TetOne-Puro system. This should then allow for the extended survival in 
culture of differentiated PLB-985 cells in culture, making them a more useful 
experimental system to study the effects of manipulation of particular genes on 
neutrophil function. However, the process of the clonal selection is still ongoing. When 
single clones are derived, the inducible induction of expression (using antibiotics) will 
enable the role of the Mcl-1 gene in control of cell survival to be studied. Moreover, 
as the Mcl-1 gene was tagged with EGFP, this allows for the intracellular tracking and 
location of Mcl-1 protein by confocal microscopy.   
 In the metabolomic study, the optimised protocols to profile of metabolome of 
human neutrophils using 1H NMR spectroscopy have been developed. This was the 
first time, the human neutrophils have described in terms of metabolomic profiles, and 
the first time that this technique has been applied to these cells. Therefore, the 
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extraction and the analysis protocols needed to be optimised in order to ensure that all 
intracellular metabolites were extracted and captured in order to accurately define the 
neutrophil metabolomic profiles. Additionally, comparison studies of neutrophil 
metabolomic profiles in resting neutrophils and neutrophils activated both in vivo 
(rheumatoid arthritis, RA), and in vitro (PMA, the protein kinase C activator) were 
conducted. The protocols to optimise the identification of the metabolomic profiles of 
synovial fluid from RA and non-RA patients were also developed and profiles 
compared. The main findings of this part of the study were as follows: 
1. The optimised extraction protocols and analysis methodologies of neutrophil 
NMR metabolomics have been established. 
2. The neutrophil NMR metabolomic study of neutrophils from healthy 
individuals and rheumatoid arthritis patients revealed distinct metabolomic 
pattern between two groups. 
 The protocols for the NMR metabolomic study in neutrophils have been 
established for the first time. However, in the preliminary studies in this thesis, some 
experiments require further repeats or additional experimental variables to be tested. 
The baseline profiles of healthy neutrophil metabolomics were highly variable, but 
studies using different neutrophil numbers and varying number of scans could improve 
the signal:noise ratio of the metabolomic spectra analysed by the principal component 
analysis. The comparison of neutrophil metabolomic profiles of healthy and diseased 
(e.g. rheumatoid arthritis) neutrophils revealed distinct metabolomic profiles between 
the two groups. However, the number of the RA patients was only 3, and so the 
increasing number of samples would improve the reliability of the results. Moreover, 
the number of scans in this experiments was at 256, but in other experiments on the 
number of scans in this thesis, 512 or higher are recommended for the future study. 
Therefore, re-analyses of the RA samples at the higher number of scans has been 
planned. 
 However, these NMR experiments revealed that this is a highly useful 
approach to study the function of neutrophils both in vivo and in vitro. Further 
experiments should also measure the metabolomic profiles of healthy neutrophils 
activated in vitro (e.g. after chemotaxis, phagocytosis, ROS production, adherence) 
and after priming in vitro with a range of cytokines or other agents (e.g. 
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lipopolysaccharide (LPS)) that could activate them during inflammation or in 
inflammatory disease. Comparison of the metabolomic profiles of neutrophils isolated 
from the blood or inflammatory lesions (e.g. synovial fluid, bronchoalveolar lavage 
(BAL)) could then be compared with those profiles of neutrophils activated in vivo 
with these different agonists. Such comparative analyses could help predict the 
functions of neutrophils activated in vivo and also the agonist/signalling pathways 
responsible for their activation. This could not only help understand the function and 
role of these cells in disease, but could help in the design of targeted therapeutic 
interventions.  
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Supplementary data 2: The synovial fluid pattern file 
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